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This thesis is focused on enzymes related to the biosynthetic pathway of fluorometabolite 
synthesis in S.cattleya. The first native fluorinating enzyme, fluorinase was isolated from a 
soil bacterium, Streptomyces cattleya in 2002. Fluorinase catalyses the reaction between 
S-adenosyl-L-methionine and inorganic fluoride to produce 5′-fluoro-5-deoxyadenosine (5′-
FDA) and L-methionine as the first step of the fluorometabolite biosynthetic pathway. 
Fluorinase has been an attractive tool for incorporating 18F into a limited number of 
substrates for applications in positron emission tomography (PET). This thesis describes 
a preparation of the fluorinase for PET, and then the production of [18F]-5-fluoro-5-deoxy-
D-ribose ([18F]-FDR) via fluorinase mediated enzymatic synthesis. S. cattleya fluorinase 
has been the only fluorinase identified until recently when four more fluorinases have been 
identified by gene mining. These new fluorinase isolations are presented in the thesis. In 
addition this thesis describes the crystallisation of 5-deoxy-5-fluoro-D-ribose 1-phosphate 
isomerase (FDRPi), an aldose-ketose isomerase involved in the biosynthetic pathway of 
fluorometabolite biosynthesis in S.cattleya.  
 
Chapter 1 presents the background of this research focusing on the enzymes involved in 
the biosynthesis of the two fluorometabolites; fluoroacetate and 4-fluoro-L-threonine, 
produced by S.cattleya.  
Chapter 2 describes the development of a practical, ‘off the shelf’ method of producing 
[18F]-FDR in remote radiochemistry labs. Enzymes, fluorinase and nucleoside hydrolase, 
isolated from Trypanosoma vivax (TvNH) were freeze-dried in their buffers to produce a 
shelf stable, potentially portable kit, where rehydration on site, would then provide catalysts 
on demand for radiochemical synthesis of [18F]-FDR. This kit was practical enough to 
conduct a successful tumour imaging using a mouse model at Vrije University in 
Amsterdam.  
Chapter 3 presents the over-expression and purification of fluorinase gene product (FLA1) 
from a newly isolated soil bacterium Streptomyces sp. MA37. The gene was identified by 
sequence mining of the Streptomyces sp. MA37 genome. This fluorinase shared high 
homology to S.cattleya fluorinase and the flA1 was cloned into E.coli, over-expressed, 
purified, assayed and shown to be a fluorinase. The FlA1 was also crystallized and the 
structure solved.  
Chapter 4 describes the successful crystallisation of FDRPi, an enzyme involved in the 
fluorometabolite synthesis of S. cattleya. The FDRPi was over expressed, purified, 





[18F]FAZA   [18F]fluoroazomycin arabinose 
[18F]-FDU   2-amino-5’deoxy-5’-fluoroadenosine 
[18F]FLT   3’-deoxy-3’-[18F]fluorothymidine 
[18F]FMISO   [18F]Fluoromisonidazole 
4-FT   4-fluoro-L-threonine 
5-FDA   5′-fluoro-5′-deoxyadenosine 
5-FDR   5-fluoro-5-deoxy-D-ribose 
5-FDRP  5-fluoro-5-deoxy-D-ribose-1-phosphate 
5-FDRulP  5-fluoro-5-deoxy-D-ribulose-1-phosphate 
aa    amino acids 
BLAST   basic Local Alignment Tool  
CCD    charge coupled device 
CFE   cell-free extracts 
ClDA   5′-chloro-5′-deoxy-adenosine 
coA    coenzyme A 
COOT    crystallographic object-oriented toolkit 
CT   computed tomography 
DHAP   dihydroxyacetone phosphate 
DNA   deoxyribonucleic acid 
DTT    dithiothreitol 
duf-62    domains of unknown fuction-62 
EDTA   ethylenediaminetetraacetic acid 
FAc   fluoroacetate 
FAd   fluoroacetaldehyde 
FDEA   5ʹ-fluoro-5ʹ-deoxy-2-ethynyladenosine 
FDI   5’-fluoro-5’deoxyinosine 
FHPA   (2R,3S,4S)-5-fluoro-2, 3, 4-trihydroxypentanoic acid 
FITR   fourier transform infrared spectroscopy 
G3P    glyceraldehyde 3-phosphate 
GC    guanine-cytosine  
h   hours 
HEPES  (4-2-hydroxyethyl)-1-piperazineethanesulfonicacid 
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HPLC    high performance liquid chromatography 
IAG-NH  inosine/adenosine/guanosine nucleoside hydrolase 
IF2    initiation factor 2 
ISP    International Streptomyces Project 
ITC   isothermal titration calorimetry 
IU-NHs   inosine and uridine 
L-AAO   L-amino acid oxidase 
LB   Luria Broth 
L-Se-met  L-selenomethionine   
MALDI-TOF matrix-assisted laser desorption/ionisation time-of-flight mass 
spectrophotometry 
MRI   magnetic resonance imaging 
min   minute  
β-ME    2-mercaptoethanol 
MTA    5′-deoxy-5′-(methylthio)adenosine 
MTRP    S-methyl-5-thioribose-1-phosphate  
MTRP   5-methylthioribose 1-phosphate 
MTRPi   5-methylthioribose 1-phosphate isomerase 
MTRuP  methylthioribulose 1-phosphate 
NAD   nicotinamide adenine dinucleotide 
NH   nucleoside hydrolase 
NI-NTA   ni-nitrilotriacetic acid 
NMR   nuclear magnetic resonance 
NP40    nonidet P40 
OD   optical density 
ORF   open reading frame 
PCR   polymerase chain reaction 
PDA   photodiode array 
PDB   protein data bank 
PEG   polyethylene glycol 
PET   positron emission tomography 
PLP   pyridoxal phosphate 
PNP   purine nucleoside phosphorylase 
QM/MM   quantum-mechanical/molecular-mechanical 
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RCY   radiochemical yield
RGD   arginylglycylaspartic acid 
rpm   rate per minute  
rRNA   ribosomal RNA 
s   seconds 
SAH    S-adenosyl homocysteine 
SAM    S-adenosyl-L-methionine 
SCX    strong cation exchange cartridge 
 SDS-PAGE  sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SEC   size-exclusion chromatography 
SHMT   serine hydroxymethyltransferase 
SPE   solid phase extraction 
SPECT  single-photon emission computed tomography 
SUV    standardized uptake value 
TCEP    tris(2-carboxyethyl)phosphine hydrochloride 
TEG   tetraethylene glycol 
TEV protease  tobacco Etch Virus endopeptidase 
TFA   trifluoroacetic acid 
 Tris-HCl  2-amino-2-(hydroxymethyl)-1,3-propanediol hydrochloride 
TvNH    Trypanasoma vivax nucleoside hydrolase  
UV   ultraviolet 
VOIs    volumes of interest  
w/v   weight/volume percent 
WAX   weak anion exchanger 
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1.1  Cell metabolism 
 
A cell's routine operations are accomplished through biochemical reactions that take 
place within the cell itself. These reactions are switched on/off and their rates 
increased/decreased in order to cater to the cell's immediate needs and overall survival. 
There are a vast number of essential enzyme-mediated pathways, involved in the 
building up and breaking down of important cellular components, and these pathways 
are often highly regulated through diverse mechanisms. 
 
Metabolism is divided into two main components: 
Primary metabolism consists of the common metabolic pathways which are essential for 
cell survival and function. It involves catabolic and anabolic reactions which leads to 
energy production, cellular reproduction, growth and development, as well as the 
synthesis of building blocks for proteins, nucleic acids and lipids. Plants and algae 
produce organic compounds from inorganic materials which are then utilised by other 
animals and microorganisms. Biomolecules produced by primary metabolism are known 
as primary metabolites and are universally found in Prokaryotes and Eukaryotes.1,2  
 
Secondary metabolism includes chemical processes dependant on primary metabolism. 
This involves the biosynthesis of metabolites that have no apparent basic function to the 
cell, but instead serve as signalling molecules, antibiotics, toxins and pigments which 
contribute to the management of limited resources and interspecies defence. Unlike 
primary metabolism, hindrance to secondary metabolism does not incur cell death, but 
may affect in the organisms survival and reproducibility. Many secondary metabolites are 
produced by bacteria, varying in their chemical nature and the biosynthetic pathways in 
which they are produced. Secondary metabolites are not necessarily produced under all 
conditions and have limited distribution in nature.3 Mostly, primary and secondary 
metabolism are competing metabolically as they share common precursors (Scheme 1).1 
The main building blocks for the biosynthesis of secondary metabolites are acetate, 
shikimate and amino acids which are used to generate highly diverse and complex 
molecules. The main classes of secondary metabolites include: polyketides and 






































Scheme 1: Interconnection between primary and secondary metabolism. Secondary 





1.2 Fluorinated natural products in nature  
 
1.2.1 Natural products in soil bacteria 
 
Plants and plant preparations have been used for thousands of years, to treat human and 
animal diseases.6 Natural products have been the largest contributors to drugs in the 
history of medicine. Estimates suggest that over 49% of all human drugs have originated 
from natural sources.7 The total number of species on Earth is estimated to be over 8 
million,8 however less than 2 million organisms have been identified and characterised, of 
which relatively few have been explored for their chemical content.9 The majority of the 
antimicrobial products currently used in the medical field have been isolated from soil 
bacteria. There is a large genetic diversity in soil microorganisms that carry out the 
biosynthesis of complex molecules. These soil microbes produce antibiotics as secondary 
metabolites mainly in order to out-compete other bacteria for the limited resources 
available in their environment and in interspecific interactions. 10,11 
More than 80% of antibiotics currently in use were originally discovered from 
actinomycetes, most importantly from the Streptomyces genus (Figure 1).12,13 The history 
of antibiotics derived from Streptomyces began with the discovery of streptothricin in 
194214 following which streptomycin15,16 was discovered soon after. Streptomycin was one 
of the first effective treatments for tuberculosis at that time.17 Following the discovery of 
streptomycin, screening for antibiotics within the Streptomyces genus increased and over 






Figure 1: A timeline of antibiotics discovered from 1940s to 2006, most of which were 
discovered from the Streptomyces genus (highlighted in orange) and the class of each 
antibiotic is enclosed in brackets .13,19,20 
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Streptomyces are aerobic, Gram positive bacteria with particularly high guanine and 
cytosine (GC) content in their DNA (deoxyribonucleic acid). Over 70% of the Streptomyces 
DNA is GC rich as oppose to an E.coli bacterium, which is around 50% GC rich. 21 They 
have a complex life cycle consisting of various morphological and physiological changes. 
Their development initiates with spores germinating to form germ tubes as they encounter 
favourable conditions and nutrients. The germ tubes grow by tip extension and branch to 
form a vegetative mycelium, which grows until the surrounding nutrients are exhausted. In 
response to nutrient depletion both the production of secondary metabolites and 
morphological differentiation are initiated. Some of these secondary metabolites are 
antimicrobials, which are excreted to the surrounding environment in order to out-compete 
other microbes and safeguard their limited resources. As the vegetative mycelium 
matures, it starts to form aerial hyphae, which disrupt the surface tension of the air-water 
interface and grow in to the air. The aerial hyphae further transform into coiled threads of 
spore particles which mature and disperse as the life cycle concludes (Figure 2). This 
process of hyphae differentiating into spores is unique among gram-positive bacteria and 









Figure 2 : Developmental life cycle of Streptomyces coelicolor. Image reproduced with 
permission from Buttner et al.22 
 
1.2.2 Halogenated natural products  
Biological halogenation occurs on a variety of organic molecules ranging from simple 
methyl halides23,24 to terpenes,25 complex polyketides26 and large nonribosomal 
peptides.27 Within these chemical structures, halogen atoms are incorporated on to 
aliphatic carbons, olefinic centers and a wide variety of aromatic and heterocyclic rings.28 
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Over 4500 halogen containing natural products have been discovered and characterised 
to date.29 The most common class of halogenated natural products are the 
organochlorines. There have been over 2300 organochlorines identified to date, among 
which vancomycin 1,30 chlortetracycline 2 31 and chloramphenicol 3 32 (all isolated from 
Streptomyces) are clinically used antibiotics (Figure 3). Rebeccamycin 4 and 
salinosporamide A 5 are organochlorines isolated from actinomycetes, and are potent 
anticancer drugs (Figure 3).33  
Around 2100 organobromines including thyrsiferyl acetate 6 34, halomon 7 35 and 
brominated acetogenins such as laurenidificin 8 36 (isolated from marine red algae) have 
been identified. Brominated compounds are predominantly produced by marine 
organisms. Nearly 120 organoiodides such as calicheamicin 9 (isolated from 
actinomycetes),37,38 and few thyroid hormones produced by thyroid gland in humans, have 
been identified. However only around 6 organofluorine compounds have been identified 

















Figure 3: Examples of halogenated natural products that have been discovered and 
identified to possess cytotoxicity or antibiotic activity.9,39 
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1.2.3 Fluorinated natural products 
Fluorine is the thirteenth most abundant element in the Earth’s crust and the most 
abundant halogen on earth (chlorine 20th, bromine 62nd and iodine 64th).40 However, most 
of the fluorine found in nature is combined within insoluble salts in the form of cryolite 
(Na3AlF6) and fluorspar (CaF2).41 Fluorinated natural products are rare as many of the 
biosynthetic mechanisms applicable to the other halogens are not mechanistically 
plausible for fluorine (i.e. oxidation to F+). This is due to fluorine being the most 
electronegative element with a very high oxidation potential. However, a major contributing 
factor in reduced participation of fluorine in biochemistry is due to its high heat of hydration. 
The high hydration energy of fluoride ion, due to its high charge density lowers its 
nucleophilicity further reducing its reactivity.42 Therefore fluorinated natural products are a 












Figure 4: The known fluorinated natural products along with some fluorinated compounds 





1.2.3.1 Fluoroacetate and (2R, 3R)-fluorocitrate 11 
Fluoroacetate (FAc) 10 is the most common organofluorine compound found in nature and 
was the first fluorinated natural product to be identified.42 This metabolite was first isolated 
from the toxic South African plant, Dichapetalum cymosum in 1943.47 FAc 10 was found 
to accumulate at around 250 ppm in its leaves, which are highly toxic to livestock.46 Very 
high concentrations of FAc 10 were observed in young leaves and seeds, and as they 
mature the FAc 10 levels seem to drop. The FAc 10 levels expressed in various plant 
species seem to vary widely depending on the season, age of the plant, parts of the plant 
and geographical locations. Since this discovery a variety of plants, mainly of the 
Dichapetalum genus along with other poisonous plants native to Brazil, Africa and 
Australia were also identified to produce FAc 10.42,46 Although the exact mechanism of 
FAc 10 biosynthesis in plants is unknown, its toxicity and the mechanism of 10 poisoning 
in mammals is well studied.  
The extreme toxicity of FAc 10 arises from its similar metabolism to acetate. Its toxicity is 
dependent on a metabolic activation or ‘lethal synthesis’ to fluoroacetyl coenzyme A 
(CoA). FAc 10 taken up by cells subsequently enters the Kreb’s cycle as fluoroacetyl-CoA 
19, by attaching to CoA in a reaction catalysed by acetyl-CoA synthetase. Usually 
acetyl-CoA synthetase catalyses the reaction between acetate and CoA in the presence 
of adenosine triphosphate (ATP) to form acetyl-CoA, a key molecule involved in cellular 
respiration. When fluoroacetyl-CoA 19 is substituted for acetyl-CoA in the Kreb’s cycle, it 
is processed by the first enzyme, citrate synthase, to generate (2R,3R)-fluorocitrate 11 in 
a condensation reaction with oxaloacetate.48 (2R,3R)-fluorocitrate 11, specifically inhibits 
acotinase,49 whereas the other diastereomer, (2S,3R)-fluorocitrate 11 is non-inhibitory. 
Aconitase is the next enzyme of the Kreb’s cycle and catalyses the stereospecific 
isomerization of citrate to isocitrate via a cis-aconitate intermediate. When citrate is 
substituted with (2R, 3R)-fluorocitrate 11 it is metabolised to fluoro-cis-aconitate. This is 
followed by hydration along with concomitant defluorination to form 4-hydroxy-trans-
aconitate 20. This intermediate binds tightly to the active site and is a potent competitive 
inhibitor of aconitase50 resulting in a total shut down of the metabolic cycle halting ATP 
production (Scheme 2).51 
Plants and bacteria, which produce FAc 10 for self-defence, require themselves to be 
resistant to the fluoroacetyl-CoA 19 mediated inhibition. The process by which plants 
achieve resistance to fluoroacetyl-CoA 19 has been widely investigated however little is 
known as plants are complex organisms, and difficult to subject to gene manipulation. 
Studies in S. cattleya, an FAc 10 producing soil bacteria presented an agreeable 
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biosynthetic system, in which to study the biosynthesis of FAc 10. The enzyme 
fluoroacetyl-CoA 19 thioesterase (FlK) was identified52 in S. cattleya which could 
selectively hydrolyse the thioester bond of fluoroacetyl-CoA 19 to form FAc 10 and CoA 
with a ~106-fold selectivity for the fluoroacetyl-CoA 19 over the intracellularly abundant 
acetyl-CoA.53 This selectivity towards fluoroacetyl-CoA 19 by the enzyme, despite the 
subtle change in chemical structure, assures that acetyl CoA remains unhydrolysed and 
available for cellular energy production. Crystal structure analysis of FlK demonstrated 
specific hydrogen bonding of catalytic site residues with the fluorine of the fluoroacetyl-
CoA 19 which grants high selectivity towards fluoroacetyl-CoA 19.54,55 In addition the 
molecular recognition of fluorine in both formation and breakdown of the acyl-enzyme 
intermediate was shown to control the active site reactivity in FlK.56,57 A similar hydrolase 
was also identified from mitochondrial extracts of the plant D. cymosum, which could also 
catalyse the specific hydrolysis of fluoroacetyl-CoA 19.58 Therefore plants and bacteria 
may have similar resistance mechanisms.  
 
 
Scheme 2: The ‘lethal synthesis’ of (2R, 3R)-fluorocitrate 11, which inhibits aconitase by 
metabolising into 4-hydroxy-trans-aconitase 20 and binding as a potent inhibitor.48,59  
1.2.3.2 Fluorofatty acids 
In 1964 a West African shrub Dichapetalum toxicarium was found to produce FAc 10 in its 
leaves, and when the plant products were analysed for fluorometabolites, -fluorofatty 
acids were isolated from the seeds.42,60 The seeds mostly contained -fluoro-oleic acid 12 
with small quantities of -fluoropalmitic acid and trace amounts of other fluorinated fatty 
acids.61 These fatty acids are produced when 19 is substituted for acetyl-CoA as a starter 
unit in the fatty acid biosynthesis. Fatty acid synthases are multi-enzyme complexes that 
are involved in fatty acid assembly. At the initial stage they perform a condensation 
reaction of acetyl-CoA (starter unit) with malonyl acyl carrier protein (extender unit). This 
enzyme has broad substrate specificity which allows incorporation of various starter units 
other than acetyl-CoA. In the case of fluorofatty acids, the starter unit is a fluoroacetyl-CoA 
19 which is consistent with the localisation of fluorine to the terminus of the fatty acid such 
as in 21 which was isolated from the saponified seed oil of D. toxicarium. The lack of 
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fluorine along the chain suggests enzyme constraints in the process or an inability of the 










Scheme 3: Biosynthetic pathway of -fluorofatty acids in D. toxicarium. Image reproduced 
and modified with permission from O’Hagan et al.46  
1.2.3.3 Nucleocidin 13 
Streptomyces calvus, a soil bacterium isolated from an Indian soil sample, was found to 
produce the adenosine derived antibiotic, nucleocidin 13. The chemical structure of 
nucleocidin 13 is significantly different to any other fluorometabolite identified to date, as 
the fluorine atom is attached to the C-4 of the ribose ring. This does not show any obvious 
biosynthetic origin from FAc 10 and suggests the presence of a novel fluorination enzyme. 
Nucleocidin 13 was found to be an effective anti-trypanosomal agent, however due to its 
toxicity clinical use had to be ceased.62 Further studies on the biosynthesis of this antibiotic 
have been challenging, as the strains available in public collections are unable to produce 
nucleocidin 14.63,64 
1.2.3.4 4-Fluoro-L-threonine 14 
In 1986, Sanada and co-workers carried out experiments optimising the productivity of the 
-lactam antibiotic, thienamycin in S. cattleya. This led to the discovery and production of 
the fluorinated antibiotic 4-fluoro-L-threonine 14 (4-FT). The antibiotic was produced only 
when a specific soya protein was used in the culture medium. The soya proteins were 
found to contain significant amounts of fluoride, which led to fluorometabolite production. 
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In addition to 4-FT 14 the organism also produced FAc 10 and the enzymes which catalyse 
the production of these fluorometabolites were subsequently identified and purified.59  
1.2.3.5 (2R,3S,4S)-5-fluoro-2, 3, 4-trihydroxypentanoic acid (5-FHPA) 15 
A novel fluorometabolite, (2R,3S,4S)-5-fluoro-2, 3, 4-trihydroxypentanoic acid (5-FHPA) 
15 was identified from Streptomyces sp. MA37 (Figure 4). The production of 15 was 
distinctive to the production of 10 and 14 and a 5-fluoro-5-deoxy-D-ribose (5-FDR) 37 
mediated biosynthesis was suggested.43 Details of the enzymes involved in the production 
of 15 will be discussed in detail in Chapter 2.  
1.2.3.6 Misidentified fluorometabolites 
There have been some misidentifications of fluorometabolites reported in the literature. 
Fluoroacetone 16 was reported from volatiles of the plant extracts of Acacia georginae in 
1970 as a dinitrophenylhydrazone derivative. However, the identity of volatile 
fluoroacetone 16 was reported to be uncertain.65,66 5-Fluorouracil 17 alkaloids and similar 
derivatives were isolated from the marine sponge, Phakellia fusca collected from the South 
China sea. However the origin of these metabolites in the sponge remains unclear due to 
the structural similarity to 5-fluorouracil 17, a well-known anti-cancer pharmaceutical, as it 
is possible that they are acquired from the ocean as a by-product of industrial 
contamination.45,67 In 2014 Marimuthu et al. reported the identification of 
fluoroarylpropionic acid 18 from Streptomyces sp. TC1 (Figure 4). This discovery 
suggested that the bacterium contains an enzyme capable of enzymatic aryl fluorination, 
which was not known before. The structure assignment was largely supported by X-ray 
crystallography where the presence of a hydroxyl group and a fluorine is not accurately 
distinguishable due to their similar electron density and the spectroscopic support was 
unclear.68 O’Hagan et al.44 synthesised the fluoroarylpropionic acid 18 and performed 
comparative spectroscopic analysis on the proposed structure to confirm its identity. The 
spectroscopic data obtained from the synthesised compound was inconsistent with the 
data of the reported structure and no supporting evidence was obtained to show the 







1.3 Fluorometabolite biosynthetic pathway of S. cattleya 
S. cattleya is a known producer of 10 and 14. Since it was the first bacterium to be 
discovered able to produce fluorometabolites, S. cattleya has become a model organism 
in which the biosynthesis of fluorometabolites are studied.  
Isotope labelling studies were carried out to probe the biosynthetic pathway of 
fluorometabolite biosynthesis by S. cattleya. Various 13C and 2H labelled precursors were 
used to analyse the incorporation of these labels into the fluorometabolites by 19F {H} NMR 
and GC/MS. Carbon-13C labelled glycine and pyruvates was observed to give high 
incorporations into the two fluorometabolites. The [2- 13C]-glycine and the [2- 13C] and 
[3- 13C] pyruvate were shown to provide both carbon atoms of FAc 10 as well as C-3 and 
C-4 of 4-FT 14, suggesting a common origin for both molecules (Scheme 4A).69 The 
labelling patterns indicated that glycine was converted first to serine, and then to pyruvate. 
Pyruvate was further metabolised to phosphenolpyruvate before incorporation into the 
fluorometabolites (Scheme 4B).70 Furthermore [2-13C]-glycerol was shown to be 
incorporated into C-1 of FAc 10 by S. cattleya.71,72 As both pyruvate and glycerol feed into 
the glycolytic pathway, the common intermediate for the fluorometabolite production was 
thought to be a product of the glycolytic pathway. Further studies confirmed that the 
phosphenolpyruvate formed from glycine is converted to fluoroacetaldehyde (FAd) 26 









Scheme 4: A) Proposed pathway resulting in labelled fluorometabolites, 10 and 14 via [2-
13C]-glycine and 13C labelled pyruvates. Image reproduced with permission from O’Hagan 
et al.59 B) Relationship between primary and secondary metabolites in fluorometabolite 
synthesis of S. cattleya. Image reproduced with permission from Harper et al.59 
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When resting cell cultures of S. cattleya were incubated with synthetically prepared 
[2,2-2H2] FAd 26, an efficient conversion to deuterated [4-2H2]-4-FT and [2-3H2]-FAc was 
observed. These studies confirmed that FAd 26 is a common precursor to both FAc 10 
and 4-fluorothreonine 14.73 Intermediates involved in the biosynthetic pathway of the 
fluorometabolites in S. cattleya are shown in Scheme 5. 
The first step in fluorometabolite biosynthesis involves the fluorinase. This enzyme 
catalyses C-F bond formation. The fluorination process involves a nucleophilic reaction 
between S-adenosyl-L-methionine (SAM) 22 and a fluoride ion to generate 5′-fluoro-5′-
deoxyadenosine (5′-FDA) 23. 5′-FDA 23 is the substrate for a purine nucleoside 
phosphorylase (PNP), which generates 5-fluoro-5-deoxy-D-ribose-1-phosphate (5-FDRP) 
24.74 An isomerase then catalyses the conversion of 5-FDRP 24 into 5-fluoro-5-deoxy-D-
ribulose-1-phosphate (5-FDRulP) 25.75 The next step, involves an aldolase, which 
converts 5-FDRulP 25 in a retro-aldol reaction, to 26 and dihydroxyacetone phosphate 
(DHAP) 31. So far the aldolase responsible for cleavage of 5-FDRulP 25 to 26, is not 
identified.76 FAd 26 is a key branch point in the biosynthetic pathway. An NAD+-dependent 
aldehyde dehydrogenase was isolated from cell-free extracts (CFE) of S. cattleya which 
oxidises 26 to 10. This enzyme has a high affinity for 26 and glycoaldehyde but not 
acetaldehyde,77 possibly due to the enzyme evolving from an aldehyde dehydrogenase 
which utilised either glycoaldehyde or a similar compound as the natural substrate. A 
pyridoxal phosphate (PLP)-dependent enzyme, 4-FT 14 transaldolase was isolated from 
CFE of S. cattleya. This enzyme catalyse a transaldol reaction between the amino acid L-
threonine and FAd 26 to produce 14 and acetaldehyde. This transaldolase does not utilise 
glycine as the amino acid donor, and for every molecule of 4-FT 14 produced, it sacrifices 




















Scheme 5: Biosynthetic pathway of fluorometabolites in S. cattleya, leading to the 
production of 10 and 14. Image reproduced and modified with permission from O’Hagan 
et al.75  
1.3.1 The fluorinase 
The key step in the biosynthesis of 10 and 14 in S. cattleya is C-F bond formation. Until 
the discovery of the fluorinase from S. cattleya in 2002,78 a native enzyme which could 
catalyse C-F bond formation from fluoride ion was unknown.  
An enzyme mediated synthesis of C-F bond formation was reported in two mutant 
glycosidases isolated from Agrobacterium sp. and Cellulomonas fimi. These mutants were 
capable of incorporating a fluoride ion into the C1 position of gluco- and 
mannosaccharides via nucleophilic displacement of 2, 4-dinitrophenol. Catalytic glutamate 
residues Glu 358 in Agrobacterium sp. and Glu-429 in C. fimi were replaced with either a 
serine or alanine respectively, which inhibited the glycosidase activity. However, in the 
presence of high fluoride concentrations (2 M) the glycosidic activity of these mutants was 
restored. Mutation of the glutamate to serine in Agrobacterium sp. provides an opportunity 
for the solvated fluoride to hydrogen bond to serine resulting in partial desolvation of the 
fluoride. This allows the fluoride ion to perform a nucleophilic attack on the highly 
electrophilic glycosyl donors to produce the glycosyl fluoride intermediate. Since these 
mutants are glycosynthases, catalysing trans-glycosidation the glycosyl fluoride 
intermediate acts as the activated substrate for glycosylation forming a new glycosidic 













can be occupied by fluoride for nucleophilic attack of β-manopyranosyl to form β-D-
mannosyl fluoride (Scheme 6B). These mutant glycosidases are fluoride specific and are 
unable to use other halides, however replacing glutamic acid with glycine produced 
mutants capable of utilising fluoride, chloride and bromide but not iodide. 79–81 










Scheme 6: A) Agrobacterium sp. E358S mutant catalyses the nucleophilic fluorination on 
2, 4-dinitrophenyl β-glycoside, followed by intermediate α-glucosyl fluoride becoming a 
substrate for glycosylation. B) C. fimi E429A β-mannosidase catalyses nucleophilic 
fluorination of enzyme bound mannosyl intermediate to form β-D-mannosyl fluoride. Image 
reproduced and modified with permission from Withers et al.79 
Fluorometabolite production was observed when CFE of S. cattleya was incubated with 
ATP and fluoride. Further experiments with the fluorinase revealed, that added SAM 22 
(in the absence of ATP) was able to support fluorometabolite production in CFEs. Since 
SAM 22 synthetase can mediate the reaction between ATP and L-methionine 27 to form 










Scheme 7: Fluorinase catalyses the conversion of 22 and a fluoride ion to 23 and 27. 
When SAM 22 was recognised as the immediate substrate it was postulated that 5′-FDA 
23 was possibly the product of the fluorinase reaction. This was confirmed by preparing a 
synthetic sample of 5′-FDA 23 and performing comparative analytical analysis with the 
product of the enzyme reaction.83  
Isolating and purifying the fluorinase, was important to investigate the characteristics of 
the enzyme. Partial purification of the wild type enzyme from CFE was carried out using a 
combination of ammonium sulphate precipitation and several chromatography steps. N-
Terminal amino acid analysis and a trypsin digestion was performed on the purified protein 
fraction which provided a partial amino acid sequence for the fluorinase gene. Using the 
partial sequence, PCR primers were designed for the fluorinase gene and the gene was 
PCR amplified using genomic DNA extracted from S. cattleya as a template. This gene 
was cloned in to pET28A (+) vector and the recombinant protein was over expressed in 
E. coli on a mg scale. Gene sequencing revealed the flA gene to be 897 base pairs long 
encoding for a protein of 299 amino acids. For ease of purification, the protein was 
overexpressed with a polyhistidine affinity tag. Sodium dodecylsulphate polyacrylamide 
gel electrophoresis (SDS-PAGE) and mass spectrometry confirmed the molecular weight 
of the fluorinase monomer to be 32 kDa. The intact mass of the fluorinase was 
approximately 196 kDa confirmed by size exclusion chromatography, suggesting a 
hexameric tertiary structure.84 
The fluorinase crystal structure was resolved to a 1.8 Å resolution. This proved the 
hexameric arrangement of the enzyme constructed as a dimer of trimers with three active 
sites (Figure 5). The secondary structure of the fluorinase monomer did not show any 
similarity to other previously characterised proteins. Figure 4 shows the hexameric 
structure of fluorinase and a single trimer. The monomer consists of two distinctive 
domains (N and C terminal) linked with a short polypeptide chain as shown in Figure 5. 
The monomer contained a unique 21 amino acid loop which spans close to the C-terminal 
domain and consists of a part of the active site.85 This amino acid loop had no relationship 
to any other protein superfamily identified at the time of discovery, possibly suggesting a 
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conserved region of the protein essential for function. Each trimer has three N-terminal 
domains, closely arranged around a three-fold axis while the three C-terminal domains are 






Figure 5: Cartoon depictions of the crystal structure of the fluorinase A) The hexameric 
fluorinase made up of a dimer of trimers. B) A single trimer made of up of three monomers 
showing 3 SAM 22 molecules bound to each catalytic site. C) A monomer unit showing the 
N-terminal (top) and C terminal (bottom) linked by a single polypeptide chain. The unique 
21 amino acid loop is highlighted in red.85 
The crystal structure of fluorinase was resolved with SAM 22 bound at the active site 
showing specific interactions surrounding the components of SAM 22. The adenine ring, 
ribose ring and the L-methionine 27 chain of SAM 22 is recognised by an arrangement of 
hydrogen bonds and van der Waals interactions. The SAM 22 molecule was observed to 
be completely concealed within the protein upon binding, suggesting the presence of an 
open conformation prior to substrate binding. The ribose ring of SAM 22 was held in an 
unusually planar conformation by hydrogen bonds between the 2′ and 3′-hydroxyl groups 
and the carboxylate side chain of Asp-16 as shown in Figure 6. Due to these hydrogen 
bonds the ribose ring appears to be held in a strained manner. Fluorinase was co-
crystallised with 2′-deoxy-FDA to better understand the importance of the strained planar 
conformation of the ribose ring in driving the substitution reaction. However this 
conformation was shown to be un-important in driving the reaction. In the SAM 22 bound 
fluorinase structure all heteroatoms of the adenine ring are involved in hydrogen bonding 
however the ether oxygen of the ribose ring is not. Studies aimed at understanding the 




1.3.1.1 Mechanism of the fluorinase  
A study of the mechanism of the fluorinase enzyme has been supported by 
crystallography,85 site-directed mutagenesis86 and quantum-mechanical/molecular-
mechanical (QM/MM) theory.87 
Co-crystallisation attempts of the fluorinase with SAM 22 in the presence of fluoride gave 
rise to a crystal structure of the fluorinase with 5′-FDA 23 and L-methionine 27 bound to 
the active site. Comparative analysis of the active sites of the two crystal structures 
provided insight into the mechanism of the reaction. The sulphur was seen to be 
positionally displaced and the C-F bond was shown to be approximately antiperiplaner to 
the C-S bond in SAM 22 indicating a substitution reaction (SN2) with an inverse 
configuration. The 5′-FDA 23 bound crystal structure showed that the fluoromethyl group 
of 23 makes contact with residues Phe-156, Tyr-77, Thr-80 and Ser-158 defining a 
hydrophobic pocket (Figure 6). Fluoride was observed to make contact with Ser-158 and 
Thr-80.85 The side chain OH of the Ser-158 also forms a divergent hydrogen bond to 3′-
OH of the ribose ring in the product 5′-FDA 23. In addition, the ether oxygen does not 
interact with any residues and this may be beneficial to the reaction. Any hydrogen 
bonding to the ether oxygen from surface residues would increase the electron 
withdrawing power of the oxygen which would strengthen the C–S+R2 bond. This would 
increase the activation energy required for the reaction thus reducing the reaction rate. 
Therefore the geometry and disposition of SAM 22 binding appears to be optimised to 
accommodate this reaction.83 
An SN2 reaction mechanism was also supported by isotope labelling studies, probing 
stereochemistry. [2H1-5′]-SAM was prepared from (R)-[ 2H1-5′]-ATP by the action of SAM 
synthetase. This generated (R)-[ 2H1-5′]-FDA when incubated with fluorinase, with an 
overall retention of configuration. However since the SAM synthetase is known to mediate 
an inversion in configuration at C-5′ of ATP, in order to retain the overall configuration in 
the resultant [2H1-5′]-FDA, the fluorinase must also be carrying out substitution with an 
inversion of configuration.88 This is consistent with a SN2 substitution process. SN2 
reactions are uncommon in enzymology and are usually related with low-activation energy 
barriers, requiring substitution reactions such as methyl transfer reactions.64 QM/MM 
studies have indicated that the fluorinase is capable of lowering the activation energy 
required for the C-F bond formation relative to solution. 87  
The proposed molecular mechanism for the fluorinase suggests the hydrated fluoride ion 
diffuses into the hydrophobic active site with low affinity and interacts with the Ser-158, 
Phe-156 and Asp-16 residues via hydrogen bonds. The fluoride ion is desolvated within 
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the active site as no water molecules are observed in the X-ray structure of fluorinase co-
crystallised with 5′-FDA 23 (Figure 5). In addition, examination of the SAM 22 bound 
crystal structure shows a 1.4-1.6 Å pocket, ideal for binding fluoride (1.3 Å ionic radius) 
rather than a halide with larger radius. This is consistent with the inability to process other 
halide ions.85 Computational studies of the surface of fluorinase does not reveal any 
channels suitable for transporting fluoride to active site indicating that fluoride may bind 
first, followed by SAM 22.85,87  
These findings are further confirmed through QM/MM theory studies, where conformation 
of reactants (SAM 22 and F-) and products (5′-FDA 23 and L-methionine 27) in the pre and 
post formation of reactive complexes and transition states were analysed.87 
Several mutants of the fluorinase were produced by site directed mutagenesis and the 
mutant proteins were expressed in E.coli. These mutant proteins were assayed for their 
activity relative to the wild type fluorinase. Residues chosen for mutations were assumed 
to be important for catalysis of the enzyme. The F156A mutant showed significant loss of 
activity which was mostly restored in F156V mutant suggesting that the hydrophobic 
pocket is involved in increasing the reactivity of fluoride ion. D16 mutants, D16A, D16S 
and D16N all showed reduced activity suggesting the aspartate residue interacting with 
the ribose ring plays a critical role in organising substrate for catalysis. The T80S mutant 
(OH group retained) was observed to retain its activity whereas T80A mutant (without the 
OH group) was observed to have a 10-fold reduction in activity suggesting the importance 
of the Thr-80 residue. In addition the S158A mutant showed a clear reduction in the 
enzyme activity due to the loss of hydrogen bond donors for fluoride in the active site 
suggesting the importance of Ser158 in F- binding. Binding is also assisted by the 
electrostatic interactions provided by the sulphonium center of SAM 22 and the negatively 
charged fluoride. QM/MM calculations also supported the importance of hydrogen bonding 












Figure 6: Interactions within the fluorinase active site with bound 5′-FDA 23 and L-
methionine 27 (magenta). Residues that make up the active site belong to two monomers 
which are represented in blue and green. Image reproduced and modified with permission 
from Naismith et al. 85 
Isothermal calorimetry analysis was used to study the steady state kinetics of the 
fluorinase. The data suggest that during the forward reaction the fluoride ion binds prior to 
SAM 22 for catalytic turnover. Fluorinase has relatively high binding affinity for SAM 22 
(Km between 6.5 M and 29M) however, fluoride was shown to have low affinity for 
fluorinase (Km > 5mM). Concentrations of SAM 22 higher than 20M were shown to inhibit 
the enzyme despite it being a substrate. Fluorinase has a turn over kcat of around 0.07 min-
1 85,86 which suggests it is a very slow enzyme. This low turnover is possibly related to the 
formation of the C-F bond under aqueous conditions.  
These data collectively suggest that the hydrated fluoride binds to an unoccupied 
hydrophobic pocket with low affinity. It exchanges water molecules for hydrogen bonds 
with Ser-158. The partial dehydration of fluoride drives the reaction forward and as SAM 
22 binds with high affinity it promotes further dehydration of the fluoride ion trapping it for 
nucleophilic attack, while a hydrogen bond to Thr-80 further stabilises the fluoride ion. The 
positive charge on SAM 22 also stabilises the transition state. Nucleophilic F- then 
attaches C-5′ of SAM 22 displacing L-methionine 27. The L-Methionine 27 is released by 

































































Although various synthetic fluorinating procedures are available, biological fluorination is 
rare. Therefore the discovery of the fluorinase opens up a new avenue in biocatalysis. 
Biotransformations offer some advantages over synthetic methods as enzymes provide a 
handle in sustainable chemistry. One area in which C-F bond formation is important is in 
positron emission tomography (PET). The fluorinase was exploited for incorporating 18F 
into compounds, which can then be used in PET imaging. This will be further discussed in 
Chapter 2.  
1.3.1.2 Reversibility of the fluorinase 
The fluorinase was observed to have high substrate specificity and able to use SAM 22 to 
produce 5′-FDA 23. When fluorinase was incubated with chloride and SAM 22 no 
conversion to the chlorinated product, 5′-chloro-5′-deoxy-adenosine (ClDA) 28 was 
observed.89 Through coupled enzyme assays it was observed that the failure to produce 
ClDA 28 was due to the equilibrium of the chloride reaction significantly favouring the 
substrates over products. This reverse reaction was exploited in performing 
transhalogenation reactions using fluorinase to catalyse the progressive conversion of 
ClDA 28 to 5′-FDA 23 via SAM 22 intermediate.89 Despite the high dissociation energy of 
C-F bond the fluorinase was able to cleave the C-F bond when incubated with 5′-FDA 23 
and L-methionine 27 to form SAM 22 and fluoride. Addition of L-selenomethionine (L-Se-
met), instead of L-methionine 27 exhibited a six-fold increase in the rate of the reaction in 
generating L-Se-SAM. ClDA 28 was shown to be a more efficient substrate for the 
fluorinase than 5′-FDA 23 for the generation of SAM 22. This is because chloride is a 
better leaving group than fluoride, and fluoride is a better nucleophile (substrate) in the 
forward reaction.90 Enzyme assays revealed that the apparent lack of chloride activity was 
due to the equilibrium of the reaction lying in considerable favour of substrates over 
products.91  
The reversibility of the fluorinase reaction was investigated via several enzyme-coupled 
assays. The reaction was coupled to L-amino acid oxidase (L-AAO) enzyme which oxidises 
L-methionine 27 to 2-oxo-acid in an irreversible reaction. Incubation of these enzymes with 
SAM 22 and chloride ions generated detectable amounts of ClDA 28 as the backward 
reaction was supressed (Scheme 8). Production of ClDA 28 from SAM 22 and Cl– was 
only detected in coupled enzyme assays which prevent the reverse reaction. Reactions 











Scheme 8: Fluorinase generates 28 when coupled to an L-AAO to remove 27 which drives 















Scheme 9: A) Trans-halogenation reaction catalysed by fluorinase which converts ClDA 
28 to 5′-FDA 23 through an L-Se-SAM intermediate. B) ClDEA-TEG-RGD converted to 
FDEA-TEG-RGD by trans-halogenation reaction catalysed by fluorinase. Image 
































This reversibility of the fluorinase reaction was exploited in a trans-halogenation reaction 
where ClDA 28 was incubated with fluoride ions, L-Se-Met and fluorinase. The fluorinase 
combines L-Se-Met and ClDA 28 to form L-Se-SAM. This intermediate acts as a substrate 
for the fluorination reaction to generate 5′-FDA 23 (Scheme 9A).91 Despite the high 
substrate specificity of fluorinase it was observed that incorporation of acetylene moiety at 
the C-2 position of the adenosine ring did not hinder catalysis. Therefore substrate 
analogues such as 5ʹ-chloro-5ʹ-deoxy-2-ethynyladenosine (ClDEA) were explored in 
trans-halogenation reactions which has led to production of novel fluorinated products 
such as 5ʹ-fluoro-5ʹ-deoxy-2-ethynyladenosine (FDEA) (Scheme 9A). FDEA was further 
explored for its ability to retain a polyethylene glycol (PEG) chain as an extension of the 
acetylene terminus which can be used to tether peptides which could be radiolabelled with 
fluorine-18. A ClDEA with a tetraethylene glycol (TEG) linker at the C-2 position of the 
acetylene substituent was designed that could be linked to an arginyl-glycyl-aspartic acid 
(RGD) peptide. This was incubated with 18F– and L-Se-met to generate the 18F labelled 
FDEA-TEG-RGD in reasonable radiochemical yield (Scheme 9B) and this was further 
explored in its ability to bind a subset of integrins 92 for studying diseases related to cell 
adhesion such as cancer, osteoporosis and thrombosis.93  
1.3.2 Purine nucleoside phosphorylase 
The second enzyme in the fluorometabolite pathway of S. cattleya is a PNP.94,95 It 
catalyses the phosphate displacement of the adenine base at the anomeric carbon of 5′-
FDA 23 to form 5-FDRP 24 and adenine 29. Studies on the PNP catalytic mechanism 
have shown that the PNP cleaves the glycosidic bond with inversion of configuration to 
produce the -anomer of the phosphorylated sugar. The PNP found in S. cattleya is similar 
to other PNPs which carry out the normal degradation of purine nucleosides. Studies 
carried out in CFE’s of S. cattleya and partially purified PNP from the CFE demonstrated 





Scheme 10: PNP enzyme from S. catttleya catalyses the cleavage of C-N glycosidic bond 





The product of the PNP reaction, 5-FDRP 24 structurally resembles 
S-methyl-5-thioribose-1-phosphate (MTRP) 3096 (Figure 7) which is a well-known 
intermediate in the L-methionine 27 salvage pathway of yeast 97 and bacteria.98 The L-
methionine 27 salvage pathway is responsible for regenerating L-methionine 27 from the 
waste by-products of SAM 22 metabolism in order to recycle sulphur within the cell.99 
MTRP 30 is the substrate for a 5-deoxy-5-methylthioribose 1-phosphate isomerase 
(MTRPi) which opens the hemiacetal group of the ribose ring into an acyclic keto-sugar.96 
This offered a model for the metabolism of 5-FDRP 24 as a substrate and the expected 




Figure 7: 5-FDRP 24, an intermediate in the fluorometabolite pathway structurally 
resembles MTRP 30 (intermediate of the methionine salvage pathway). 
A CFE of S. cattleya incubated with 5-FDRP 24 was monitored by 19F NMR, and this 
showed the production of 5-FDRulP 25 which was unambiguously identified by GC-MS, 
following derivatisation. These experiments proved that 5-FDRulP 25 was a biosynthetic 
intermediate in fluorometabolite biosynthesis. When 5-FDRP 24 was incubated with the 
S.coelicolor MTRPi, the production of 5-FDRulP 25 was observed.This supports the 
hypothesis for the presence of a similar homologue in S. cattleya.75  
An isomerase was purified from the CFE of S.cattleya was indeed able to convert 5-FDRP 
24 to 5-FDRulP 25. The gene was identified, over-expressed in E.coli and purified to obtain 
a 42 kDa isomerase 75,76 Chapter 4 of this thesis focus on solving the crystal structure of 
this S. cattleya isomerase (5-FDRPi).  
1.3.4 Aldolase 
Production of 5-FDRulP 25 by the isomerase in S. cattleya suggested a biosynthetic route 
to 26, as ribulose phosphates are known to be common products/substrates of DHAP 31 
dependent aldolase enzymes.100 Thus a ribulose aldolase in S. cattleya would be sufficient 











Scheme 11: A) A surrogate L-fuculose-1-phosphate aldolase from S. coelicolor was 
capable of catalysing the retro-aldol reaction to produce 26 and 31. B) Natural substrate 
for L-fuculose-1-phosphate aldolase is L-fuculose-1-phosphate 75 
When 26 and 31 were incubated with CFE of S. cattleya, two diastereoisomeric aldolase 
products were isolated suggesting the presence of two aldolase activities. Fractionation of 
the CFE resulted in the isolation of a Type II Zn2+-dependent fructose aldolase which 
catalyses the conversion of 26 and 31 to an alternative diastereoisomer, 
5-fluorodeoxyxylulose phosphate in the reverse reaction. In addition a fuculose-
1-phosphate aldolase was also identified which is important in fructose and mannose 
metabolism.  
In order to perform an in vitro reconstruction of fluorometabolite biosynthesis, an 
alternative fuculose aldolase from Streptomyces coelicolor was isolated and 
over-expressed in E.coli. This aldolase was able to catalyse the efficient cleavage of 25 to 
26, (Scheme 11A) although the natural substrate of this enzyme is L-fuculose-1-phosphate 
(Scheme 11B). To this date the aldolase involved in the fluorometabolite pathway in 
S.cattleya has not been identified or characterised. A putative fuculose aldolase gene is 
observed in the genome of S.cattleya, however this putative aldolase has not been 
over-expressed as of yet. 101 
1.3.5 PLP-dependent transaldolase 
FAd 26 is a branch point metabolite proceeded by two enzymes to form the two 
fluorometabolites, FAc 10 and 4-FT 14. A transladolase generates 4-FT 14 whereas an 
aldehyde dehydrogenase generates FAc 10. The transaldolase is a PLP dependent 
enzyme, which uses L-threonine and 26. In 1986 Sanada et al., suggested that 14 is 


































following common L-threonine aldolase reactions.47 Surprisingly however glycine is not the 
substrate for this transaldolase enzyme. The data suggest that 4-FT 14 transaldolase has 
a mechanism according to Scheme 12 where PLP activates L-threonine and then 
undergoes a retro-aldol reaction, forming a glycyl-PLP aldimine followed by the aldimine 
attacking FAd 26. Thus for every molecule of 4-FT 14 formed a molecule of L-threonine is 
sacrificed. S.cattleya produces 4-FT 14 at the expense of depleting the L-threonine pool 
suggesting that this interplay is crucial in increasing its fitness within its ecological 
niche.64,76,102 
Subsequently the transaldolase enzyme was purified and was shown to exist as a dimer 
of around 120 kDa. Investigations into the gene encoding for PLP- transaldolase (flFT) 
showed that it has 40% homology to L-serine hydroxymethyl transferase (SHMT) from 
other bacteria. The transaldolase was found to consist of two domains, a 
PLP-transaldolase and a sugar phosphate epimerase. The larger domain (440 aa) was 
shown to be homologous to a PLP-binding domain of SHMT enzymes (~35% identity). 
The smaller domain (145 aa) was found to have homology with a phosphate binding 
domain of bacterial ribulose-1-phosphate-4-epimerases or L-fuculose-aldolases. These 
two domains are connected by a 35 amino acid chain, which does not have any obvious 
function.76  
The transaldolase gene was introduced, induced and over expressed in Streptomyces 
lividans and these cultures were incubated with L-threonine, PLP and 26. The 4-FT 14 
production of these cultures was monitored by 19F NMR and this confirmed 4-FT 14 
transaldolase as the last enzyme in the 4-FT 14 biosynthetic pathway of S. cattleya.76 4-
FT 14 biosynthesis was reconstructed in vitro by over-expressing the five enzymes 
identified in the biosynthetic pathway and incubating these enzymes together with fluoride 
and SAM 22. The reaction progress was followed by 19F NMR and confirmed the 






Scheme 12: Mechanism of PLP mediated 4FT-transaldolase which catalyses a retro aldol 
reaction on the PLP activated L-threonine forming glycyl-PLP aldimine which in turn 
attacks 26 to form 14 and acetaldehyde.76 
 
1.3.6 Aldehyde dehydrogenase 
Aldehyde dehydrogenase was the first enzyme to be identified on the fluorometabolite 
pathway of S. cattleya. It is an NAD+ dependent aldehyde dehydrogenase which can 
catalyse the oxidation of 26 to 10. This aldehyde dehydrogenase was able to oxidise a 
variety of aldehydes however the most efficient transformations were reported from 26 
and glycolaldehyde. This indicates that the electronic factors maybe more important for 
reactivity than steric properties. When chloroacetaldehyde was tested as a substrate for 
the aldehyde dehydrogenase the rate of the reaction decreased significantly. Incubation 
time with chloroacetaldehyde was increased and this reduced activity, suggesting 
chloroacetaldehyde might also be a time-dependent inhibitor. This is possibly due to 
alkylation of the active site thiol following nucleophilic attack by the sulphur to the 
chloromethyl group. Since fluoride is a poor leaving group this type of inhibition is not 
observed with 26. As the aldehyde dehydrogenase is capable of accepting glycolaldehyde, 
it is possible that this enzyme evolved from an enzyme that used glycolaldehyde or a 
similar compound as its substrate.77 
 
Chapter 2 attempts to develop a practical, user friendly, shelf stable enzyme kit using 
freeze-dried fluorinase to incorporate 18F to generate [18F]-FDR ([18F]-37) for PET imaging 
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2. Production of radiotracer [18F]-5-FDR [18F]-37 using 
fluorinase 
 
2.1 Positron emission tomography (PET) 
Positron emission tomography (PET) is a molecular imaging tool used widely to image 
tumours in the clinical environment. There is a considerable demand for novel PET 
radiopharmaceuticals, which can be rapidly generated using clean synthetic procedures. 
Enzymatic methods are attractive due to their chemo-specificity, ability to perform 
reactions under aqueous conditions at a neutral pH with low generation of side-products. 
Identification of the fluorinase enzyme has opened up an enzymatic approach to 
incorporating 18F into compounds for PET, as the enzyme utilises fluoride ions as the 
fluorine source. 
2.1.1 PET as a molecular imaging tool  
Molecular imaging is an emerging technology by which cellular processes and functions 
can be visualised in vivo. Anatomical techniques like computerised tomography (CT) and 
magnetic resonance imaging (MRI) are used in conjunction with other molecular imaging 
techniques to provide topographical information. Appropriate radioisotopes are used to 
label biological molecules and these are injected into the subject for imaging. Two of the 
most widely used molecular imaging techniques, are single photon emission tomography 
(SPECT) and PET1. SPECT uses gamma-emitting radioisotope such as 99mTc, 123I and 
111In and the direct emission of gamma rays produced by these radiotracers1 are observed, 
whereas PET uses positron-emitting radioisotopes, where the positron annihilates to form 
gamma photons. PET is at least tenfold more sensitive than SPECT and the positron-
emitting isotopes (18F, 13N, 15O, 11C) can be substituted directly for atoms in bioactive 
molecules without affecting the chemical characteristics of the molecule. Therefore, PET 
is known to be a more versatile technique for imaging most molecular events and has 
become a major imaging tool in oncology, cardiology and neurology. 2 
The PET technique has good resolution, high sensitivity, accurate quantification2,3 and 
provides quantitative information on: physiological, biochemical and pharmacological 
processes of living subjects. The sensitivity of PET is relatively high in the range of 
10-11-10-12 moles/L4 therefore picomolar (10-12) concentrations of radiotracers are 
administered to the subject. These radiotracers decay through the emission of a positron 
and as this encounters an electron from surrounding tissue it annihilates to produce two 
gamma 511keV photons that travel in opposite directions to each other (Figure 1A). These 
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gamma photons are detected by a circular array of gamma detectors (Figure 1B) and the 
registered events are reconstructed into a three dimensional image representing the 
spatial distribution of the radioactive source in the subject.2,5 The spatial resolution of 
common PET scanners are ~ (6-8)3 mm3, however there are higher resolution brain 
scanners with ~33 mm3 resolution.6 For a PET scanner to visualize a clear signal against 
the background it requires a few hundred million cells in relatively close proximity to 
accumulate the radiotracer. PET images are usually displayed in colour reflecting gamma-







Figure 1: A) Two gamma rays travelling 180° from each other are produced as a positron 
(emitting from the radioisotope) and an electron annihilate. B) The 511KeV photons are 
registered by the circular gamma ray detector array in the PET camera. Image 
reproduced with permission from Conti et al.2  
In PET the most widely used radioactive isotopes are 11C, 13N, 15O and 18F, as they have 
relatively short half-lives (20.4 min, 9.9 min, 2.0 min and 109 min respectively) and as 
they are elements which can be substituted for their stable counterparts in biological 
molecules and drugs. Due to the short half-life of the 11C isotope multistep synthesis is 
not generally used for 11C containing radiotracers. 13N, 15O are useful labelling isotopes 
as they are universal in biological molecules; however both have very short half-lives 
making it very difficult to perform more than one synthetic step and therefore are rarely 
used in synthesis of complex molecules. They are used to prepare simple radiolabelled 
molecules such as [15O] CO2, [15O] H2O, and [13N] NH3 which can be obtained directly 
from the cyclotron. The availability of such isotopes offers a wide range of possibilities 
for the investigation of various in vivo biological processes.2 
18F is the most widely used radioisotope for PET as it has the relatively long half-life of 109 
min which allows time for synthesis, biological incorporation and imaging. The half-life of 
18F is long enough to allow for transportation of doses to sites a few hours away. In addition 
35 
 
18F-labelled radiopharmaceuticals, can be produced in sufficient quantities for multiple 
injections from a single synthesis.7 
18F labelling for PET has some disadvantages; not all bioactives contain fluorine and thus 
fluorine tagging can alter the physiological response relative to the molecule of interest, 
as well as the synthetic methods to introduce 18F into molecules are limited. The two main 
strategies for incorporating 18F are either via direct or indirect fluorination. For direct 
fluorination the 18F isotope is introduced into the target molecule in one step whereas 
indirect fluorination involves labelling a prosthetic groups such as 18F-labelled alkyl or aryl 
moiety of a reactive molecule. Indirect methods are used when incorporating 18F into 
complex biological molecules which might not withstand direct fluorination conditions.7 
Direct methods involve electrophilic or nucleophilic fluorination. Electrophilic fluorination 
uses elemental fluorine [18F]F2 produced by deuteron irradiation of neon gas supplemented 
with F2. [18F]F2 is highly reactive resulting in nonspecific reactions generating a mixture of 
products. This method also produces labelled products with low specific activity as the 
[18F]F2 is produced by a carrier-added method. Therefore currently electrophilic fluorination 
is an unfavoured method. However there are still some 18F radiotracers such as [18F]fluoro-
L-DOPA and 2-L-[18F]fluorotyrosine which depend on electrophilic fluorination methods for 
their preparation.7,8  
Nucleophilic fluorination methods are much more widely used as they provide greater 
selectivity and higher specific activities. Radiotracers widely used in cancer detection, 
such as [18F]-2-deoxy-2-fluoroglucose ([18F]FDG) [18F]-32 and 3’-deoxy-3’-
[18F]fluorothymidine ([18F ]FLT)9,10; radiotracers used in dopamine studies, [18F]fallypride,11 
[18F]haloperidol12 and [18F]spiperone13; popular hypoxia imaging radiotracers such as 
[18F]fluoroazomycin arabinose ([18F]FAZA) and [18F]Fluoromisonidazole ([18F]FMISO) 14 
are all prepared via nucleophilic fluorination (Table 1).  
Nucleophilic 18F– is produced in a cyclotron by bombarding 18O-enriched water ([18O]H2O) 
with high energy protons. This reaction generates a dilute solution of [18F]F– along with 
some unreacted [18O]H2O. In order to separate the [18F]F– from its aqueous environment 
the reaction is passed through an ion exchange column. 18F– produced is then trapped on 
the column and unreacted [18O]H2O is recovered.7 The trapped 18F– is eluted in a 
water/acetonitrile solution containing potassium carbonate. The aqueous fluoride obtained 
is a poor nucleophile due to its high degree of solvation, therefore the production is 
followed by the removal of water and the phase-transfer reagent kryptofix-222 (K222) is 
added to bind the potassium (K+) counter ion, improving the reactivity of [18F] fluoride ion 
for nucleophilic substitution reactions.7,8 
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In order for radiotracers to be successful imaging probes for PET, they should fulfil the 
following requirements; the positron-emitting isotope should be chemically linked to the 
tracer so as not easily dissociate chemically or removed metabolically. Isotope labelling 
should not alter the behaviour or chemical properties of the parent molecule. The 
radiotracer should efflux from non-target sites and blood to achieve a good image contrast 
between the background and the target tissue which would increase the spatial 
resolution.5,15 
 
2.1.2 [18F]FDG [18F]-32 as PET radiotracer 
 
The most common radiopharmaceutical, used in over 90% of PET imaging is [18F]-2-
deoxy-2-fluoroglucose ([18F]-FDG) [18F]-32, which is the fluorinated analogue of D-glucose 
where the 2-hydroxyl group has been replaced with 18F.8,16 [18F]FDG [18F]-32 is used to 
analyse glucose utilization and metabolism of tumours, as they require a higher rate of 
glucose uptake, which leads to higher accumulation of [18F]-32. When [18F]-32 is injected 
into a subject it is transported through the blood stream to cells, where specific glucose 
transporters (GLUT 1) recognise these molecules and transport [18F]-32 across the cell 
membrane.17 Usually glucose molecules taken up this way are processed through several 
enzymes in the glycolysis pathway to form pyruvate which enters Krebs’s cycle and plays 
a key role in cellular respiration.  
 
[18F]FDG [18F]-32 also enters the glycolysis pathway and is phosphorylated at C-6, by 
hexokinase to generate FDG-6-phosphate 33. Unlike glucose however, [18F]-32 lacks the 
2′-hydroxyl group and therefore, cannot act as a substrate for the second enzyme in the 
pathway, glucose-6-phosphate isomerase. Efflux of the phosphorylated [18F]FDG-6-P 33 
from the cell is low, thus [18F]FDG [18F]-32 accumulation can be measured by PET (Figure 
2). In addition [18F]-32 is removed through the renal system and unlike glucose, is not 
reabsorbed well in renal tubules, which leads to reduced levels of [18F]-32 in the blood. 
This provides a high contrast between the background and the target of interest being 
imaged. Tumours are associated with high energy demands, a decrease in glucose-6-
phosphate and upregulation of glucose transporters (GLUT-1) and hexokinase which 
















[18F]FDG [18F]-32 can be synthesised by either electrophilic fluorination or nucleophilic 
fluorination. The first synthesis of [18F]-32 was based on direct electrophilic substitution. 
3,4,6-Tri-O-acetyl-D-glucal 34 was used as a precursor and treated with [18F]F2 to produce 
18F-labelled difluoro-glucose 35 with mannose derivatives. The 18F-labelled difluoro-
glucose 35 was then hydrolysed with HCl to form [18F]-32 (Scheme 1A) with a yield of ~8% 
in a 2 h synthesis. In order to increase the yield and reduce the synthesis time, attempts 
were made to develop a nucleophilic approach for [18F]FDG [18F]-32 synthesis.19 This was 
achieved in 1986 when Hamacher et al. reported a method by which Kryptofix 222 was 
used to increase the reaction yield to over 50% and in under 50 min reaction time. The 
method involves fluoride displacement of triflates (Scheme 1B).20 To date [18F]FDG [18F]-







Figure 2: GLUT1 transporters 
transport [18F]FDG 32 into the 
cell cytosol which is 
phosphorylated by hexokinase 
forming [18F]FDG-6-phosphate 
33. This gets trapped inside the 













Scheme 1: A) [18F]FDG [18F]-32 synthesis by electrophilic fluorination using [18F]fluoride 
ion. B) [18F]FDG [18F]-32 synthesis by nucleophilic fluorination using kryptofix222 as a 
catalyst. 
 
The success of [18F]FDG [18F]-32 in PET has encouraged further research on the 
incorporation of 18F into novel tracers. Some of the currently known fluorinated PET 













Table 1: Some [18F]-labelled PET radiotracers produced from [18F]F–. 21 
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2.2 Application of the fluorinase for producing [18F]-labelled PET radiotracers 
A current challenge in the 18F-labelled PET radiopharmaceuticals industry is to develop 
efficient chemistry for the rapid and clean synthesis, along with straightforward purification 
protocols to produce PET radiotracers in an appropriate time scale. Enzymatic methods 
are in principle attractive due to their chemoselectivity and low generation of side-products. 
Enzymes enable fast chemical conversions yielding highly pure products under mild 
aqueous conditions. Until now, there are only a few examples in PET radiotracer synthesis 
where enzymes have been used to introduce isotopically-labelled atoms, mostly because 
enzymes are substrate specific and finding suitable enzymes for a particular reaction 
maybe difficult in addition to having stability issues.22–24 There are few examples where 
enzymes have been used for synthesis of different 11C 25,26 and 13N 27 labelled radiotracers. 
The identification of the fluorinase enzyme has opened up an enzymatic approach to 
incorporating 18F into compounds.  
 
It has been reported that 18F-labelled fluorodeoxyadenosine analogues have potential as 
tumour imaging radiotracers28 therefore, the use of [18F]-FDA ([18F]-23) as a potential PET 
radiopharmaceutical was considered.29 In 2003 the first radiolabelling study with the 
fluorinase was carried out for the production of [18F]-23.29 A partially purified fluorinase 
fraction from S.cattleya was incubated at 40 °C with [18F]F– and SAM-Cl 22 to form [18F]-
23. The reaction time was 5 h and the radiochemical yield (RCY) was ~1%, clearly too 
inefficient for a PET radiotracer synthesis. Subsequently, realisation of the revers ibility of 
the fluorinase reaction lead to optimisation where various enzymes were used in coupled 
reactions to obtain novel [18F]-labelled purine nucleosides. Over-expressed fluorinase was 
coupled to an L-AAO which actively removes L-methionine 27 and supresses the reverse 
reaction to produce [18F]-23. This protocol increased the rate of [18F]-23 synthesis and 















Scheme 2: Fluorinase mediated 18F labelling, coupled to various enzymes to produce 18F-
labelled compounds.30,31 
Furthermore various [18F]-nucleosides were synthesised by coupling the fluorinase to 
appropriate nucleoside phosphorylases (mediating base swap reactions). In the 
biosynthetic pathway of S. cattleya (Scheme 5 Chapter 1), 5′-FDA 23 is converted to 5-
FDRP 24 by a PNP in a reversible reaction. The reversibility of this reaction was exploited 
for its ability to ‘swap’ adenine 29 with another purine base (Scheme 2). 5-FDRP 24 
produced by PNP was incubated with 2, 6-diaminopurine to produce the fluorinated 
nucleoside, [18F] labelled 2-amino-5′deoxy-5′-fluoroadenosine 35. 5′-Fluorinated uridine 
derivatives such as fluorouracil 36 were produced by coupling the fluorinase reaction to a 
pyrimidine nucleoside phosphorylase isolated from Bacillus stearothermophilus. This 
enzyme catalyses the reversible phosphorolysis of uridine and thymidine by displacing the 
pyrimidine base. These experiments illustrate the use of the fluorinase and the versatility 
of these base swap bio-transformations to generate a variety of 5’-deoxy-5’-
fluoronucleosides 32,33. 
 
The fluorinase reaction was also coupled to an adenylate deaminase isolated from 
Aspergillus sp. to produce [18F]-5′-fluoro-5′deoxyinosine ([18F]-5′-FDI) 34 as shown in 
(Scheme 2). This provided access to another labelled purine nucleoside. In addition 
coupling of the fluorinase to a PNP and then a phytase, which catalyse a depurination and 
hydrolysis of phosphate, respectively generated [18F]-5-fluoro-5-deoxy-D-ribose ([18F]5-





[18F]-FDA [18F]-23 was explored for its role as a potential PET radiotracer by incubating 
with human breast cancer cells (MDA-MB-453). [18F]-FDA [18F]-23 showed active uptake 
by cancer cells, and addition of cold adenosine 47 decreased [18F]-23 uptake significantly, 
suggesting that [18F]-23 uptake is probably facilitated by adenosine transporters.34 
Comparison of the influx and efflux data showed that only about 60% [18F]-23 remained 
inside the cancer cells.29,30,34 However small animal PET studies demonstrated that [18F]-
23 experiences rapid defluorination to release [18F]F– in vivo which binds avidly to bone. 
Accumulation of radioactivity in bone disrupts the spatial resolution of PET which would 
make imaging inaccurate. Therefore [18F]-23 was ruled out as an unsuitable radiotracer 
for PET.35  
 
In addition to the above mentioned 18F-labelled compounds (Scheme 2), [18F]FAc [18F]-10 
was explored as a radiotracer with selective uptake and metabolism in glial neurones in 
the brain.36 [18F]FAc could be used as an acetate analogue in place of [11C] acetate, which 
has much shorter half-life, to observe acetate metabolism in prostate tumours.37,38 A 
chemo-enzymatic synthesis was designed for the preparation of [18F]-23. Fluorinase was 
incubated with SAM-Cl 22 and [18F]F– to produce [18F]-23, a product, which was then 
chemically oxidised with a solution of chromium trioxide and sulfuric acid to form [18F]-10. 
The tracer was obtained as the sodium salt in high RCY.38 
 
Cell uptake studies in human breast cancer cells (MDA-MB-453) done previously have 
demonstrated almost 10 fold higher uptake of [18F]5-FDR ([18F]-37) in comparison to [18F]-
FDG ([18F]-32). 31 Therefore the prospects of producing [18F]-37 in sufficient quantities and 
purity for PET were explored.  
 
2.2.1 Shortened enzymatic route to produce [18F]-5-FDR [18F]-37 
The three-step enzyme route coupling the fluorinase to a purine nucleoside phosphorylase 
(PNP) and then a phytase produced [18F]5-FDR [18F]-37 with a ~45% RCY in 4 h. This was 
an inefficient route to produce [18F]-37, and an alternative shorter route was considered. 
An alternative approach to synthesise [18F]-37 was proposed, by coupling the fluorinase 
reaction to an enzyme which acts upon [18F]-23 directly by hydrolysing the N-glycosidic 










Scheme 3: Three enzyme route reduced to two enzyme route as TvNH catalyses the 
hydrolysis of adenine 29 from [18F]-23 to form [18F]-37.31 
 
The two enzyme routes to produce [18F]-37 required the fluorinase to be coupled to a 
nucleoside hydrolase, isolated from the parasitic protozoa, Trypanosoma vivax (TvNH).31 
TvNH hydrolyses the N-glycosidic bond of inosine, adenosine 47 and guanosine most 
efficiently and therefore was considered to catalyse the direct conversion of 23 to 37, 
substituting the PNP and phytase enzymes of the three step route.31 
 
2.2.2. Nucleoside hydrolase  
 
Nucleoside hydrolases (NHs) are a group of enzymes that catalyse the hydrolysis of the N-
glycosidic bond between the anomeric carbon of ribose 39 and the purine or pyrimidine 
base of -ribonucleosides forming the free nucleic acid base and ribose 39 (Scheme 4). 
These enzymes are widely distributed across many organisms such as: bacteria 39–41, 
protozoa42,43, yeast44, insects45, plants46,47 and archaea 48,49 but never in mammals. 
Therefore, these enzymes are attractive targets for drug design against parasitic protozoa50 
and several parasitic protozoan NHs have been studied intensively.  
All parasitic protozoa are unable to synthesise purine nucleotides de novo, therefore 
salvage enzymes are used to obtain purine bases and nucleosides from their hosts. NHs 
have high specificity for the ribose 39 moiety, however they show varying preferences to 
different nucleoside bases. Nucleoside Hydrolases are divided to four classes according to 
their substrate specificity. Base non-specific NHs which hydrolyse inosine and uridine (IU-
NHs) 42,43; purine-specific inosine/adenosine 47/guanosine NHs (IAG-NH) 51; the 6-
oxopurine-specific guanosine/inosine NHs52; and the pyrimidine nucleoside-specific 







Scheme 4: TvNH catalyses the irreversible hydrolysis of the N-glycosidic bond of β-





Trypanasoma vivax nucleoside hydrolase (TvNH) is a key enzyme involved in the purine 
salvage pathway of Trypanosoma vivax.55 It belongs to the IAG-NH class of enzymes and 
thus prefer inosine, adenosine 47 and guanosine nucleosides. TvNH has Km of 5M for 
inosine, 8.5 M for adenosine 47, and 3.8 M for guanosine whereas Km for pyrimidines 
such as cytidine and uridine are above 500M demonstrating the high affinity for purines.55  
The crystal structure of TvNH demonstrate that it exists as a homodimer with a hydrophobic 
interface and has two active sites which function independently as demonstrated by kinetic 
assays which showed no co-cooperativity in binding. Sodium dodecyl sulphate- 
polyacrylamide gel electrophoresis (SDS-PAGE) analysis confirmed the molecular mass of 
TvNH monomer to be ~37000 Da. The co-crystallised structure of TvNH with 3-deaza-
adenosine revealed an octa-coordinated calcium ion bound to the lower part of the active 
Figure 3: Schematic representation 
of the active site of TvNH bound to 3-
deaza-adenosine. The catalytic 
water is indicated in red. Image 
reproduced and modified with 
permission from Steyaert et al. 55 
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site which interacts with the 2′OH and 3′OH groups of the ribose ring (Figure 3). TvNH is 
believed to catalyse the N-glycosidic bond cleavage by a direct displacement mechanism. 
The Asp-10 from a conserved motif acts as a general base and abstracts a proton from a 
catalytic water molecule (shown in red in Figure 3), which then attacks the C1′ atom of the 
ribose moiety of the nucleoside. Ca2+ is thought to be involved in lowering the pKa of the 
water molecule prior to proton transfer to Asp-10. Subsequently Asp-40 donates a proton 
to N-9 of the purine base. All hydroxyl groups of 39 are shown to interact with residues in 
the active site, and interactions with 5′-OH are shown to be involved in substrate binding 
whereas interactions with 2′OH and 3′OH are required for stabilising the intermediate, 
oxocarbenium ion. The purine leaving group is shown to be involved in extensive aromatic 
stacking interactions with Trp-83 and Trp-260.55  
5′-FDA 23 became a potential substrate of interest for TvNH as it contains a ribose ring with 
the 5′-OH group substituted to fluorine, which has not been studied with this enzyme before. 
Previous experiments performed by Onega 34 had established that purified TvNH can 
effectively catalyse the conversion of 23 to 37 when incubated with synthetically prepared 
23 in buffer supplemented with CaCl2 at 37 °C for 2-4 h.34 Efficient synthesis of [18F]-37 with 
considerable RCY was necessary in order to explore [18F]-37 as a PET radiotracer and thus 
optimisation of the coupled enzyme reaction was attempted.  
 
2.2.3 Previous studies conducted on production of [18F]5-FDR [18F]-37 using the 
fluorinase 
 
The TvNH enzyme and fluorinase were over-expressed in E.coli and purified. The purified 
enzymes were then used in their aqueous form in a one-pot enzyme reaction to generate 
[18F]5-FDR [18F]-37 which ultimately proved to be inefficient and slow. Through optimisation, 
a sequential one-pot reaction proved to be considerably more efficient. Fluorinase and L-
AAO were incubated with SAM-Cl 22 in the presence of [18F]F– at 37 °C, pH 7.0. The L-
methionine 27 produced during the reaction is removed by L-AAO promoting the forward 
reaction. The reaction was analysed by radio-HPLC and a RCY of 97% to [18F]-FDA [18F]-
23 was observed after 1 h. Subsequently the reaction was heated to 95 °C to denature the 
fluorinase and L-AAO and the precipitated protein was removed by centrifugation. To the 
supernatant, TvNH was added at a final concentration of 20 mg/ml in HEPES buffer (pH 
8.0) and incubated for further 2 h at 37 °C. Post incubation, the [18F]-37 production was 
analysed by radio-HPLC to be ~ 80% RCY. 31 The three-enzyme route produced 45% RCY 
in 4 h 30compared to which this two enzyme approach had increased the RCY considerably, 
and somewhat managed to reduce the reaction time.31  
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Despite reducing the incubation time of the two-enzyme route to 3 h, the actual processing 
time including: heat denaturing of the enzymes, centrifugation, removing any unreacted 
[18F]F–and [18F]-23 by HPLC, increased the total preparation time to 4 h.31 Therefore further 
optimisation of this reaction was encouraged. Preliminary experiments revealed that 
increasing both fluorinase and TvNH enzyme concentrations increased the rate of the 
reaction, however due to the reduced reaction volumes (600-700 l), it was necessary to 
implement a method by which the two enzyme concentrations could be increased evading 
the dilution of the reaction. In addition previous studies used HPLC to separate and remove 
any unreacted [18F]F– and [18F]-23 which was found to be time consuming and added to the 
total preparation time [18F]-37 with an increased risk of radioactive exposure. Therefore, an 
alternative approach to removing any unreacted [18F]F– and [18F]-23 was explored. The 
focus of this chapter was to develop a safe, practical and user-friendly method of producing 
[18F]-37 in a clinical environment.56  
 
2.3 Project aims 
 
The current trend is to develop enzymatic processes of organic synthesis, as the enzymes 
are attractive catalysts that match the fundamental principles of sustainable development 
and green chemistry.57,58 Enzymes are considered costly with limited availability and may 
be unstable with a narrow substrate specificity. These issues are being addressed by 
ongoing advances in genetics and protein engineering.59 Gene mining is increasing the 
number of genes/enzymes available and developments in enzyme immobilisation 
techniques have rendered enzymes much more stable for process development.58,60 
Natural enzymes or genetically modified enzymes are available which can be screened for 
broader specificity acting on non-natural substrates. Despite their high potential, enzymes 
are not immediately attractive as catalysts in synthesis of PET radiotracers as the industry 
is not sufficiently acquainted to deal with biological material.  
 
Studies conducted by Onega et.al demonstrated the use of fluorinase and TvNH in a 
sequential one pot reaction to form [18F]-37 as a prospective PET radiotracer.31 A practical 
method for producing [18F]-37 in the clinical environment in a ready to use, ‘off the shelf’ 
formulation using two enzymes was designed. And thus, preparation of a two enzyme kit 
for use in radiochemical laboratories, would offer a user-friendly technology for [18F]-37 
production. It was an objective to increase the RCY for [18F]-37 production and further 
reduce the reaction time. The enzymes (fluorinase and TvNH) were freeze-dried in their 
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buffers to produce a potentially portable kit, where rehydration on site would then provide 













Figure 4: The project aim was to produce a PET ‘enzyme kit’ using freeze-dried fluorinase 
and TvNH which could be used by radiochemical laboratories to produce [18F]5-FDR [18F]-
37 in good RCY.  
 
2.4 Results and discussion 
 
2.4.1 Over-expression of the fluorinase 
 
The first attempt at purifying the fluorinase was reported in 2003,61 where an ammonium 
sulphate precipitation was performed on a cell free extract (CFE) of S.cattleya. The proteins 
were separated according to their solubility in the presence of a high concentration of 
ammonium sulphate.62 Subsequently the precipitate was applied to a gel filtration column 
and the fractions obtained were evaluated for fluorinase activity. Partial amino acid 
sequence of the fluorinase was obtained from these fractions and used to design 
degenerate DNA primers, which in turn were used to amplify the corresponding gene 
fragments by PCR (polymerase chain reaction). Amplified gene products were cloned into 
a suitable vector and sequenced. The sequencing data was used to design primers to 
perform gene walking to reveal the complete flA gene.63 Subsequently the flA gene was 





The protocol for over-expression using E.coli containing pET28-flA in Luria Broth (LB) 
media has been reported previously and is described in detail (Experimental 2.6.1).63 
Cloning of the flA gene into the pET28 (+) vector offers the advantage of conferring 
kanamycin resistance to the E.coli carrying the pET28-flA recombinant plasmid. 
Furthermore an N-terminal poly-histidine tag (His6-tag) is incorporated to the translated flA 
gene product which is useful during the purification of the final protein. Small scale cultures 
of E.coli carrying pET28-flA in LB were used to inoculate larger cultures supplemented with 
kanamycin (50 g/ml). These cultures were shaken at 37 °C until the optical density (OD600) 
reached 0.6, following which protein expression was induced by isopropyl β-D-1-
thiogalactopyranoside (IPTG). The cultures were then incubated at 25 °C for 16 h before 
harvesting the cells by centrifugation.  
 
The harvested cell pellet was re-suspended in lysis buffer supplemented with 
Deoxyribonuclease I from bovine pancreas and protease inhibitor cocktail.64 The cell 
suspension was lysed by sonication at 4 ºC and centrifuged to remove the cell debris. The 
lysate was purified by affinity chromatography using Ni-NTA (Ni-Nitrilotriacetic acid) 
agarose. The fluorinase was eluted from the Ni-NTA column by applying an elution buffer 
containing high concentration of imidazole which displaces the His6-tagged fluorinase. The 
fractions obtained from the affinity purification were analysed by SDS-PAGE (Figure 5). 
Eluted fractions are shown to contain fluorinase monomer at 32 kDa and dimer at ~64 kDa 
(confirmed by matrix-assisted laser desorption/ionisation time of flight mass 
spectrophotometry (MALDI-TOF)). The presence of the dimer is possibly due to incomplete 
denaturing during sample preparation for SDS-PAGE analysis. Some fluorinase was also 
present in the insoluble fraction which accounts for misfolded proteins during over-
expression. However sufficient fluorinase was obtained in the soluble fraction. The elution 
fractions containing fluorinase were pooled and dialysed in 20 mM Tris-HCl pH 7, 150 mM 
NaCl. Further purification of the fluorinase fraction was carried out by size exclusion 
chromatography (SEC) (Figure 6) which differentiates proteins according to their molecular 
weight. In order to obtain fluorinase free from impurities the cleanest fractions were pooled 
and run on SDS-PAGE (Figure 7). The identity of the fluorinase was confirmed by MALDI-
TOF. The fractions obtained from SEC containing protein were pooled, concentrated and 
the protein concentration was measured by Nanodrop. This method produced high yield of 













Figure 5: The SDS-PAGE gel electrophoresis of fractions obtained from Ni2+ affinity 
purification of fluorinase M: un-stained PageRuler protein ladder, I- insoluble fraction, S- 













Figure 6: Size-exclusion column chromatography of S. cattleya fluorinase showing the UV 


















Figure 7: SDS-PAGE of the fractions obtained from size exclusion column 
chromatography: M- un-stained PageRuler protein ladder, SEC fractions- fractions 
containing fluorinase.  
2.4.2 Over-expression of the TvNH  
 
The over-expression and purification of TvNH was carried out by modification of previously 
established protocol 55,65 and is described in detail in the Experimental 2.6.2WK6 E.coli cells 
were transformed66 with recombinant pQE-30-TvNH. The pQE-30 plasmid carries an ampR 
gene which confers ampicillin resistance. In addition the plasmid was designed to 
incorporate an N-terminal His6-tag into TvNH. The recombinant plasmid, pQE30-IAGNH 
was kindly donated by Prof J. Steyaert and Dr J. Barlow (Vrije Universtiteit Brussel, 
Belgium).  
WK6 E.coli with pQE-30-TvNH was used to inoculate large shake flasks containing LB (1 
L) supplemented with ampicillin. The flasks were incubated at 37 °C shaking until the OD600 
reached 0.6 and the over-expression was induced by adding IPTG (0.5 mM). The cells were 
grown for 16 h at 28 °C and harvested by centrifugation. The cell pellet was re-suspended 
in lysis buffer supplemented with Deoxyribonuclease I from bovine pancreas and protease 
inhibitor cocktail. The cells were lysed by sonication at 4 ºC and centrifuged to remove cell 
debris. The lysate was purified by affinity chromatography by applying the cell lysate on to 
Ni-NTA agarose. TvNH was eluted with elution buffer containing high imidazole 
concentration and analysed by SDS-PAGE confirming the presence of TvNH ~ 35 kDa in 
the elution fractions (Figure 8A). The SDS-PAGE also showed the presence of a ~70 kDa 
protein which was confirmed by MALDI-TOF to be the dimer of TvNH due to partial 
denaturation prior to SDS-PAGE. The fractions containing TvNH were pooled and dialysed 
against 20 mM HEPES pH 7, 150 mM NaCl supplemented with CaCl2 (1 mM) to remove 
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imidazole 40 and permitting CaCl2 to bind the active site and stabilise the TvNH protein. 
Subsequently TvNH was further purified by SEC (Figure 8B) and the fractions obtained 
were run on SDS-PAGE (Figure 8A). The fractions containing protein was pooled, 
concentrated and the protein concentration was measured by Nanodrop. This method 



















Figure 8: A) The SDS-PAGE gel electrophoresis of fractions obtained from Ni2+ affinity 
purification M- un-stained PageRuler protein ladder (Thermo scientific), I- insoluble fraction, 
S- soluble fraction F- flow-through, W1- wash 1, W2- Wash 2 E- elution and fractions 
obtained from SEC of TvNH. B) Size-exclusion column chromatography (SEC) of TvNH 







2.4.3 Enzyme immobilisation  
 
In order to produce a user-friendly PET ‘enzyme kit’ it was a requirement to immobilise 
fluorinase and TvNH on a solid support as the aqueous protein may decompose during 
transportation and storage. It was envisaged that a Ni-NTA resin would be suitable to trap 
the purified fluorinase and TvNH through their His6-tags which had been used to purify the 
proteins. These enzyme-bound resins could then be incubated with a reaction mixture 
containing the substrates, SAM-Cl 22 and KF and washed with buffer containing no 
imidazole 40, which would elute the products/unreacted substrates but the enzymes will 
remain secured. 
 
Purified fluorinase (2 mg) and TvNH (6 mg) was applied to a cartridge containing 1 ml of 
Ni-NTA agarose™ (Qiagen). A cocktail containing SAM-Cl 22 (20 M) and KF (100 mM) in 
20 mM Tris-HCl pH7 buffer with 10 mM NaCl (Figure 9, reaction mixture) was applied to 
the column and the flow-through was collected. Prior to loading the column a sample of the 













Figure 9: HPLC analysis showing the reaction mixture containing SAM 22 and KF prior to 
loading the cartridge containing immobilised fluorinase, first wash with buffer and elution with 
high imidazole containing buffer.  
The cartridge was loaded with the reaction mixture and incubated for 1 h, after which was 
washed with 20 mM Tris-HCl (5 ml) (Figure 9, wash) following this the sample was 
freeze-dried and analysed by HPLC. The wash did not contain detectable quantities of 5′-
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FDA 23 or adenine 29, demonstrating that either the substrates, (22 and 23) were 
inaccessible to fluorinase/TvNH or any products generated were trapped within the Ni-NTA 
agarose. The cartridge was washed with buffer containing high imidazole 40 concentration 
(400 mM) to elute both bound enzymes/substrates/products. The eluted fraction was heat 
treated (95 ºC) to precipitate the enzymes and the aqueous fraction analysed by HPLC 
(Figure 9, elution). The HPLC data showed only the presence of 23 in the eluted fraction 
suggesting 22 was converted to 23. This suggests that 23 was possibly trapped in the 
immobilised fluorinase inaccessible to TvNH or 23 released from the fluorinase was bound 
by the Ni2+ via it adenosine moiety. The adenosine moiety of 23 and imidazole 40 are 
structurally similar (Figure 10) and is possible that 23 released from fluorinase was trapped 
by Ni-NTA beads. It is possible that the nitrogen atoms in the adenosine ring of 23 could 
participate in Ni2+ chelation, resulting in 23 being bound the Ni-NTA beads. Maher et al. had 
observed this previously and exploited it in trapping DNA and RNA molecules containing 
an oligo(adenosine) tract using Ni2+-NTA.67 These data suggest that 23 is produced, but 
trapped and is not processed by immobilised TvNH. 
 
As such an alternative method of ‘immobilising’ the two enzymes was considered. A freeze-
dried preparation of enzymes would potentially provide convenience in both transportation 






Figure 10: Structural similarity between 5′-FDA 23 and imidazole 40. 
 
2.4.4 Lyophilisation of the enzymes  
 
In protein pharmaceuticals it is important to design a formulation which is stable during 
transport and storage. During production, an aqueous solution of protein is easier to handle, 
economical and is the most convenient for the end user. However, protein solutions are 
inclined to chemical (eg: deamidation or oxidation) and physical (eg: aggregation and 
precipitation) degradation.68 The degradation of protein solutions can be reduced by storing 
at low temperature (~ 4 ºC) with minimal agitation, however these conditions cannot be 




Lyophilisation is a technique used widely in the pharmaceuticals and food industry in order 
to increase the shelf life, stability and transportability of products. It is a process where the 
water in the sample is frozen and then removed by sublimation in a three step process 
consisting of freezing, primary drying and secondary drying. The freezing stage takes 
several hours as the water is solidified and separates solutes from ice. The primary drying 
involves the sublimation of ice which commences as the pressure in the chamber is reduced 
to well below the vapour pressure (partial vacuum) of ice and sufficient heat is supplied to 
assist the sublimation process. Secondary drying then commences as most of the water 
had sublimed and at this stage any residual water bound to protein is removed by further 
increasing the temperature and further lowering the pressure. 69,70 
 
Most commercially available enzymes are available in their freeze-dried form for storage, 
handling and transport. Although lyophilisation has its advantages, the use of cold 
temperature in the freezing process can denature proteins due to cold shock,69 along with 
pH changes and dehydration stress. The cold denaturation is dependent on the 
temperature, pH and the nature of additives. Some proteins are freeze-dried in the 
presence of an excipient system to stabilise the protein against the stress induced by 
freezing. Mostly proteins are susceptible to denaturing during the secondary drying stage 
due to the removal of the water layer hydrating to the protein, a process which de-stabilises 
the native conformation of the protein. Stabilising agents such as sucrose, mannitol and 
trehalose (lyoprotectants) are used to avoid protein denaturation during freeze-drying.71 
Carpenter and Crowe et al. 72,73 have shown by fourier-transform IR (FITR) that specific 
carbohydrates have the capability to protect proteins from denaturing by forming H-bonds 
substituting the role played by water. Some enzymes are shown to lose over 50% of their 
activity in a concentration dependent manner during the lyophilisation process in the 
absence of lyoprotectants.74 This suggests that freeze-dried enzymes will benefit from 
added lyoprotectants. 
 
2.4.5 Heat mediated SAM-Cl 22 decomposition  
 
All of the fluorinase assays monitored by HPLC were observed to have a distinct peak with 
a retention time of around 11.4 min. Assays conducted with control samples of each 
compound added to the reaction showed it was originating from 22. It was observed that 
this was a heat decomposition product of 22 (Figure 11) and was identified as 5′-deoxy-5′-

















Figure 11: HPLC chromatogram demonstrating that SAM-Cl 22 decomposes to MTA 41 
when heated.  
The stability and hydrolysis products of 22 have been described in literature.75,76 According 
to Stolowitz and Minch, heating 22 at 100 °C in the pH range of 4-7 produces 41 and -
amino--butyrolactone 42, followed by further decomposition to homoserine 43 (Scheme 5). 
SAM-Cl 22 decomposition was explored by analysing samples of heat treated 22 (95 °C for 
10 min) along with reference compounds of 22 and 41 by HPLC (Figure 11). The reference 
22 sample which was not heat treated produced negligible amount of 41 relative to the heat 
treated 22 which produced considerable amount of 41. During the fluorinase assays the 
reactions are stopped by denaturing the enzyme via heating, during which residual 22 










2.4.6 Use of a sucrose-glycine excipient system for enzyme lyophilisation 
 
A sucrose-glycine excipient with the addition of polysorbate 80, enabled complete recovery 
of model proteins as described in the literature.71,77 Therefore, fluorinase and TvNH were 
freeze-dried in their respective buffers at 0.2 mg/ml concentrations containing a 
lyoprotectants cocktail of sucrose (18 mg/ml) and glycine (2 mg/ml) and polysorbate 80 (0.1 
mg/ml) as described in the Experimental 2.6.4. When freeze-dried with these lyoprotectants 











The activity of the freeze-dried fluorinase and TvNH was analysed before (in the aqueous 
form) and after freeze-drying. Fluorinase (0.2 mg/ml), either freeze-dried in a sucrose-
excipient system or in its aqueous form was incubated with SAM-Cl 22 (20 M) and KF 
(100 mM) for 30 min at 37 °C. Each reaction was heat treated (95 ºC) and centrifuged to 
precipitate the enzyme. Each reaction was monitored by HPLC which revealed the 
production of 5′-FDA 23 and unreacted SAM-Cl 22 with its heat-mediated, decomposition 
product MTA 41 (Figure 13A). Some adenosine 47 was also visible by HPLC which was 
residual from fluorinase precipitation. Similarly the activity of TvNH was analysed by 
incubating with adenosine 47 (20M), which is a natural substrate55 for TvNH and 
monitoring its conversion to adenine 29 by HPLC (Figure 13B). The activity of the freeze-
dried enzymes relative to aqueous enzymes was analysed by HPLC. The production of 23 
and adenine 29 was observed by HPLC in multiple runs and the activity of the enzymes 
was calculated as a percentage of the activity of the aqueous enzymes. The data indicates 
a clear reduction in enzyme activity for both freeze-dried enzymes relative to aqueous 
enzymes. A 19% reduction of activity for freeze-dried fluorinase and 11% reduction of 
activity for freeze-dried TvNH relative to aqueous enzymes were observed. Despite the loss 
of activity observed when both enzymes were freeze-dried, freeze drying was found to be 
a better method for enzyme preparation for the enzyme kit considering the advantages of 
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freeze-drying which may prolong the stability during storage 78,79 of the enzyme and may 




















Figure 13: A) HPLC chromatogram of fluorinase enzyme assays with either freeze-dried 
or aqueous enzyme. (SAM-Cl 22; tR = 2.3 min (blue), adenosine; tR= 3.7 min (yellow), 5′-
FDA 23; tR= 13.7 min (green), MTA 41; tR = 11.4 min (orange) B) HPLC chromatogram of 
TvNH enzyme assay with either freeze-dried or aqueous enzyme (adenine 29 tR = 3.5min 





Similar activity studies were carried out to assess if freeze-drying with or without sucrose-
glycine excipient system would have a significant effect on the activity of either enzymes. 
Multiple HPLC assays were carried out on both fluorinase and TvNH that were either freeze-
dried with or without a sucrose-glycine excipient system. The production of 5′-FDA 23 
(Figure 14A) or adenine 29 (Figure 14B) was monitored as before and the activity of the 
enzymes were calculated as a percentage of the freeze-dried enzymes with lyoprotectants. 
A 5% loss of activity was observed in fluorinase freeze-dried without lyoprotectants and ~2% 
loss of activity was observed for TvNH when freeze-dried without any lyoprotectants.  
 
However, when using the freeze-dried enzyme preparations with lyoprotectants for 
generating 5-FDR 37 the formulation was found to be very viscous. This was not an issue 
when performing cold reactions with non-labelled F– however when using labelled [18F]F– 
where the reaction volumes were reduced to 1/2 that of the volumes used in cold reactions 
this stickiness posed a problem in the handling and transferring of samples. Therefore it 





























Figure 14: A) HPLC chromatogram of fluorinase assay using either enzyme freeze-dried 
with lyoprotectants or freeze-dried without lyoprotectants. SAM-Cl 22; tR = 2.3 min (blue), 
adenosine 47; tR= 3.7 min (yellow), 5′-FDA 23; tR= 13.7 min (green), MTA 41; tR = 11.4 min 
(orange) B) HPLC chromatogram of TvNH enzyme assay either freeze-dried with 
lyoprotectants or freeze-dried without lyoprotectants adenine 29 tR= 3.5min (purple) 







2.4.7 Evaluating long term enzyme stability during storage 
 
The major requirement in the designing of an enzyme kit for the efficient production of 
[18F]5-FDR [18F]-37, is that the enzymes should be stable over a few weeks during storage. 
Thus the activities of the freeze-dried enzymes were assayed over a 4 week period as 
described in the Experimental 2.6.6.  
 
The activity of both enzymes was monitored either by HPLC and 19F NMR for the fluorinase 
and TvNH, respectively. Fluorinase was purified and freeze-dried with buffer (1 mg) and 
stored at -20 °C over eight weeks. Every week an aliquot of the fluorinase was removed 
and incubated with SAM 22 (0.2 mM), KF (100 mM) and sodium benzoate 44 (2 mM) (as 
an internal standard). This reaction was incubated at 37 °C and every 5 min an aliquot was 
removed, heat-treated, centrifuged and the supernatant was analysed by HPLC. In order 
to assess the activity of the enzyme, it was necessary to quantify the concentration of 23. 
For this an internal standard of 44 was used in each reaction. Sodium benzoate 44 was 
chosen as the internal standard as its retention time (tR= 9.8 min) is close to the retention 
time of 23 (tR= 13.2 min), and is a non-participating reference. The concentration of 23 
produced at each time point was calculated relative to the known concentration (2 mM) of 
44. The level of 23 was measured at each time point as a ratio of the peak height of 44. 
Figure 15A depicts the increase in 23 production over time. Some un-reacted 22 along with 
the decomposed 22 derivative, MTA 41 could also be seen in the HPLC traces. 
 
TvNH was purified and freeze-dried in aliquots (20 mg) and stored at -20 °C over eight 
weeks. Every week an aliquot of TvNH was removed and assayed. The progress of the 
assays were monitored by 19F NMR over 3 h (Figure 15B). TvNH was incubated with 5′-
FDA 23 (0.5 mg) at 37 °C and samples were removed every hour for 3 h. The samples 
were heat treated to remove the enzyme, supplemented with D2O and analysed by 19F NMR. 
In order to quantify the 5-FDR 37 production a known concentration of an internal standard, 
2-fluoroethanol 45 (1 mM) was used. Integration of the 37 peaks relative to the standard, 
provided the concentration of the 37 α/β anomers depicted in the 19F NMR spectra as the 
reaction progressed with time, the production of both anomers of 37 can be observed as 































Figure 15 : A) A time course of HPLC assays over 30 min showing the production of 5′-
FDA 23 by freeze-dried fluorinase which was stored at -20 °C for a week.(SAM-Cl 22; tR = 
4.14 min (blue), NaC7H5O2; tR= 9.8 min (pink); 5′-FDA 23; tR= 13.21 min (green); MTA 41; 
tR = 18.68 min (orange)). B) A time course of 19F {1H} NMR assays over 2 h showing the 
production of two 5-FDR 37 anomers from freeze-dried TvNH which was stored at -20 °C 
for a week. (2-fluorethanol = -225.0 ppm, 5′-FDA 23 = -231.6 ppm, 5-FDR 37 = -231.4 




The concentration of 5′-FDA 23 and the two 5-FDR 37 anomers α/β were calculated as a 
ratio with respect to internal standards for each enzyme reaction. This data was used to 
produce a graph showing the rate of each enzyme reaction assayed on successive weeks. 
Absorbance of 5′-FDA 23 relative to the absorbance of the known concentration of sodium 
benzoate 44 was recorded against time (Figure 16). And for TvNH the integration of 2-
fluoroethanol 45 was used as a reference and the NMR signal for 37 anomers were 
integrated relative to the internal standard to obtain the concentrations of both anomers 













Figure 16: The initial rate of reaction of freeze-dried fluorinase determined by measuring 
the concentration of 5′-FDA 23 over 8 weeks. 
 
 
Figure 17: The initial rate of reaction of TvNH over 4 h from assay samples analysed over 
8 weeks. A) Rate of the reaction determined by measuring the concentration of 5-FDR- 




The activity for fluorinase and TvNH is depicted as a percentage of the original activity over 
time in Figure 18. The stability of the freeze-dried fluorinase and TvNH when stored at -
20 °C over 8 weeks was mostly retained, albeit with a modest loss of ~20% reported for 









Figure 18: Activity profiles of freeze-dried fluorinase and TvNH when stored at -20 °C over 
a 8 week period. 
The freeze-dried enzymes were used in producing [18F]5-FDR [18F]-37 for PET imaging.  
 
2.4.8 Non-labelled enzyme assays ’cold reactions’ 
Prior to performing hot labelling assays, cold assays were carried out with freeze-dried 
fluorinase (of varying concentrations) incubated with SAM-Cl 22 (0.1 mM) and KF (100 mM). 
The reaction was incubated for 20 min at 37 ºC, heat denatured (95 ºC), centrifuged and 
the supernatant was added to freeze-dried TvNH (of varying concentrations). The reaction 
was incubated for 40 min, heat denatured and centrifuged as before, prior to analysing on 
HPLC for the production of FDA 23 and adenine 29. Various concentration combinations of 
fluorinase and TvNH were tried in order to obtain the optimal ratio of fluorinase to TvNH to 
provide the best conversions in a total reaction time of 1 h. These cold assays demonstrated 
that 3 times more TvNH, relative to fluorinase was necessary for best conversions in the 








2.4.9 [18F]-5-FDR [18F]-37 production using freeze-dried fluorinase and TvNH 
 
Cold assays demonstrated that 3 times more TvNH was required than fluorinase for optimal 
conversions in the absence of L-AAO. However addition of L-AAO is required for hot 
labelling experiments in order to drive the reaction forward. Initially it was necessary to 
evaluate the minimum concentration of freeze-dried enzymes necessary for [18F]-37 
production and develop a method by which unreacted [18F]F-23 and [18F]F– could be 
removed to obtain pure [18F]-37. Performing numerous trial hot experiments was not 
possible due to limited access to the radioactivity lab. Hot labelling experiments are 
performed under significantly different reaction conditions to the cold reactions and require 
very high concentrations of TvNH relative to fluorinase. 80 
 
All experiments with [18F]F– were carried out by Dr Sergio Dall’Angelo assisted by Dr Lutz 
Schweiger at the John Mallard PET Center (Aberdeen University) and described in detail 
in Experimental 2.6.7. Preliminary hot experiments with freeze-dried fluorinase (3 mg) and 
TvNH (10 mg) demonstrated an RCY of ~66% of [18F]-37 within 2 h (Figure 19). It was 
observed that increasing the enzyme concentrations would shorten the reaction time and 
increase the RCY therefore a range of freeze-dried enzyme concentrations were explored 















Figure 19: Preliminary radiolabelling studies using freeze-dried fluorinase (3 mg) and 
freeze-dried TvNH (10 mg) to generate ~66% conversion to [18F]5-FDR [18F]-37 within 2 h. 
Experiments were conducted by Dr Sergio Dall’Angelo at University of Aberdeen. 
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The optimal RCY was obtained using freeze-dried fluorinase (6.5 mg) and TvNH (39 mg) 
(the reaction was set up following Experimental 2.6.8). Freeze-dried fluorinase (6.5 mg) 
was re-hydrated and incubated with SAM-Cl 22 (0.16 mM), L-AAO (1 mg) and [18F]F–at 
37 °C (pH 7.0) for 20-30 min. This generated a ~98% RCY of [18F]F-23 (Figure 20A). 
Subsequently the enzyme mixture was heated and centrifuged to remove the precipitated 
fluorinase and the supernatant was added to the freeze-dried TvNH (39 mg). The reaction 




Figure 20: A) Radio-HPLC showing the production of [18F]-FDA [18F]F-23 after 30 min 
incubation with [18F]F–, SAM-Cl 22 and freeze-dried fluorinase B) Radio-HPLC showing the 
production of [18F]-37 followed by 1 h incubation of the supernatant obtained from fluorinase 
reaction containing [18F]F-23 with freeze-dried TvNH. Experiments were conducted by Dr 
Sergio Dall'Angelo at VU University Medical Centre in Amsterdam.56  
 
2.4.10 PET studies on tumour mice using enzymatically produced [18F]5-FDR [18F]-37 
as a radiotracer. 
 
An in vitro imaging experiment was conducted to explore the enzymatically produced [18F]5-
FDR [18F]-37, as a radiotracer for tumours. This was conducted at the VU University of 
Medical Center in Amsterdam by Dr Sergio Dall’Angelo, with the assistance of Dr Danielle 
Vugts and Prof A. Windhorst. The freeze-dried enzyme preparations were prepared in St 
Andrews (described in detail in Experimental 2.6.3) and the [18F]-37 production using the 
freeze-dried enzymes was slightly modified as described in Experimental 2.6.8.  
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For the imaging study four mice were injected with the A431 human epithelial carcinoma 
cell line81 in their right and left thighs. All mice developed tumours and the freeze-dried 
enzyme kit was used to generate [18F]5-FDR [18F]-37 which was injected to mice with 
tumour and PET imaged. The following day the same mice were injected with [18F]FDG 32 
in order to compare the [18F]-37 uptake with this common radiotracer. Cross-sectional 
images were taken of the whole body of the mouse following the [18F]-37 injection at a set 
of time frames (600-1200 sec after injection) (Figure 21A) (described in detail in 
Experimental 2.6.9). 56 
 
As shown in the Figure 21A, the [18F]-37 uptake was clearly observed in the PET images. 
The relative uptake of [18F]-37 against [18F]-32 was analysed (Figure 21B). In the initial 400 
sec (5 min) post injection, [18F]-37 uptake was higher compared to that of [18F]-32 (Figure 
21C). The [18F]-37 uptake remained constant until around 1200 sec (20 min) however from 
this point the efflux rate of [18F]-37 from the cell increases and eventually the efflux rate is 
greater than the influx rate, reducing the image intensity. Meanwhile the [18F]-32 uptake 
steadily increases as does the image intensity. This is consistent with [18F]-32 becoming 
metabolically trapped in the cells due to phosphorylation. In Figure 21C the comparative 
uptake of [18F]-37 against [18F]-32 is plotted.  
 
There was no observable accumulation of [18F]F– in the bone during these imaging studies 
suggesting that [18F]-37 is metabolically stable and resistant to fluoride elimination unlike 
[18F]F-23.34 In addition [18F]-37 was not observed in the brain, suggesting inefficient uptake 
of [18F]-37 by trans-membrane GLUT transporters. High [18F]-37 uptake was observed in 





























Figure 21: A) A tumour induced mouse was injected with [18F] 5-FDR [18F]-37 prepared 
using freeze-dried enzymes and PET images were obtained in a time frame of 20 min. Two 
tumours on the legs are shown in arrows. B) The uptake of [18F]-37 into the tumours of the 
mouse at a given time frame was compared to the uptake of [18F]-32 in the same mouse. 
C) Uptake of [18F]-37 and [18F]-32 was plotted against their backgrounds to obtain the 
corrected reading for each uptake. Experiments were conducted by Dr Sergio Dall'Angelo 






2.5 Conclusions  
 
A user-friendly, shelf-stable method using the fluorinase and TvNH was demonstrated for 
the efficient production of [18F]-37. [18F]5-FDR [18F]-37 could be prepared within 1 h by this 
method, and when injected into tumour induced mice (A431 cells) PET imaging 
demonstrated the initial uptake of [18F]-37 was higher than that of [18F]FDG [18F]-32. The 
[18F]-37 uptake remained stable for up to 20 min before the signal diminished as the efflux 
rate of [18F]-37 was increased during which the [18F]-32 was constantly up taken. Therefore 
[18F]-32 was found to be a better PET radiotracer overall when compared to [18F]-37, as the 
rate of [18F]-37 efflux from the cells competed with its influx, reducing image resolution. 
Nonetheless [18F]-37 provided reasonable imaging resolution as a PET tracer for the initial 
10-20 min post injection and during this period [18F]-37 was as effective as [18F]-32. 
However [18F]-32 proved to be the more effective radiotracer in imaging tumours over a 
longer period of time. The stability analysis of the freeze-dried enzymes showed that they 
were stable over 8 week period at -20 °C with a 20% loss in activity. 
 
[18F]5-FDR [18F]-37 may have some prospects as a PET radiotracer for imaging tumours 
which are not responsive to [18F]-32 such as prostate and neuroendocrine tumours.3 This 
study has shown that a user friendly preparation of the fluorinase can be utilised in remote 
radiochemical labs to generate a radiotracer, which then can be used to conduct clinical 
imaging studies. 
 
2.6 Experimental  
 
2.6.1 Purification of Fluorinase enzyme in E.coli 
The fluorinase was purified using a modified method from a previously established 
protocol.63 E. coli BL21 (DE3) Gold cells were transformed with pET-28a(+)-flA recombinant 
vector inoculated into a small culture of LB (Luria Broth) media (10 ml) and incubated 
overnight at 37 °C. This culture was used to inoculate 2 L baffled flasks containing 1 L of 
LB media supplemented with kanamycin (100 g/ml) and incubated at 37 °C until the OD600 
had reached 0.6. These cultures were then induced by addition of isopropylthiogalactoside 
(IPTG; 0.5 mM) and incubated for 16 h at 25 °C. Cells were harvested by centrifugation 
(3200 rpm; 20 min) and the pellet was re-suspended in lysis buffer (20 mM Tris-HCl pH 8, 
150 mM NaCl; 50 ml) supplemented with protease inhibitor cocktail (1 x Complete Mini-
EDTA free, Roche) and Deoxyribonuclease I from bovine pancreas (Sigma; 0.1 mg/ml). 
The cells were lysed by sonication using SoniPrep 150 Plus (MSE™, UK) pulsing for 15-20 
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sec with 2 min pauses at 4 ºC. The lysate was centrifuged (15000 rpm; 20 min) and the 
supernatant was filtered through a syringe filter (0.45m) before loading onto a column 
packed with Ni-NTA resin™ (Qiagen; 5ml). The column was washed twice with wash buffer 
(20 mM Tris-HCl pH 8, 400 mM NaCl, 20 mM imidazole 40 pH 8) and then eluted with 
elution buffer (20 mM Tris-HCl pH 8, 400 mM NaCl, 400 mM imidazole 40 pH 8). The protein 
containing fractions were analysed by SDS-PAGE then dialysed into buffer 20 mM Tris-HCl 
pH 7, 150 mM NaCl at 4 ºC for 12 h. The protein was concentrated using a centrifugal filter 
unit (10000 Da, GE Healthcare). The concentrated protein was loaded on to a gel filtration 
column Superdex S-200(HR 16/60) column, Pharmacia Biotech) connected to an FPLC 
(ÄKTA purifier GE healthcare) pre-equilibrated with buffer (10 mM Tris-HCl pH 7, 30 mM 
NaCl) and the protein was eluted in the same buffer. Elution fractions were analysed by 
SDS-PAGE and the purified protein was concentrated using a centrifugal filter unit (10000 
Da, GE Healthcare) and the protein concentration was measured by Nanodrop 1000 
spectrophotometer (Thermo Fisher Scientific Inc.) 56.  
2.6.2 Purification of Nucleoside hydrolase in E.coli 
TvNH was purified according to a modified method from a previously established 
protocol55,56. E. coli WK6 cells were transformed with pQE-30-TvNH and small LB cultures 
were inoculated and grown at 37 ºC overnight. These cultures were used to inoculate 2L 
baffled flasks containing LB (1 L) supplemented with ampicillin (50 g/ml). The cultures 
were incubated at 37 °C until the OD600 reached 0.6 and then induced with IPTG (0.5 mM). 
The cultures were incubated for 16 h at 28 °C with shaking. The cells from the cultures were 
harvested by centrifugation (3200 rpm; 20 min) and the cell pellet was re-suspended in a 
lysis buffer (10 mM phosphate buffer pH 7.8, 150 mM NaCl) containing protease inhibitor 
cocktail (1 x Complete Mini -EDTA free; Roche) and Deoxyribonuclease I from bovine 
pancrease (Sigma; 0.1 mg/ml). The cells were then lysed by sonication using SoniPrep 150 
Plus (MSE™, UK) pulsing for 15-20 sec with 2 min pauses at 4ºC followed by centrifugation 
(20000 rpm; 20 min). The supernatant was filtered with a syringe filter (0.45 µm) and loaded 
on to a column packed with Ni-NTA agarose™ (Qiagen; 5ml). The column was washed with 
wash buffer (10 mM phosphate buffer pH 7.8, 150 mM NaCl, 20 mM imidazole 40 pH 7.8) 
and then eluted with elution buffer (10 mM phosphate buffer pH 7.8, 150 mM NaCl, 500 
mM Imidazole pH 7.8). Fractions were analysed by SDS-PAGE, pooled, dialysed against 
20 mM HEPES, 1 mM CaCl2, 150 mM NaCl and then concentrated using centrifugal filter 
unit (10000 Da, GE Healthcare) prior to loading on to a gel filtration column Superdex S-
200(HR 16/60) column; Pharmacia Biotech) connected to an FPLC (ÄKTA purifier GE 
healthcare) pre-equilibrated with buffer (50 mM HEPES pH 8, 10 mM NaCl). The protein 
was eluted in the same buffer. Fractions containing the protein were analysed by SDS-
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PAGE and concentrated (10000 Da, GE Healthcare) prior to measuring the concentration 
by Nanodrop 1000 spectrophotometer (Thermo Fisher Scientific Inc.). 55 
2.6.3 Freeze drying enzymes 
The purified fluorinase (10 mM Tris-HCl pH 7, 30 mM NaCl) and TvNH (20 mM HEPES, 1 
mM CaCl2, 150 mM NaCl) in their final buffers were freeze-dried (Christ Alpha 1-2 LD freeze 
drier) in eppendorf tubes at -54 ºC under 0.27 mBar vacuum for 17-20 h until the protein 
was a white amorphous solid was achived. 
2.6.4 Freeze-drying with sucrose excipient system  
Purified fluorinase and TvNH in their respective buffers in an excipient system consisting of 
glycine (2.5 mg/ml), sucrose (50 mg/ml) and polysorbate 80 (0.01%) were freeze-dried 
(Christ Alpha 1-2 LD freeze drier) in eppendorf tubes at -54 ºC under 0.27 mbar vacuum for 
17-20 h until a white amorphous solid was achieved. 
2.6.5 Non-labelled enzyme assays ’cold reactions’ 
Fluorinase (1 mg, 2 mg and 3 mg) was incubated with SAM-Cl 22 (0.1 mM), KF (100 mM) 
and 20 mM Tris pH 7, 10 mM NaCl in a total volume of 500 l for 20 min at 37 ºC. The 
reaction was heat denatured (95 °C; 10 min), centrifuged (13000 rpm; 5 min) and the 
supernatant was added to freeze-dried TvNH (1 mg, 2 mg and 3 mg) and the resulting 
solution incubated at 37 ºC for 40 min. The reaction was analysed by HPLC for the 
production of FDA 23 and adenine 29. The supernatant (20 l) was injected into a Kinetix 
5µm XB-C18 100 Å (150 mm x 4.6 mm) column with a mobile phase of: 50 mM KH2PO4, 5% 
MeCN in water (solvent A) and 50 mM KH2PO4, 20% MeCN (solvent B) using a linear 
gradient from 0% to 100% solvent B in 20 min was used. The HPLC analysis was performed 
on a Varian Prostar system with a flow rate of 1 ml/min and the UV absorbance was 
measured at 260 nm. 
2.6.6 Assaying both enzymes for stability 
Fluorinase 
Fluorinase (1 mg) was freeze-dried and stored at -20 °C for over 8 weeks. Each aliquot was 
removed every week and incubated with SAM-Cl 22 (0.2 mM) and potassium fluoride (100 
mM) in a final volume of 1 ml. Sodium benzoate 44 (2 mM) was added to each reaction as 
an internal standard and the reactions were incubated at 37 °C. Samples (140 l) were 
removed every 30 min for 2 h, heat treated (95 °C; 5 min) and centrifuged (13,000 rpm; 10 
min). The supernatant (20 l) was injected into a Kinetix 5µm XB-C18 100 Å (150 mm x 4.6 
mm) column with a mobile phase of : 50 mM KH2PO4, 5% MeCN in water (solvent A) and 
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50 mM KH2PO4, 20% MeCN (solvent B) using a linear gradient from 0% to 100% solvent B 
in 20 min. The HPLC analysis was performed on a Varian Prostar system with a flow rate 
of 1 ml/min and the UV absorbance was measured at 260 nm. 
Nucleoside hydrolase 
TvNH (20 mg) was freeze-dried and stored at -20 °C for over 8 weeks. Each aliquot was 
removed and incubated with 5′-FDA 23 (0.5 mg) in a total reaction volume of 2 ml. 2-
Fluoroethanol (1 mM) was added to each reaction as an internal standard, the reactions 
were incubated at 37 °C and samples (500 l) were removed every 1 h for 4 h and heat 
treated (95 °C; 5 min) and centrifuged (13,000 rpm; 10 min). The supernatant (400 l) was 
diluted with D2O (300 l). The reaction was assayed by 19F {1H} NMR on a Bruker AVIII-HD 
500 MHz with a SmartProbe BBFO+ and all experiments were conducted at 298K.  
 
2.6.7 Enzymatic preparation of [18F]5-FDR [18F]-37 (experiments were carried out by Dr 
Sergio Dall'Angelo in University of Aberdeen) 
Freeze-dried fluorinase (6.5 mg) was incubated with SAM-Cl 22(10 mM), L-AAO (1 mg) and 
a solution of [18F]fluoride (200–350 MBq), to reach a final reaction volume of 600 l. The 
reaction was incubated at 37 °C for 30 min and a sample of ~1-5 l was removed and 
diluted with 45-49 l of distilled water. The sample was heated (100 °C for 1 min) and 
centrifuged (13,000rpm, 5 min) and supernatant analysed by radio-HPLC (20 l injection) 
for [18F]F-23 production. 
To the reaction mixture freeze-dried TvNH (39 mg) reconstituted in 50l of water was 
added. The reaction was incubated at 37 °C for 1 h and an aliquot ~1-5 l was removed 
and diluted with 45-49 l of distilled water, heat treated (100 °C for 1 min) and centrifuged 
(13,000rpm, 5 min). The sample was analysed by radio-HPLC (20 l injection) for [18F]-37 
production. 56 
 
2.6.8 Modified method for enzymatic preparation of [18F]5-FDR [18F]-37 for tumour 
mice imaging (experiments were carried out by Dr Sergio Dall'Angelo at VU University 
Medical Centre in Amsterdam) 
The previously mentioned method was altered to perform tumour mice imaging studies at 
VU University Medical Centre in Amsterdam. The freeze-dried fluorinase (10 mg) was 
resuspended in saline solution and a glass reactor vessel designed to fit the radiosynthesis 
system was used to perform the reaction. In the reactor 0.16 mM SAM-Cl 22 and 1 mg L-
AAO was added to the fluorinase mixture followed by the addition of 600 l of 10 GBq 
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[18F]F– the reaction mixture was then incubated at 37 °C for 30 min. The entire reaction 
vessel was heated to 100 °C for 2 min to denature the protein. The reactor was then cooled 
to 37 °C and a buffered solution of freeze-dried TvNH (60 mg) was added directly to the 
reaction mixture. The reaction was incubated at 37 °C for 30min and the reactor was heated 
as before. The reactor was cooled to 20 °C before the precipitated protein was removed by 
diluting with sterile water and filtering through a DLL filter (0.22m). The sample was passed 
through a pre-equilibrated solid phase extraction (SPE) cartridge system consisting of PS-
Ag+ (Macherey-Nagel, Germany), C18Plus (Waters, Netherlands) and PS-HCO3 (Macherey-
Nagel, Germany) to remove any unreacted [18F]F–, [18F]-23 and unreacted 22. The purified 
[18F]-37 was eluted in sterile water (4 ml).56 
 
HPLC monitoring used to detect the radiochemical and UV purity of [18F]-37. The RP-HPLC 
analysis was carried out using a Phenomenex Luna column and radioactivity detector. Two 
detection methods were utilised, a refractive index detector and a Photodiode array (PDA). 
A synthetically prepared reference 5-FDR 37 was used to identify [18F]-37 peak. 56 
2.6.9 PET imaging of tumour induced mice using [18F]5-FDR [18F]-37 (experiments 
carried out by Dr Sergio Dall'Angelo at VU University Medical Centre in Amsterdam) 
 
Four mice (nu/nu) were injected in their thighs with A431 cells (tumour inducing cells) and 
the tumours were left to grow for 1 week until they reached a size of 5–7 mm. Prior to the 
PET scan, mice were provided with plenty of food and then subsequently fasted for 2 h. 
They were anesthetised with isoflurane (2% in oxygen, 1 l/min via a nose mask) and 
cannulated in the jugular vein for administration of the radiopharmaceuticals. Following 
cannulation the mice were mounted onto the PET scanner and the body temperature was 
maintained between 35 °C and 37 °C. All animal experiments were carried out in 
compliance with Dutch law and approved by the VU University Animal Ethics Committee.56 
 
Four mice were scanned using a double LSO/LYSO layer High Resolution Research 
Tomograph (HRRT; CTI/Siemens, Knoxville, USA). For attenuation and scatter correction, 
a transmission scan was acquired using a 740 MBq 2-dimensional (2D) fancollimated 137Cs 
(662 keV) moving point source. Dynamic emission scans were then acquired and data were 
acquired in list mode and allocated into 28 frames, 20 frames of 60 s and 8 frames of 300 
s. Following corrections for decay, dead time, scatter and random scans were reconstructed 
using an iterative-3D ordered-subsets weighted least-squares (3D-OSWLS) method. On 
the initial day [18F]5-FDR [18F]-37 was administered at ~3 MBq per mouse and in the second 
day [18F]FDG [18F]-32 was administered at a similar dose (as a control). PET image data 
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were analysed using the publically available software package, Amide 0.8.22. Volumes of 
interest (VOIs) were drawn by hand over the tumours, in the X, Y and Z direction. The VOIs 
were then projected onto all frames of the scan, resulting in time– activity curves for each 
scan, tumour and mouse. These time–activity curves were then normalized for the injected 
activity and animal weight to yield standardized uptake values (SUVs) evaluated over time. 
Whole body uptake was determined by a whole body VOI and this value was taken as 100% 
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3. Identification of other fluorinases 
 
3.1 S. cattleya fluorometabolite gene cluster 
 
The physical clustering of genes involved in secondary metabolite biosynthetic pathways 
in bacteria, filamentous fungi and in some plants is a common occurrence as identified 
by whole genome sequencing.1 Genes encoding consecutive steps in a biosynthetic 
pathway are prone to group together in this manner on the chromosome, although their 
organisation within these clusters has been found to be highly variable.2 Secondary 
metabolite biosynthetic gene clusters most often operate as self-contained cassettes 
comprising of the genes required for various processes, such as; forming the frame of 
the secondary metabolite, subsequent modifications of this metabolite, as well as 
pathway specific regulators and often resistance genes for coping with any toxic traits of 
the final product. These secondary metabolite gene clusters often lay dormant and are 
only expressed in response to specific metabolic stress.2,3 
In order to explore if the genes involved in fluorometabolite production by S. cattleya 
might be clustered, Dr Jonathan Spencer and co-workers (University of Cambridge) used 
genomic library screening to identify the genes clustered around the fluorinase gene (flA) 
of S. cattleya. The study revealed a 12kb gene cluster (the ‘Spencer cluster’, Figure 1) 
containing twelve open reading frames (ORF’s) centered around the flA gene.4  
To determine the function of the genes, each one was knocked-out and the resulting 
mutant was analysed for its ability to produce fluorometabolites. When the flA gene was 
knocked-out, the bacterium’s ability to produce 4-fluorothreonine (4-FT) 14 and 
fluoroacetate (FAc) 10 was lost. Further investigation found that the addition of 
synthetically prepared 5′-FDA 23 to cultures of this mutant restored the production of 
these fluorometabolites. The second enzyme in this pathway, PNP (Scheme 5; Chapter 
1) is encoded by the flB gene, which lies adjacent to the flA gene. Inactivation of flB was 
found to arrest the fluorometabolite production similar to flA inactivation.4 
The Spencer cluster also contains genes involved in the regulation of this 
fluorometabolite pathway including fII, encoding for an adenosylhomocysteine hydrolase 
involved in the removal of excess S-adenosyl homocysteine (SAH) 46, a potent inhibitor 
of the fluorinase. The gene flK encodes for a 139 amino acid thioesterase, which 
catalyses the selective breakdown of fluoroacetyl-CoA. This enzyme is proposed to 
confer resistance to S. cattleya against FAc 10 toxicity.5 The knockout mutant of flK was 
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unable to produce any fluorometabolite in the presence of fluoride, confirming a tight 
regulation of fluorometabolite production. The genes flE, flF and flG are also located 
within this cluster and were found to encode for DNA binding regulatory proteins.4  
The expression of many genes involved in this fluorometabolite pathway was found to 
be dependent on fluoride ion levels. For instance; an increase in fluoride concentrations 
was shown to upregulate the expression of flG and flA gene over 2 fold.6 The flH gene 
was found to encode a transmembrane Na+/H+ antiporter. Na+/H+ antiporters transport 
protons out of the cell in exchange for Na+, which is essential for regulation of cell volume 
and pH. It was observed that fluoride uptake in resting cells of S. cattleya peaked at pH 
6.0 and dropped significantly as pH increased, indicating that a certain level of 
extracellular H+ was required for transport of F- in to cells. It follows that Na+/H+ 
antiporters may buffer the accumulation of HF by exchanging intracellular H+ for a Na+, 
and thus regulate the intracellular pH and net accumulation of NaF.7 However, a flH gene 
knockout mutant did produce fluorometabolites suggesting that flH is not essential for 










Figure 1: The Spencer cluster, showing genes encoding for enzymes involved in 
fluorometabolite biosynthesis in S. cattleya. Image reproduced with permission from 
O’Hagan et al. 8 
Two research groups collaborated in completing the full genome sequence of S. cattleya 
which was released in 2011.9,10 The complete genome sequence of S. cattleya consists 
of a linear chromosome of 6.28 Mb (containing 5822 genes) and a linear mega-plasmid 












Figure 2: The genome map showing the arrangement of biosynthetic genes involved in 
fluorometabolite biosynthesis of S. cattleya. Image reproduced and modified with 
permission from O’Hagan et al.11 
Genes encoding the remaining enzymes involved in the biosynthetic pathway of 
fluorometabolites in S. cattleya are absent from the Spencer cluster. Full genome 
sequencing has found that they are distributed over the chromosome.  
The mega-plasmid was revealed to contain only two genes involved in the fluorometabolite 
biosynthesis, the 4FT-transaldolase and a putative aldolase, whereas most of the genes 
required for fluorometabolite production are located on the chromosome or within the 
Spencer cluster. The flFT gene knock-out mutant was able to produce FAc 10 but had lost 
the ability to produce 4-FT 14 consistent with a branch point on the fluorometabolite 
pathway (Scheme 5; Chapter 1).4 
The genes encoding for isomerase (flIso) and dehydrogenase enzymes are located on the 
chromosome, but they are distant from the Spencer cluster. Inactivation of the flIso gene 
also generated mutants unable to produce any fluorometabolite.4,7 
3.1.1 Enzymes with homology to fluorinase 
The fluorinase is a unique enzyme in that it catalyses a nucleophilic substitution reaction 
involving fluoride ion and the C-5′ carbon of SAM 22, as discussed in Chapter 1.12 Only a 
small number of genes possess some sequence similarities to the fluorinase, these consist 
of the larger class of proteins expressed by the domains of unknown fuction-62 (duf-62) 
genes present in many prokaryotes and the chlorinase isolated from the marine bacterium 
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Salinispora tropica. The duf-62 family genes have ~25-32 % gene homology to the 
fluorinase whereas chlorinase has ~40% gene homology.13 
Over 300 duf-62 genes are evident in publicly available genome sequences with their 
distribution limited to mostly extremophiles and pathogen-related microbes. Duf-62 genes 
encode for a protein, which mediates the hydrolytic conversion of SAM 22 to adenosine 
47 and L-methionine in what is believed to be an SN2 reaction requiring hydroxide as the 
nucleophile (Scheme 1A). Although functionally the duf-62 enzyme mediates a reaction 
very similar to that of the fluorinase and chlorinase, they are distinctive both in the 
organisation of their active site and the mechanism by which they activate the nucleophile 
for attack on 22. Fluorinase and chlorinase activate halide ions through dehydration via a 
combination of hydrogen bonds to active site residues which is further reinforced by the 
binding of 22. However the duf-62 proteins use a highly conserved amino acid triad (His-
Arg-Asp) which assists in activating water towards nucleophilic attack on the adenosine 
47 C-5′ carbon of SAM 22.13,14 Mutation of His-127 in the catalytic triad was shown to retain 
some enzyme activity, however any mutation to either Asp-68 or Arg-75 of the catalytic 









Scheme 1: A) The duf-62 family of enzymes use water as a nucleophile to convert SAM 
22 to adenosine 47. B) Chlorinase (from Salinispora tropica) catalyses the conversion of 
22 to ClDA 28, several subsequent enzymatic steps lead to the production of the final 
chlorometabolite, salinosporamide A 5.  
The chlorinase enzyme was isolated during a genome mining study carried out in 2008 by 
the Bradley Moore group at the Scripps Institution of Oceanography, San Diego. An entire 



























































salL gene encodes for the SAM 22-dependent chlorinase. This enzyme mediates the 
reaction between chloride ion and 22 to form 5′-chlorodeoxy adenosine (ClDA) 28, as 
shown in Scheme 1. The chlorinase is capable of utilising both Br- and I- for halogenation, 
however it is unable to utilise fluoride as the halide source for these reactions. The 
chlorinase is the first enzyme in a chlorometabolite biosynthesis pathway, in which the 
final product is salinosporamide A 5, which is an effective proteasome inhibitor and a 
potential anticancer drug.15 The chlorinase is a homotrimer similar to the fluorinase 
although the latter organises as a hexamer constructed as a dimer of trimers. Although 
the reaction catalysed by the fluorinase and chlorinase follow similar mechanisms, the key 
residues co-ordinating the halide ions are different. During fluorinase-catalysed 
halogenation, Ser-158 aids in fluoride ion binding, for the chlorinase Gly-131 serves the 
same function.16 Site directed mutagenesis has been carried out on the chlorinase 
replacing Gly-131 with serine in order to analyse if this mutant would be able to 
accommodate a fluoride ion, however this was not the case and the mutant was found to 
inhibit chlorination activity. The chlorinase also lacks a 21 amino acid loop unique to the 
fluorinase enzyme, suggesting the importance of this motif in the selectivity of fluoride over 
other halides. Enzymes located downstream of the chlorinase involved in salinosporamide 
biosynthesis are capable of accepting fluorinated substrates evident by the production of 
fluorosalinosporamide 48 on addition of 23 (Scheme 2).17 A genetically engineered S. 
tropica mutant with salL replaced by flA (encoding for fluorinase from S. cattleya) was 
cultured in the presence of inorganic fluoride. This mutant was capable of producing 48 
as a novel fluorinated natural product. Despite this observation S. tropica was seen to be 
extremely sensitive to fluoride concentrations during these experiments, limiting the 





Scheme 2: Novel fluorinated natural product, fluorosalinosporamide A 48 produced by 
genetically altered S. tropica mutant.17 
The fluorinase isolated from S. cattleya was the only known fluorinase enzyme for over a 
decade, since its discovery in 2003.18 However in 2014, three more fluorinases were 
identified, through genome mining, one of which was found in Streptomyces sp. MA37 
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recently isolated from Ghana.11 The crystal structure, characteristics and kinetics of the 
new fluorinase from Streptomyces sp. MA37 in comparison to other fluorinases are 
discussed below.  
3.2 Characterisation of a fluorinase isolated from Streptomyces sp. MA37. 
3.2.1 Isolation and growth of Streptomyces sp. MA37  
 
Streptomyces sp. MA37 is a soil bacterium, isolated from the rhizosphere of a Moraceae 
Bark Cloth tree (Antiaris toxicaria, Africa) in 2011 by Dr Hai Deng of the University of 
Aberdeen and Dr Kwaku Kyeremeh of the University of Ghana. The tree from which the 
Streptomyces sp. MA37 was isolated was growing in the grounds of the University of Ghana 
Botanical Gardens.  
 
 
Figure 3: Streptomyces sp. MA37 cultured on 






The Streptomyces sp. MA37 bacterium was cultured (Figure 3) by Dr Hai Deng and Zhiwei 
Qin at the University of Aberdeen. The cultures were supplemented with 2 mM potassium 
fluoride and grown at 28 ºC for 7 days, following which the supernatant was analysed for 
fluorometabolites by 19F{1H} NMR. The extract was observed to contain FAc 10 similar to 
S. cattleya and therefore it was of interest to analyse the genome of Streptomyces sp. MA37 
for genes related to synthesis of FAc 10.  
 
Full genome sequencing of Streptomyces sp. MA37 was carried out by Dr Yi Yu at Wuhan 
University, using paired-end sequencing (Illumina). In addition, 16S ribosomal RNA (rRNA) 
sequencing of Streptomyces sp. MA37 was performed to identify the evolutionary 
relationship of this organism relative to other Streptomyces species. The 16S rRNA gene 
sequences of the small subunit of prokaryotic ribosomes are highly conserved within 
prokaryotes. This relationship is exploited in creating phylogenetic trees and identifying 
novel bacteria.19 A phylogenetic tree was reconstructed based on the 16S rRNA gene 
sequences of Streptomyces sp. MA37 where it was observed to share a distant relationship 
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to a clade consisting of S. cattleya, S. coelicolor, S. avermitilis and S. scabiei. Consequently 
Streptomyces sp. MA37 was proposed to have diverged at an earlier branch than S. 













Figure 4: Phylogenetic relationship between Streptomyces sp. MA37 and other 
Streptomyces strains based on 16S rRNA gene sequencing. Image reproduced with 
permission from Deng et al.11  
 
3.2.2 Genome analysis of Streptomyces sp. MA37 
 
Full genome sequencing of Streptomyces sp. MA37 identified a flA1 gene, which possesses 
an 87% homology to the flA gene of S. cattleya. flA1 also contained a signature 21 amino 
acid loop, which is unique to the fluorinase (flA) and absent from the chlorinase and duf-62 
enzymes.  
  
Streptomyces sp. MA37 was also found to contain the 4-FT 14 transaldolase gene (flFT1), 
responsible for catalysing the final enzymatic step in the biosynthetic pathway of 14 in S. 
cattleya.8 This suggested that Streptomyces sp. MA37 was able to synthesise 14 in addition 
to its previously established FAc 10 production. When comparing the gene organisation of 
Streptomyces sp. MA37 relative to that of S. cattleya, the flFT1 gene was located adjacent 
to the flA1 gene. This is a significant observation, as the S. cattleya gene is located in a 
megaplasmid isolated from the chromosome. This indicated advanced gene clustering in 
Streptomyces sp. MA37. The ability of Streptomyces sp. MA37 to produce 14 was 
subsequently confirmed by Dr Long Ma at the University of St Andrews, by analysing the 
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supernatant of cultures via 19F{1H} NMR. Production of 14 was observed which was further 
confirmed by GC-MS fragmentation (Figure 5).11 
 
Figure 5: 19F{1H} NMR spectrum obtained from cultures of Streptomyces sp. MA37 showing 
the production of 14 and 10 along with new fluorometabolites.11 
19F NMR analysis of a CFE of Streptomyces sp. MA37 revealed the production of several 
new fluorometabolites in addition to 10 and 14. One of these fluorometabolites was 
identified as (2R, 3S, 4S)-5-fluoro-2,3,4-trihydroxypentanoic acid (5-FHPA) 15 (Figure 4, 
Chapter 1). 5-FHPA 15 production was also observed during these experiments when 5-
FDR 37 was added to the CFE, suggesting a 37 mediated biosynthesis. Detailed analysis 
of the genome of Streptomyces sp. MA37 revealed an fdr gene cluster which possesses a 
homologous gene cluster to that which has been extensively studied in S. tropica (the 
salinosporamide A producer). The fdr gene cluster consists of fdrA, encoding a metal-
dependent phosphoesterase, FdrA with high sequence identity (56%) to SalN of the 
salinosporamide biosynthetic pathway. Immediately downstream of fdrA, two ORF’s, fdrB 
and fdrC was found to encode two proteins FdrB and FdrC which share high sequence 
identity to SalH (68%) and SalM (69%), respectively. Therefore, a related biosynthetic 
pathway analogous to that in S. tropica was proposed for Streptomyces sp. MA37, which 
was subsequently confirmed by 19F NMR.11 Following this a candidate gene fdrC expressing 
an NAD+ dependent dehydrogenase was investigated as the enzyme responsible for the 
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conversion of 5-FDR 37 to 5-FHPA 15. Indeed over-expressed FdrC was found to catalyse 
the NAD+ dependent oxidation of 5-FDR 37 to an intermediate 5-fluoro-5-deoxy-lactone 
which then underwent hydrolysis to form 15 (Scheme 3) and these reactions could be 
followed by 19F-NMR.20 





Scheme 3: A) The biosynthesis pathway of 5-FHPA 15 in Streptomyces sp. MA37.20  
3.2.3 Gene mining for the flA gene 
 In 2012, the genome sequence of a hospital pathogen, Nocardia brasiliensis HUJEG-1 
was added to the National Center for Biotechnology Information GenBank database.10,11 
Genome analysis of Nocardia brasiliensis revealed a flA2 gene at an ORF (YP_006809254) 
which had 81% homology to flA of S. cattleya. The predicted amino acid sequence of the 
flA2 gene contained the 21 amino acid loop along with some conserved amino acids found 
within the active site of the S. cattleya flA gene (Figure 6). A gene encoding a 4-FT 14 
transaldolase (flFT2) was also located close to the flA2 gene, similar to the gene 
organisation of Streptomyces sp. MA37 (Figure 7C). N. brasiliensis is an actinomycete 
belonging to family Norcardia, a soil bacterium which degrades soil matter. It is an 
opportunistic bacterium which can cause sporadic diseases in humans and animals. In 
humans, it can cause nocardiosis, an infectious disease affecting the lungs or other organs, 








Figure 6: Sequence identity alignment of FlA from S. cattleya (WP_014144878.1), FlA 1 
from Streptomyces sp. MA37 (CDH39444.1), FlA2 from Nocardia brasiliensis 
(WP_014985135.1), FlA3 from Actinoplanes sp. N902-109 (WP_015619887.1), FlA4 from 
Streptomyces xinghaiensis (WP_019711456.1) and SalL (chlorinase from S. tropica). Over 
80% sequence identity is represented by dark blue and less than 40% identity is 
represented by white, lighter shades represent moderate sequence identity. The 21 amino 
acid loop unique to fluorinases is highlighted by the red box. 
Furthermore, in 2012 an Actinoplanes sp. N902-109 was found to contain a flA3 gene with 
80% homology to the flA gene of S. cattleya which also possessed the conserved 21 amino 
acid loop (Figure 6). Actinoplanes sp. N902-109 is an actinomycete, first isolated from a 
soil sample collected in Shizuoka Prefecture, Japan in 1995 and investigated for its ability 
to produce large quantities of rapamycin in comparison with Streptomyces 
hygroscopicus .22 The genome sequence of this organism also revealed a 4-FT 
transaldolase (flFT3), organised in close proximity to the flA3 gene, suggesting the 
possibility of the biosynthesis of 14. (Figure 7D).7  
More recently in 2014, gene mining revealed a flA4 gene in a marine bacterium, 
Streptomyces xinghaiensis.23 This flA4 gene also contained the 21 amino acid loop specific 
to fluorinases (Figure 6). This bacterium was isolated and cultured for its ability to produce 
a novel broad-spectrum antibiotic, xinghaiamine A, and it was also discovered to be a 
fluoroacetate producer. S. xinghaiensis was first isolated in 2009 from a marine sediment 
sample collected from Dalian, China.24 This S. xinghaiensis gene cluster (Figure 7E) also 
contained a truncated flFT4 gene located adjacent to flA4 which suggests that this is a 
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pseudogene,25 particularly as the strain could not produce 14 when grown in the presence 
of fluoride. The FAc 10 production by S. xinghaiensis was also found to be sea salt 
dependent.23 
In S. cattleya the PNPase (flB) is located immediately adjacent to the flA gene. Upon 
comparing the genome sequences of Streptomyces sp. MA37, Nocardia brasiliensis, 
Actinoplanes sp., and S. xinghaiensis it was apparent that all four organisms possess the 
PNPase gene (flB 1, 2, 3, 4 respectively) located in close proximity to the fluorinase gene 
(Figure 7).11 The arrangement of the genes involved in fluorometabolite biosynthesis in the 
more recently discovered fluoroacetate producing organisms appear to have a higher 













Figure 7: A) Genome map of S. cattleya showing the location of fluorometabolite 
biosynthetic genes. 4-FTtransalodolase and isomerase are remote from the Spencer 
cluster containing the flA gene. B) Streptomyces sp. MA37 C) N. brasiliensis; D) 
Actinoplanes sp. N902-109 E) S. xinghaiensis. Image reproduced and modified with 
permission from Deng et al.23  
 
Through these studies, three new candidate fluorinase genes were identified (flA2, flA3 and 
flA4) via gene mining in three different species of bacteria, each belonging to different 
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families in the actinomycetales order. Genes isolated with similarities to the fluorinase could 
possibly be pseudogenes which possess similar gene sequences but are non-functional. 
Therefore it was necessary to express and purify the gene products of flA1, flA2 and flA3 
and determine if they are functional fluorinases. If all three fluorinase homologs are 
functional it would suggest that the fluorinase gene either evolved independently (parallel 
evolution) in three different families of actinomycetales or was acquired through an ancient 
common ancestor (collateral evolution).26 
3.3 Project aims 
The aim was to express, purify and characterise the fluorinase (flA1) of Streptomyces sp. 
MA37 and establish it as a ‘true’ fluorinase.12 
As such, an initial objective was to clone the flA1 gene into a suitable vector and over-
express it in E.coli. The over-expressed protein would then be purified via affinity 
chromatography and assayed for fluorinase activity to confirm it as a functional fluorinase. 
It was also important to analyse the kinetic parameters (Km, Vmax) of the Streptomyces sp. 
MA37 fluorinase, and attempt crystallisation of the protein in order to compare the 
crystallography structures with that of the S. cattleya fluorinase.  
3.4 Results and discussion 
3.4.1 Isolation and Cloning of flA1 
The gross DNA was extracted (described in detail in Experimental 3.6.1) from a 
Streptomyces sp. MA37 culture which was donated by Dr Hai Deng at the University of St 
Andrews. The purified DNA and PCR primers were used to set up PCR reactions to amplify 
the flA1 gene (sequence of the gene is mentioned in Appendix 3) as detailed in the 
Experimental 3.6.2. The pEHISTEV plasmid was chosen as the vector for this study, which 
is derived from a pET vector containing an amino terminal hexahistidine tag (His6-tag) and 
a tobacco etch virus (TEV) protease recognition site 27 between the His6-tag and the 
inserted gene. This design allows for the expression of a protein of interest with a TEV 
protease cleavable His6-tag.28 The resultant PCR product (900 bp) and the pEHISTEV 
plasmid were digested with restriction enzymes NcoI and HindIII and analysed by DNA gel 











Figure 8: A) DNA gel electrophoresis of PCR product digested with NcoI and HindIII (900 
bp); pEHISTEV digested with NcoI and HindIII (5369bp); M- marker B) Colony PCR of 10 
E.coli DH5α transformants out of which lanes 1,2,5 and 6 are positives with the PCR product 
ligated to the vector.  
The digested PCR product was ligated into digested pEHISTEV28 and the ligation mixture 
was transformed29 into DH5α E.coli cells13, plated on agar containing kanamycin. Twelve 
transformants were isolated and analysed for the presence of the PCR product (900 bp) 
using colony PCR and DNA gel electrophoresis analysis (Figure 8A). From the ten 
transformants, four were found to contain the PCR product at 900 bp (Figure 8B). 
Subsequently all four were minipreped to obtain plasmid DNA and sequenced. Three of 
these transformants (1, 2 and 6, Figure 8B) did not possess mutations and thus the PCR 
product was ligated in the correct orientation. Transformant 5 however contained a small 
number of mutations within the gene itself. Transformant 2 was ultimately chosen for further 
study, and the recombinant plasmid was transformed29 into E.coli BL21-Gold (DE3). 
3.4.2 Over-expression and purification of MA37 fluorinase 
 
Studies were carried out to determine if the fluorinase enzyme was over-expressed as a 
soluble protein. Initially the protein was expressed in mg/ml quantities, however over 80% 
was obtained as insoluble protein. Two key factors that affect protein solubility are 
temperature and inducer concentration. An over-expression study was carried out using 
cultures of BL21-Gold (DE3) transformed with pEHISTEV-flA1. These cultures were 
induced with either 1mM or 0.2 mM IPTG concentration and grown at either 16 ºC or 30 ºC 
for 24 h shaking at 180 rpm. Mature cultures were analysed via SDS-PAGE for soluble and 
insoluble protein (Figure 9). High FlA1 (MA37 fluorinase) protein expression was observed 
with 1 mM IPTG induced cultures grown at 30 ºC when compared to those grown at 16 ºC. 
However most of the expressed protein was still observed via SDS-PAGE in the insoluble 
fraction. A moderate amount of soluble protein was also observed, however a second 
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unwanted E.coli protein (28 kDa) was also detected at significant levels. Therefore the IPTG 
concentration was further lowered and an over-expression with 0.03 mM IPTG at 16 °C was 
performed. As before an SDS-PAGE was run on the soluble and insoluble fractions (Figure 
10). These conditions also produced some insoluble MA37 fluorinase, however sufficient 











Figure 9: SDS-PAGE of samples from the over-expression study of Streptomyces sp. 
MA37 fluorinase in BL21-Gold (DE3) E.coli cells with varying temperatures and IPTG 
concentrations. M: un-stained PageRuler protein ladder. 
Cultured at 16 ºC for 24 h 1: no IPTG; soluble fraction, 2: no IPTG; insoluble fraction, 3: 1 
mM IPTG; soluble fraction, 4: 1 mM IPTG; insoluble fraction, 5: 0.2 mM IPTG; soluble 
fraction, 6: 0.2 mM IPTG; insoluble fraction. 
Cultured at 30 ºC for 24 h 7: no IPTG; soluble fraction, 8: no IPTG; insoluble fraction, 9: 1 
mM IPTG; soluble fraction, 10: 1 mM IPTG; insoluble fraction, 11: 0.2 mM IPTG; soluble 









Figure 10: SDS-PAGE of the samples of over-expressed BL21-Gold (DE3) E.coli cells 
containing pEHISTEV-flA1 induced with 0.03 mM IPTG and grown at 16 ºC. 
M: un-stained PageRuler protein ladder (Thermo scientific), 1: no IPTG; insoluble fraction, 
2: no IPTG; soluble fraction, 3: 0.03 mM IPTG; insoluble fraction, 4: 0.03 mM IPTG; soluble 
fraction. 
 
Further screening was carried out to optimise the soluble protein concentration of the MA37 
fluorinase by altering the buffers used during cell lysis. Many methods for solubilising 
protein are available; expressing in specialised E.coli strains,30 creating fusion protein 
constructs (such as using maltose binding protein31,32 and Small Ubiquitin-like Modifiers33) 
and including molecular chaperones34. However each additional method requires significant 
optimisation without guaranteed success. Studies have shown that some insoluble protein 
can be solubilised during the purification process by utilising specific buffer conditions35 and 
by addition of co-solvents such as detergents, salts, buffers and reducing agents during the 
cell lysis.36  
Additional screening was therefore performed using two buffers containing varying salt 
concentrations and additives. A BioSprint 96® was used to perform the screening. This is 
an automated system capable of performing rapid small scale affinity purifications 
independently. E.coli cultures expressing MA37 fluorinase were first lysed and processed 
through the BioSprint 96® system using ten different buffers, each supplemented with 
different salt and additive combinations, composed of either 20 mM Tris-HCl or 20 mM Bis-
Tris at pH 8.0 or 6.8 along with additives such as glycine, 2-mercaptoethanol (β-ME), NP40 
(Nonidet P40 ) and Triton X-100.35 
The pH and ionic strength of the solution both have a strong influence on protein solubility, 
as such specific buffers and salts are commonly added to sample preparation solutions. 
Salts such as MgSO4, NaCl and KCl stabilise the native intramolecular protein interactions, 
and thus outcompete the protein-protein intermolecular interactions that lead to 
aggregation.37–39 Small amino acids such as glycine and L-arginine are aggregation 
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inhibitors stabilising the unfolded proteins by interacting favourably with majority of amino 
acid side chains on the protein surface.39 Reducing agents such as β-ME assist in 
maintaining the protein in a reduced state by preventing oxidation of cysteine residues, 
which may ultimately cause protein aggregation through intermolecular disulphide 
bridges.35  
Non-ionic detergents such as NP40 and Triton X-100 have uncharged and hydrophilic head 
groups. They are considered mild surfactants as they break protein-lipid and lipid-lipid 
associations, but not protein-protein interactions, and most do not denature proteins. 
Therefore, through use of these detergents, proteins are solubilized and isolated in their 
native and active forms, retaining important intermolecular interactions.40 
Ten buffers supplemented with various co-solvents (discussed above), were analysed as 
potential lysis buffers, in order to optimise the solubility of the MA37 fluorinase. Soluble 
fluorinase was obtained when cells were lysed and purified in 20 mM Bis-Tris pH 6.8, 150 
mM NaCl and 0.1 M Glycine (Figure 11; buffer #5). Therefore these conditions were used 







Figure 11: SDS-PAGE of fractions obtained from Biosprint 96® (small scale affinity 
purifications), investigating the optimal buffer-additive combination which solubilise the 
MA37 fluorinase. The ten buffer conditions are listed, from which #5 yielded the most 
soluble protein (20 mM Bis-Tris pH 6.8, 150 mM NaCl, 0.1 M Glycine buffer).  
Streptomyces sp. MA-37 fluorinase was purified using the protocol reported in the 
Experimental 3.6.3. The purified MA-37 fluorinase was relatively unstable compared to the 
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more robust S. cattleya fluorinase, and was found to be sensitive to short term interaction 
with high imidazole 40 and high salt concentrations, as well as exposure to mechanical 
agitation, causing the protein to precipitate over time. Therefore, it was necessary for the 
protein to be desalted immediately following affinity purification, as removing the imidazole 
40 through dialysis was too slow a process and resulted in aggregated protein. Through 
trial and error, the optimised protocol (Experimental 3.6.3) was utilised to obtain pure 








Figure 12: SDS-PAGE of fractions obtained from Ni-NTA column for MA37 fluorinase. M- 
marker, S- soluble fraction, I- insoluble fraction, W1- wash 1, W2- wash 2, F- flow through, 
E1- elution 1, E2- elution 2 
E.coli cells transformed 29 with pEHISTEV-flA1 and were grown in 1 L cultures, harvested 
and lysed in Bis-Tris (20 mM) pH 6.8 buffer supplemented with glycine to obtain the soluble 
lysate. The lysate was applied to a Ni His-trap column which was first equilibrated with wash 
buffer containing Bis-Tris (20 mM) pH 6.8, supplemented with glycine (0.1M) and imidazole 
40 (40 mM). The column was then flushed using wash buffer to remove any proteins bound 
by non-specific interactions. The protein was eluted using Bis-Tris (20 mM) pH 6.8 buffer 
supplemented with glycine (0.1M) and imidazole 40 (400 mM) (Figure 12). This process 
was followed by an immediate desalting column using wash buffer to reduce the final 
imidazole 40 concentration.  
The S. cattleya fluorinase purifies with adenosine 47 bound to its active site. A successful 
strategy is to remove the 47 by treatment with adenosine deaminase.41 Similarly MA37 
fluorinase was also found to contain bound 47 following purification, as shown by HPLC 
analysis carried out following heat denaturing of purified MA37 fluorinase. Therefore the 
desalted MA37 fluorinase was incubated with adenosine deaminase which converts 47 to 
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inosine, which does not bind to fluorinase and can be readily removed via dialysis, thus 
generating apo- MA37 fluorinase.15 HPLC analysis was carried out during (12 h) and post 
(22 h) adenosine deaminase treatment to assess the progress of adenosine 47 removal 
(Figure 13). Post treatment, a Ni His-trap column was used to separate the adenosine 
deaminase (non His6-tagged) from treated MA37 fluorinase (His6-tagged). The treated 










Figure 13: HPLC analysis of heat denatured MA37 fluorinase showing the presence of 
adenosine 47 tR= 2.8 min. A standard sample of 47 was run to confirm the peak.  
His6-tags are significantly smaller than most affinity tags and are thought to cause minimal 
disturbance to protein structure and function. However some instances are reported where 
the His6-tag may affect the protein structure, activity and binding affinity and42 can also be 
a disadvantage during protein crystallisation.43  
The pEHSITEV-flA1 contains a TEV recognition site located between the His6-tag and the 
main polypeptide sequence, which is identified by the TEV protease. Therefore the 
deaminase-treated MA37 fluorinase was incubated with a TEV protease and purified by 
another Ni His-trap column to perform a ‘subtractive’ purification, where cleaved MA37 
fluorinase is collected with the flow through. Following this the deaminase-treated, His6-tag-
cleaved, MA37 fluorinase was concentrated and injected into a gel filtration column as a 
refining step.  
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An equilibrated size exclusion column (SEC) was loaded with the concentrated protein and 
eluted with HEPES buffer (Figure 14A). The MA37 fluorinase was then dialysed into 
phosphate buffer (20 mM) using Vivaspin concentrators (GE Healthcare). Fractions 
obtained from the SEC column were pooled and analysed by SDS-PAGE gel to confirm the 
purity of the protein. The SDS-PAGE revealed a single band at ~32 kDa (Figure 14B), the 
gel band was collected and analysed by MALDI-TOF to confirm the identity of the protein 
(Figure 15). The trypsin digested protein gel band was analysed for distinct cleavage 
patterns dictated by the amino acid sequence of the protein.44 The sequence coverage for 
Streptomyces sp. MA-37 fluorinase was over 66% confirming the identity of the protein 













Figure 14: A) Size exclusion column chromatography of MA37 fluorinase showing the UV 
absorption in blue, concentration of the buffer in brown, flow rate in green and fractions in 
red. B) SDS-PAGE of the pooled fractions of MA37 fluorinase following size exclusion 















Figure 15: MALDI-TOF mass spectrum of trypisin digested SDS-PAGE gel band of MA37 
fluorinase. Red peaks depict the peptide ions which matched the amino acid sequence of 
His6-tagged MA37 fluorinase which were over 66% for MA37 fluorinase.  
 
3.4.3 Crystallization of MA37 fluorinase 
Purified MA37 fluorinase was used in crystallisation trials as reported in the Experimental 
section 3.6.4. The success of protein crystallisation depends upon many variables such as; 
pH, ionic strength, temperature, protein concentration, additives or ligands and salts. 
Therefore it is difficult to predict the best crystallisation conditions prior to optimisation 
studies for a given protein.  
Initial crystallisation screens for the MA37 fluorinase were set up using pre-made 
commercial screens JSCG+ and PEGs II suite and incubated at 20 ºC and 4 ºC for 3-5 
days. Screens incubated at 4 ºC produced mostly spherulites and contained precipitated 
protein. The screens incubated at 20 ºC all contained PEG in which thin needle like crystals 
were observed after 5 days. Therefore, optimisation screens were prepared for all four 
conditions with varying concentrations of PEG and additives (Experimental 3.6.4; Table 2). 
The best crystals (most suitable for diffraction) were obtained in 7% w/v PEG 6000, 0.5 M 
NaCl with 6.6 mg/ml of apo-MA37 fluorinase, incubated at 20 ºC. Octahedron shaped 
crystals appeared after ~3 days which grew in size to approximately 0.03- 0.05 mm. They 
were harvested after 1.5- 2 weeks (Figure 16). The crystals were cryoprotected and shot in 
an in-house X-ray diffractometer at 100K. The data was used to determine the structure up 
to 2.5 Å resolution with an R value of 0.21 (a measure of the quality of the atomic model 
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obtained from the crystallographic data). The crystal structure were resolved by molecular 
replacement from previous fluorinase structures by Greg Mann (Professor J. Naismith 
group) at the University of St Andrews (X-ray diffraction data is presented in Appendix 1). 
The crystal structure of the MA37 fluorinase with bound adenosine 47 is shown in Figure 


















Figure 17: A) Hexameric arrangement of Streptomyces. sp. MA37 fluorinase 
superimposed on S. cattleya fluorinase B) Superimposition of Streptomyces sp. MA37 
fluorinase on S. cattleya fluorinase. C) Superimposition of monomeric unit of Streptomyces 
sp. MA37 fluorinase to S. cattleya fluorinase. (Streptomyces sp. MA37 fluorinase is 
represented in dark colours (blue, green, red, orange, purple and cyan) and S. cattleya 




fluorinase in corresponding light colours) D) The active site of the Streptomyces sp. MA37 
fluorinase with bound adenosine 47. Residues Asp16, Trp50 , Asn 215 and Phe254 play a 
key role in substrate recognition, while Ser158 is reported to bind fluoride, all of which are 
highly conserved.12 (The crystal structure was resolved by molecular replacement by Greg 
Mann (Professor J. Naismith group) at the University of St Andrews). 
  
Despite deaminase treatment of the MA37 fluorinase, the solved crystal structure had 
adenosine 47 within active site of the enzyme. This clearly suggests that the removal of 
bound 47 using adenosine deaminase was an inefficient process.15 The adenosine-MA37 
fluorinase co-crystal structure, was then compared to that of the adenosine 47 bound S. 
cattleya fluorinase (Figure 17D). The two structures are almost identical at the monomeric 
level. FLA1 was also found to be arranged into a hexameric structure (Figure 17A) formed 
by two dimers (Figure 17B), where each dimer unit is a trimer of three monomeric units. 
The residues that form the active site of the Streptomyces sp. MA37 fluorinase are shared 
between two monomers and their arrangement is the same as that in S. cattleya fluorinase 
(Figure 17D). Only a small number of amino acids are dissimilar, and as these are situated 
remote from the active site they and do not cause any major structural changes to FLA. The 
conserved 21 amino acid loop is also present in FLA1, albeit in a more disordered manner 
than that found in FLA (Figure 17C).  
 
3.4.4 Enzymatic assays- evaluation of kinetic parameters 
 
The MA37 fluorinase was assayed, varying the concentrations of SAM 22, and the kinetic 
parameters (Km, Vmax) were evaluated in order to perform a comparative study to the S. 
cattleya fluorinase.45,46 
A standard curve for 5′-FDA 23 was prepared by measuring the relative absorption of known 
concentrations of synthetic 23 (Figure 18). The data obtained was plotted as UV 
absorbance against the concentration of 23. This was used to quantify the concentration of 










Figure 18: A standard curve obtained for 5′-FDA 23 concentrations vs UV.  
Enzyme assays were set up using 0.5 mg/ml of purified Streptomyces sp. MA-37 fluorinase, 
KF (200 mM) and varying concentrations of SAM 22 (2 µM to 1000 µM) in phosphate buffer 
at pH 7.8, as reported in Experimental 3.6.5. Periodically, small aliquots of each assay were 
removed and analysed by HPLC. Figure 19A shows one such HPLC reaction profile where 
the MA-37 fluorinase was incubated with 40 µM SAM 22 and an HPLC profile analysed 
over 30 min. Multiple reactions were performed for each reaction to correct for any pipetting 
or handling errors and the data was also corrected for any dilutions performed.  
The data obtained from multiple runs were averaged, and the initial rates of reaction 
determined by plotting 5′-FDA 23 concentration against time for varying concentrations of 
SAM 22 in a linear regression plot (using GraphPad Prism software, Figure 19B). The 
gradient of each line in Figure 19B represents the rate of each reaction at a given 
concentration of 22. A general increase in 23 production was observed over time as the 
concentration of 22 was increased up to 500 µM, after which the maximum rate of reaction 
(Vmax) was achieved, most likely due to substrate saturation. 
The rate of reaction of each assay was plotted against corresponding 22 concentrations 
and fitted to non-linear regression model for enzyme kinetics using GraphPad prism. The 
best fit was obtained for Michaelis-Menten kinetic profile (Figure 19C) which revealed the 



























Figure 19: A) HPLC time course of a single set of assays where the MA37 fluorinase was 
incubated with 40 µM SAM 22 and assayed over 30min. B) Linear regression model fitting 
5′-FDA 23 concentration against time for varying concentrations of 22 C) Non-linear 




The Km of MA-37 fluorinase for SAM was calculated from data shown in Figure 19C, (the 
substrate concentration at half maximum velocity). The maximum reaction rate for MA-37 
fluorinase was reported as 4.75 ±0.01 µM/min and the approximate Km for SAM 22 was 
calculated to be 105.5 µM ±7.68 µM. Since the 22 (Sigma) used in all enzyme reactions was 
80% pure, the approximate Km was corrected to 84.4 µM ±6.12µM. The h value (the hill slope 
that accounts for the steepness of the curve) was equal to 1 (1.004 ± 0.08739) which is 
consistent with non co-operative binding.  
The same kinetic analysis was performed for the S. cattleya fluorinase and the data was 
fitted also using GraphPad Prism software to calculate Km (Figure 20).  
The maximum reaction rate for S. cattleya fluorinase was observed to be 1.147 ± 0.1 
µM/min and the approximate Km for 22 was calculated to be 29.2 µM ± 2.41 µM, in line with 








Figure 20: Non-linear regression model fitting of the initial reaction rate against 
corresponding SAM 22 concentrations from which Km and kcat of S. cattleya fluorinase was 
calculated. 
S. cattleya fluorinase was reported to possess a kcat (turnover number) of approximately 
0.07 min-1, confirming the fluorinase to be a slow enzyme.45 The kcat defines the number of 
substrate molecules that each catalytic site of the enzyme converts per unit of time, and is 
usually expressed in s-1. The turnover number for Streptomyces sp. MA-37 fluorinase was 
calculated to be around 0.292 min-1, three times faster than the S. cattleya fluorinase (0.083 
min-1). However the Streptomyces sp. MA-37 fluorinase was also observed to have a higher 
Km (84.4µM) compared to Km of S. cattleya (29.2 µM). Therefore, the S. cattleya fluorinase 
has a higher affinity for SAM 22 compared to the Streptomyces sp. MA-37 fluorinase. The 
specificity constant of an enzyme is defined by the ratio of the kinetic constants kcat/Km. It is 





SAM concentration ( M)
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useful as a guide to compare the relative efficiencies of enzymes. Streptomyces cattleya 
fluorinase was calculated to have a specificity constant of 2.84 mM-1 min-1 less than the 
Streptomyces sp. MA-37 fluorinase at 3.6 mM-1 min-1, suggesting that the MA37 fluorinase 
is a little more efficient.  
3.4.5 Comparison of all fluorinases  
The two S. cattleya fluorinase gene homologs identified from Nocardia brasiliensis (flA2) 
and Actinoplanes sp. N902-109 (flA3) were also successfully over-expressed in E.coli using 
codon optimised synthetic genes. Both flA2 and flA3 gene products were purified and found 
to be functional fluorinases capable of catalysing the conversion of 22 and fluoride to 23. 
The kinetic analysis of these additional fluorinase enzymes was conducted in similar 
manner to that used for the Streptomyces sp. MA-37 fluorinase. The protein purification and 
kinetic analysis of Nocardia brasiliensis and Actinoplanes sp. N902-109 fluorinases were 
carried out by Dr Long Ma at the University of St Andrews. 11  
The kinetic data of the three newly identified fluorinases (flA1, flA2, flA3) and the S. cattleya 
fluorinase (flA) were compared. The S. cattleya fluorinase is the least efficient. The N. 
brasiliensis and Actinoplanes sp. N902-109 fluorinases were the most efficient, each having 
specificity constants of around 4.4 mM-1 min-1. The affinity (Km) of N. brasiliensis fluorinase 
for SAM 22 was similar to that observed with S. cattleya fluorinase at around 27 µM (Table 
1).  













After almost a decade since the characterisation of the S. cattleya fluorinase (FlA)12,17, a 
new bacterium Streptomyces sp. MA37 was identified from the soil below a Bark Cloth tree 
in Ghana and the genome successfully sequenced. The genome of Streptomyces sp. MA37 
revealed a homologue of the flA gene with 87% homology to the original fluorinase gene. 
This gene (flA1) was cloned in E.coli, over-expressed and the enzyme purified for assay 
analysis and crystallization studies. The crystal structure of Streptomyces sp. MA37 
fluorinase was found to be almost identical to that of the S. cattleya fluorinase. The kcat/Km 
of the Streptomyces sp. MA37 fluorinase was moderately more efficient than that of the S. 
cattleya fluorinase. Furthermore, three additional fluorinase homologs have since been 
discovered and their individual kinetics were assessed by discontinuous assay using the 
HPLC.  
3.6 Experimental 
3.6.1 Genomic DNA extraction from Streptomyces sp. MA-37 
Streptomyces sp. MA-37 was cultured following the protocol provided by the International 
Streptomyces Project (ISP) 247 (provided by Dr Hai Deng, University of Aberdeen). The 
mycelium was obtained from the cultures and was flash frozen in liquid nitrogen and finely 
ground using pestle and mortar. The ground mycelium was re-suspended in TE25S buffer 
(Tris-base 25 mM, EDTA disodium salt 25 mM and sucrose 10% and adjusted to pH 7.0; 5 
ml) and lysozyme was added to a final concentration of 2 mg/ml. The suspension was 
incubated for 40 min at 37 ºC. After which Proteinase K from Aspergillus melleus (Sigma, 
2U) and 10% sodium dodecylsulfate was added and incubated at 55 ºC for 1 h. To this 
preparation, 5 M NaCl (1ml) and phenol/chloroform (1:1 v/v; 5 ml) was added and mixed by 
inversion for 30 min. The resulting mixture was centrifuged (5000 rpm; 5 min) and the 
supernatant transferred to a clean eppendorf tube. The DNA was precipitated and dried 
using standard isopropanol precipitation48 before re-dissolving in water (0.3 ml) and the 
resulting genomic DNA of Streptomyces sp. MA-37 was stored at -20 ºC until further use. 
The purity of the gross DNA was analysed by Nanodrop 1000 spectrophotometer (Thermo 
Fisher Scientific Inc.). 
3.6.2 Cloning of flA1 gene into pEHISTEV plasmid 
The Streptomyces sp. MA-37 flA1 gene was amplified by PCR using previously purified 
genomic DNA as the template. Primers pMAF-F (5′- AATCCCATGGTGGCTGCAAACGGC 
-3′) and pMAF-R (5′-CACAAGCTTTCAGCGCGCTTCCAC-3′) were designed to match the 
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template DNA incorporating restriction sites NcoI and HindIII (restriction sites are 
underlined). The primers were synthesised by Eurogentec, Belgium. The PCR program 
included 35 cycles of 1 min at 95 °C (denaturation), 1 min 30 sec at 60 °C (annealing) and 
1 min at 72 °C (elongation) and a final extension for 2 min at 68 °C. The amplified PCR 
product and empty pEHISTEV vector28 was digested with NcoI and HindIII (Promega) in a 
double restriction digest in the presence of Buffer C at 37 °C for 2h. The digested PCR 
product and plasmid were analysed by DNA gel electrophoresis following which the gel 
bands were excised and gel purified using a Wizard® SV gel and PCR clean-up system 
(Promega). A ligation was set up using a Takara® DNA ligation kit, between the digested 
PCR product and digested pEHSITEV plasmid. The ligation was transformed in to E.coli 
DH5α (Thermo Fisher) cells and plated out on LB agar medium supplemented with 
kanamycin. Ten colonies were isolated from the transformation and analysed for the 
presence of flA1 by colony PCR. The colony PCR was conducted using pMAF-F and pMAF-
R and the PCR programme included 20 cycles of 15 s at 98 ºC, 2 s at 55 ºC and 20 s at 72 
ºC. The colonies containing the flA1 gene were cultured (10 ml) in LB supplemented with 
kanamycin. The pEHISTEV-flA1 plasmid was extracted from the culture using QIAprep® 
Spin Miniprep, Qiagen kit (Qiagen). The plasmids were sent for sequencing (DNA 
Sequencing & Services, University of Dundee) using standard primers T7 and T7 Term. 
The sequencing results were analysed by Chromas (Technelysium, Australia) for mutations 
and orientation of the insert and the most appropriate transformant was chosen for protein 
expression. The pEHISTEV-flA1 plasmid of the chosen transformant was then transformed 
into E.coli BL21 (DE3) cells (Agilent ®). 
3.6.3 Over-expression and purification of Streptomyces sp. MA37 fluorinase 
Transformed BL21 (DE3) Gold E.coli containing the pEHISTEV-flA1 plasmid were cultured 
in 10 ml of LB media supplemented with kanamycin, at 37 ºC overnight. This culture was 
used to inoculate 1 L LB media supplemented with 100 µg/ml kanamycin and incubated at 
37 ºC until the OD600 reached 0.6. Following which the cultures were then induced by 
isopropylthiogalactoside (IPTG, 0.03 mM) and incubated for 24 h at 16 ºC. The cultured 
E.coli was harvested by centrifugation (3200 rpm; 20 min) and small scale affinity 
purifications were performed using BioSprint 96® (Qiagen) to test 10 buffers (with varying 
pH and additives). The list of buffers used are reported in Figure 11. The fractions obtained 
from BioSprint 96® were analysed by SDS-PAGE and the optimal condition (20 mM Bis-
Tris pH 6.8, 150 mM NaCl and 0.1 M Glycine) providing the most amount of soluble protein 




The harvested cell pellet was re-suspended in lysis buffer (20 mM Bis-Tris pH 6.8, 150 mM 
NaCl, 0.1 M Glycine ; 200 ml) supplemented with protease inhibitor cocktail (1x Complete 
Mini -EDTA free®, Roche) and Deoxyribonuclease I from bovine pancreas (Sigma, 0.1 
mg/ml). The cells were lysed using a cell disruptor (Constant systems™; UK) at 30 kPSI 
and 4 ºC. Subsequently, the lysate was centrifuged (20000 rpm, 20 min, 4 ºC) and the 
supernatant filtered (0.45 µm syringe filter) following which the lysate was loaded onto a 10 
ml pre-packed Ni-Sepharose® High performance His-Trap HP (GE Healthcare) column 
connected to a FPLC. Protein-bound Ni2+ beads were washed with 20 mM Bis-Tris pH 6.8, 
150 mM NaCl, 0.1 M Glycine, 40 mM imidazole 40 pH 6.8 and 2.5 mM β-ME and eluted 
with 20 mM Bis-Tris pH 6.8, 150 mM NaCl, 0.1 M Glycine, 400 mM imidazole 40 pH 6.8, 
2.5 mM β-ME.  
 
The eluted protein was immediately loaded to a HiPrep 26/10 Desalting column (GE 
Healthcare) equilibrated with buffer 20 mM Bis-Tris pH 6.8, 150 mM NaCl and 0.1M Glycine. 
The purified MA37 fluorinase was incubated with adenosine deaminase (bovine 
recombinant, Sigma, 0.8 U) for 16 h- 24 h at 4 ºC, rocking at 30 rpm. The deamination 
process was analysed by HPLC until completion. An enzyme sample was removed after 16 
h, heat denatured (95 ºC, 5 min) and centrifuged (13000 rpm, 10 min) and the soluble 
fraction was analysed by HPLC for the presence of adenosine 47. HPLC column and 
method used is as described in 2.7.5. Once the deaminase treatment was complete, the 
resulting mixture of proteins, adenosine deaminase and MA37 fluorinase was loaded on to 
a pre-packed Ni-Sepharose® High performance His-Trap HP (GE Healthcare) column, 
washed and eluted as before, followed by a desalting column as mentioned previously.  
 
Subsequently the de-aminase treated MA37 fluorinase was incubated with (tobacco etch 
virus (TEV) protease (recombinant protein expressed in E.coli and kindly provided by 
Professor J. Naismith research group) at 1:20 ratio (TEV : protein) for 16 h, rocking at 30 
rpm at 4 ºC. The progress of the cleavage was monitored by SDS-PAGE gel as the 
molecular weight of the uncut protein (His6-tagged MA37 fluorinase) is larger than cut 
protein. In order to separate the TEV protease, cleaved His6-tag and His6-tag removed 
MA37 fluorinase, the enzyme mixture was loaded to a pre-packed Ni-Sepharose® High 
performance His-Trap HP (GE Healthcare) column equilibrated with wash buffer. The flow-
through from the column was collected as the His6-tag removed MA37 fluorinase would not 
interact with the Ni-NTA beads, whereas the His6-tagged TEV and cleaved His6-tags will be 
bound to the Ni-NTA beads. The MA37 fluorinase obtained in the flow-through was 
concentrated to ~ 7 ml using a centrifugal filter unit (30000 Da, GE Healthcare) following 
which the protein was loaded on to a gel filtration column Superdex S-200 (HR 16/60; GE 
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Healthcare), connected to a FPLC (ÄKTA express, Amersham Biosciences) equilibrated 
with 10 mM HEPES pH 7.4,150 mM NaCl, 1 mM TCEP (tris (2-carboxyethyl) phosphine). 
The fractions containing MA37 fluorinase were pooled and concentrated using a centrifugal 
filter unit (30000 Da, GE  
Healthcare). For crystallisation trials, the buffer was exchanged using centrifugal filter unit 
(30000 Da, GE Healthcare) to 20 mM phosphate pH 7.8 and 150 mM NaCl. The final protein 
concentration was measured via Nanodrop 1000 spectrophotometer (Thermo Fisher 
Scientific Inc.) and aliquots were flash frozen and stored in -80 ºC until further use. 
 
 
3.6.4 Crystallization of Streptomyces sp. MA37 fluorinase 
Initial screening was carried out using commercial screens in a 96-well format (JSCG+; 
Molecular dimensions and PEGs II suite; Qiagen) set up with 6 mg/ml and 12 mg/ml of 
purified Streptomyces sp. MA-37 fluorinase using a sitting drop vapour diffusion technique 
at 20 ºC and 4 ºC. All crystal trials were set up with an Arts Robbins Gryphon at protein to 
precipitant ratios of 2:1 and 1:1. Thin needle like crystals were observed in 4 conditions 
(Table 2), optimisation screens were designed for each condition varying the PEG 
concentrations and the additive concentrations, keeping the protein concentration at 
6mg/ml. Crystals were observed in several conditions of the optimisations however the best 
diffracting single crystals (octahedron shaped) were obtained with 7% w/v PEG 6000 and 
0.5 M NaCl at 20 ºC. These crystals were grown to their maximum size over 1.5- 2 weeks 
and a single crystal was picked and flash-frozen in cryoprotectant containing precipitant 
supplemented with 30% glycerol. Data were collected in-house at 100 K on a Rigaku 007 
HFM rotating anode X-ray generator with a Saturn 944 CCD detector. A dataset of 236 
frames of 0.5° oscillation with a crystal-to-detector distance of 60 mm and 240 sec exposure 
per frame was collected. The data were indexed and integrated using MOSFLM and scaled 
using SCALA. 
The structure was solved using PHASER molecular replacement, using the S. cattleya 
fluorinase. The structure was refined iteratively through manual building in COOT 









Table 2: Crystal forming conditions of the commercial screens, PEGs II suite (Qiagen) and 
JSCG+ (Molecular dimensions) which were the basis to design optimisation screens. 
 
 
3.6.5 Km determination of Streptomyces sp. MA37 fluorinase 
Purified MA-37 fluorinase was used to set up a series of HPLC assays to determine the Km 
for SAM 22. 0.5 mg/ml of MA-37 fluorinase was incubated with 200 mM KF, 20 mM 
phosphate buffer (pH 7.8) and varying concentrations of SAM 22 (2 µM, 5 µM, 10 µM, 25 
µM, 40 µM, 60 µM, 100 µM, 250 µM, 500 µM, 800 µM and 1000 µM), in a total reaction 
volume of 1 ml and incubated at 37 ºC. Aliquots from each reaction was removed 
periodically (100 µl every 5 min, 10 min, 15 min, 20 min, 25 min and 30 min), heat denatured 
(95 ºC, 5 min) and centrifuged (13000 rpm, 10 min) to precipitate the enzyme. The 
supernatant (50 µl) was diluted with water (100 µl) out of which 100 µl was injected to the 
Phenomenex® Kinetix 5µm C18 100 Å (150 mm x 4.6 mm) column using mobile phase : 
water with 0.05% TFA (solvent A) to MeCN with 0.05% TFA (solvent B). The HPLC analysis 
was performed using a Shimadzu Prominence system with a two-step gradient 5% to 23% 
solvent B over 14 min, then from 23% to 95% solvent B over 16 min; then 95% solvent B 
for 3 min followed by a re-equilibration with 5% solvent B for 5 min. The flow rate was 
1ml/min and the UV absorbance was measured at 260nm.  
The standard curve for 5′-FDA 23 was prepared by running known concentrations of 23 
using the same HPLC method.  
Commercial Screen ; Well in 
which crystals were observed 
Contents of the well Concentration range for 
optimisation 
PEGs II ; D6 30% w/v PEG 4000, NaOAc 
0.1 M pH 4.6, 0.1M MgCl2 
25- 36% w/v PEG 4000 and 
0.04 - 0.18 M MgCl2 
PEGs II ; F7 25% w/v PEG 4000, 0.1 M 
NaOAc, 0.2 M Li2SO4, 0.1 M 
HEPES pH 7.5 
20- 31% w/v PEG 4000 and 
0.02 - 0.16 M NaOAc 
PEGs II ; G5 12% w/v PEG 6000 and 2 M 
NaCl 
6 -17% w/v PEG 6000 and 0.5- 
4 M NaCl 
JSCG+ ; B2 20% w/v PEG 3350, 0.2 M 
NaSCN 
15- 26% w/v PEG 3350 and 
0.1 -0.35 M NaSCN 
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4. Crystallisation of 5-FDRPi Isomerase 
 
4.1 Methionine salvage pathway 
The methionine salvage pathway also known as the 5′-methylthioadenosine (MTA) 4 cycle 
is an essential cellular process in all organisms as it recycles sulphur-containing 
metabolites to regenerate L-methionine 27. The amino acid L-methionine 27 is essential for 
numerous important cellular functions including: protein synthesis, the regulation of gene 
expression (via DNA and rRNA methylation), as well as the biosynthesis of secondary 
metabolites, hormones, phospholipids and polyamines. The cell utilises L-methionine 27 as 
both a proteinogenic amino acid and a component of the cofactor SAM 22, which is formed 
by an enzyme catalysed condensation reaction between L-methionine 27 and ATP.1 As the 
amount of 27 in a cell is limited it is essential for it to be recycled for cell survival. Most L-
methionine 27 consumed in the generation of 22 is ultimately converted to the by-product, 




















Scheme 1: The methionine salvage pathway of B. subtilis highlighting the MTRPi in red 



















































































The enzymes involved in the methionine salvage pathway of model bacterial organisms, 
such as E. coli 1,3,4 and Klebsiella pneumoniae5,6, have been widely studied and the pathway 
is well characterised. However, studies on other species of bacteria have revealed the use 
of alternative enzymes and different intermediates throughout the pathway, indicating a 
diversity of the methionine biosynthetic pathway dependent on the organism in which it 
resides.7 In bacteria and plants, MTA 41 is first depurinated and phosphorylated to form 5-
methylthioribose 1-phosphate (MTRP 30) in two steps via 5-methylthioribose (MTR) 49, 
utilising both a nucleosidase and a kinase (Scheme 1). In animals, 30 is formed in a single 
step reaction catalysed by a phosphorylase. Subsequently, 30 is transformed to 5-
methylthioribulose 1-phosphate (MTRuP) 50 by an 5-deoxy-5-methylthioribose 1-
phosphate isomerase (MTRPi) which catalyses the ring opening of 30. The MTRulP 50 
produced by MTRPi undergoes several enzyme catalysed reactions including dehydration 
and oxidative decarboxylation to generate 4-methylthio-2-oxobutyrate 51, an immediate 
precursor for SAM 22 (Scheme 1).1 The final step in the L-methionine 27 salvage pathway 
involves a transaminase which produces free methionine.  
 
4.2 Aldose ketose isomerase  
Aldose-ketose isomerases are crucial enzymes involved in the methionine salvage 
pathways present in all types of organisms, from unicellular bacteria to plants and animals. 
Such an isomerase catalyses the reversible isomerisation between α-hydroxyaldoses and 
α-hydroxyketoses (Scheme 2). In principle this class of enzymes can proceed via two 
mechanisms, the most common of which involves a cis-enediol intermediate as observed 
in the triose phosphate isomerase, which catalyse the interconversion of dihydroxyacetone 





Scheme 2: A simplified reaction scheme of the aldose-ketose isomerases. 
Isotopic labelling studies investigating triose phosphate isomerase have demonstrated that 
the pro-R proton on C1 was removed by a glutamate residue (Glu165) acting as a base. As 
glutamate residues easily undergo proton exchange with the solvent, when the reaction is 
carried out in D2O, deuterium incorporation is observed at the C1 position of DHAP 31 and 
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C2 of G3P 52 (Scheme 3A).8 The enediol intermediate is stabilised by a neutral His-95 and 
a positively charged Lys-12 side chain residue. These cis-endiol mediating enzymes do not 
require any metal ions to catalyse the reaction. Phosphoglucose isomerase is also an 
aldose-ketose isomerase which proceeds via cis-enediol intermediate and catalyses the 











Scheme 3 A): Cis-enediol mediated reaction mechanism for triose phosphate isomerase.8 
B) Active site arrangement of the intermediate and final product for S. olivochromogenes 
xylose isomerase showing the proposed mechanism.9 In both cases the transferred proton 
is highlighted in dark blue and the catalytic triad involved in catalysis is highlighted in green.  
Aldose-ketose isomerases are also found to proceed via metal dependent 1,2-hydride shift 
mechanism as observed for S. olivochromogenes xylose isomerase. These enzymes 
catalyse the interconversion of several aldose and ketose sugars. Primarily they catalyse 
the interconversion of xylose to xylulose 53 and glucose to fructose. Structural analysis of 
the xylose isomerase of S. olivochromogenes revealed it to be a tetrameric enzyme 
containing a bridged bimetallic system that acts as an electrophilic centre to promote 
hydride transfer within the active site. The two divalent metal ions secured by xylose 
coordination are thought to be involved in stabilising the transition state. During the hydride 
shift mediated interconversion, the hydrogen moves directly between C1 and C2 as a 
hydride, and as such cannot exchange with the solvent (Scheme 3B). Therefore when the 
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reaction is carried out in the presence of D2O, no deuterium exchange is observed, unlike 
the cis-enediol mechanism.11,12 
The enzyme, 5-deoxy-5-fluoro-D-ribose 1-phosphate isomerase (5-FDRPi) identified in S. 
cattleya was also found to be an aldose-ketose isomerase.13,14 The Basic Local Alignment 
Tool (BLAST) analysis of the protein sequence of 5-FDRPi revealed some sequence 
identity to the Bacillus subtilis MTRPi (35%) and the Ypr118w of Saccharomyces cerevisiae 
(PDB code: 1W2W; 26%) (Figure 1).13 Therefore these MTRPi enzymes were used as 
reference structures for the study of 5-FDRPi, and this Chapter describes the over-
expression and crystallisation of 5-FDRPi in an effort to provide an insight in to its 
mechanism.  
4.3 Ribose 1-phosphate isomerases 
4.3.1 Identification of 5-deoxy-5-fluoro-D-ribose 1-phosphate isomerase (5-FDRPi) 
from S. cattleya 
 
NMR studies conducted on cell free extracts of S. cattleya have confirmed the conversion 
of 5-FDRP 24 to 5-FDRulP 25 to be the third step in fluorometabolite production.14 
Subsequently, the B. subtilis MTRPi gene homolog in S. coelicolor ( gene SCO3014) was 
isolated, cloned and over-expressed in E. coli, as the full genome sequence of S. cattleya 
was unavailable at the time, in 2008. Using the protein sequence of the S. coelicolor 
isomerase, the equivalent gene in S. avermitilis (gene SAV6658) was identified, as this was 
the most closely related organism to S. cattleya. Primers were designed close to highly 
conserved regions of SAV6658 and these primers were used to amplify the homologous 
isomerase in S. cattleya (gene SCATT 20080). Primer walking was performed on the 
amplified PCR product which provided the gene sequence for the S. cattleya isomerase. 
The SCATT 20080 gene was then cloned, and over-expressed in E. coli, and was 
subsequently shown (19F NMR assay) to catalyse the conversion of 24 to 25.15 
 
In 2011 the full genome sequence of S. cattleya was published16 following which another 
isomerase was identified in S. cattleya (SCATT 32590). SCATT 32590 was observed to be 
clustered among other genes expressing proteins related to the methionine salvage 
pathway suggesting its involvement in primary metabolism. The isomerase expressed by 
gene SCATT 20080 was not associated with any primary metabolic pathways and assumed 
to be exclusively involved in the fluorometabolite pathway. Consistent with this a SCATT 
20080 gene knock out mutant of S. cattleya was viable, but incapable of producing the two 
fluorometabolites; FAc 10 and 4FT 14. 15 
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4.3.2 Enzymes related to 5-FDRPi by sequence 
When 5-FDRPi from S. cattleya was first identified in 2008 the BLAST analysis showed that 
the S. avermitilis SAV6658 gene and S. coelicolor SCO3014 gene possessed the highest 
sequence identities to 5-FDRPi.15 However, more current BLASTp (protein BLAST) 
analysis of S. cattleya 5-FDRPi revealed hits for hundreds of bacterial MTRPi’s involved in 
the methionine salvage pathway, along with proteins related to the initiation factor 2 (IF2) 
subunit family, which are important regulators of translation initiation in eukaryotes.17 As 
genome sequencing has become popular and cost effective, several thousand bacterial 
genomes have been sequenced and made available, and as such have led to increased 
hits in BLASTp analysis.18 Most IF2 protein hits matching S. cattleya 5-FDRPi originate from 
yeast (predominantly Saccharomyces cerevisiae). These IF2 family proteins are thought to 
form a ternary complex consisting of Met-t-RNA, GTP and an initiation factor protein elF2. 
Once formed, this ternary complex associates with the smaller subunit of the ribosome to 
form a preinitiation complex which subsequently binds to mRNA and initiates protein 
translation. 17,19 Prior to the crystallisation and characterisation of B. subtilis MTRPi20 most 
MTRPi of prokaryotic origin were mis-annotated as IF2 family proteins.  
Currently, 27 genes annotated as MTRPi, have been identified from various Streptomyces 
species, each of which have sequence identity ranging from 75% to 80% to 5-FDRPi and 
possess a 0 E value (a statistical parameter describing the probability of the number of hits 
one can expect to see by chance when searching a database, the closer the value to 0 the 
lesser the chance that it is a random hit). These Streptomyces species include S. 
olivochromogenes with a 75% sequence identity, the organism from which xylose 
isomerase was identified (as previously discussed in section 4.2). S. aurantiacus and S. 
iranensis, which both have over 80% sequence identity to the S. cattleya 5-FDRPi (Figure 
1) S. aurantiacus was first isolated in 1969 in China21, whereas S. iranensis was first 
isolated in 2010 from soil sample in Isfahan city, Iran. Both these locations are 
geographically disparate to New Jersey, USA where S. cattleya was first identified in 
1979.22 S. xinghaiensis, a marine Streptomyces (discussed in Chapter 2) identified in 2011 
from China, also contains an MTRPi gene with 76% sequence identity to 5-FDRPi of S. 
cattleya (Figure 1). In addition, over hundreds of genes in other Streptomyces species 
annotated as either MTRPi or IF2 with acceptable E values were also observed.  
Actinobacteria OK006 gene annotated as MTRPi were also shown to have approximately 
75% sequence identity to 5-FDRPi (Figure 1). Actinobacteria OK006 belongs to the 
Streptomyces genus and was first isolated in Oregon USA in 2015.23 Despite the existence 
of many genes with high sequence identity to 5-FDRPi, most of these genes have not been 
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explored in detail. The closest representative of 5-FDRPi, which has been studied 
structurally for its mechanism and binding is the MTRPi of B. subtilis, which has 35% 
sequence identity to 5-FDRPi (Figure 1). 
Figure 1: Sequence identity alignment of MTRPi from S. aurantiacus (WP_016640738.1), 
S. iranensis (WP_044574421.1), S. xinghaiensis (WP_019711652.1), Actinobacteria 
OK600 (WP_054229590.1), B. subtilis (WP_041333442.1) and 5-FDRPi of S. cattleya 
(WP_014142773.1). Over 80% sequence identity is represented by dark blue and less than 
40% identity is represented by white, lighter shades represent moderate sequence identity. 
The red box indicates the two catalytic residues which are highly conserved in all of the 
above mentioned MTRPi’s.  
 
4.3.3 The MTRPi from Bacillus subtilis 
MTRPi plays a key role in the methionine salvage pathway of B. subtilis by catalysing the 
interconversion of 30 and 50 (Scheme 1). MTRPi has protein sequence identity to other IF2 
family proteins isolated from Saccharomyces cerevisiae (38%). In addition to this, other 
proteins possessing some sequence identity to B. subtilis MTRPi were observed in 




















Figure 2: Schematic representation of MTRulP 50 bound active site of B. subtilis MTRPi, 
showing the interactions of 50 with the surrounding amino acids in the active site. The 
residues involved in binding of the phosphate group (orange), the backbone oxygens or 
hydroxyls (green) along with the hydrophobic interactions with methylthio group (magenta) 
is displayed. Image reproduced and modified with permission from Matsumura et al.20 
 
Enzymology studies carried out on MTRPi have shown that it does not require metal ions 
for catalysis, analogous to enzymes that are believed to catalyse a cis-enediol intermediate 
isomerisation mechanism. However, NMR studies performed on MTRPi reactions carried 
out in the presence of D2O have shown that deuterium was not incorporated into the 
product, MTRulP 50,24 resembling observations found in enzymes involved in a hydride 
transfer mechanism, as a cis-enediol mechanism should promote the deuterium exchange 
with the solvent. Therefore, attempts were made to obtain a crystal structure of the MTRPi 
complexed with the product, 50. The MTRulP 50 bound structure of the B. subtilis MTRPi 
protein was solved by Matsumura in 2008 (PDB: 2YVK). Close analysis of the active site of 
MTRPi identified the positively charged residues: Arg51, Arg94 and Lys 251 (Figure 2; 
residues in orange) participating in hydrogen bonding to the phosphate group along with 
Gln199, to form the enzyme-substrate complex. The methylthio group of 50 was observed 
to be surrounded by a hydrophobic pocket formed by the conserved residues Pro54, 
Thr167, Ala158 and Ala162 (Figure 2; residues in magenta). Despite the product-bound 
crystal structure of MTRPi, these data did not shed any light on the mechanism. Two highly 




















































the active site as crucial for enzyme catalysis. Asp240 was suggested to act as a proton 
donor/acceptor and Cys160 was suggested to become deprotonated and act as a base for 
catalysis in cis-enediol mechanism or stabilise a transient positive charge on the 
intermediate during 1, 2 hydride shift (Scheme 4).20,24 A small number of residues adjacent 
to these catalytic residues were also found to be conserved (highlighted by dark blue in 
Figure 1). 
 
The co-crystal structure of the MTRPi enzyme bound to ring opened product MTRulP 50 
did not provide any evidence supporting either mechanism. However if a crystal structure 
of the MTRPi with a ring closed substrate was obtained, it may provide evidence to support 
one of the potential mechanisms, as such a structure might demonstrate the active site in 



















Scheme 4: Possible mechanisms of B. subtilis MTRPi reaction.20 
  
The following section will discuss previous crystallisation studies carried out on 5-FDRPi in 





























































4.4 Previous studies on Streptomyces cattleya 5-deoxy-5-fluoro-D-ribose 1-
phosphate isomerase (5-FDRPi) 
 
4.4.1 Site directed mutagenesis of 5-FDRPi 
 
Sequence analysis of the enzymes closely related to 5-FDRPi; the MTRPi of B. subtilis 
(35%) and yeast Ypr118w (26%)17, reveal several conserved residues which may be 
involved in catalysis. In the 5-FDRPi, Cys177 with Asn178, along with Asp257 and four 
adjacent residues were found to be conserved. The crystal structures of the MTRPi 
enzymes from both B. subtilis and yeast were both observed as dimers with the two active 
sites closely resemble each other. The active sites were found to be located in a pocket 
formed by α-helices held together by loops in their open conformation, and therefore it was 
postulated that the catalytic site of 5-FDRPi would be similar to that of B. subtilis MTRPi.17,20 
 
In order to assess the importance of the Cys177 and Asp257 residues for catalysis, site-
directed mutagenesis on 5-FDRPi was carried out. Cys177 was replaced with either an 
alanine, possessing an unreactive functional group or a serine, where -SH was replaced 
by -OH. Both mutants were found to be inactive demonstrating the importance of the 
cysteine residue at this position. 25 
 
Asp257 is postulated to be a proton donor/acceptor, and this was replaced by directed 
mutagenesis with either a glycine; or an asparagine where the carboxylate group is 
replaced with an amide. Both of these mutants were also found to be inactive. The highly 
conserved hydrophobic pocket within the active site restricts the side chain rotation of 
Asp257, which is believed to increase the pKa of the carboxyl group from 3.8 to 
approximately 7.5.20 This enables Asp257 to act as a general acid/base during catalysis, a 
function the amide group of asparagine would not be able to achieve, despite providing the 
required hydrogen bonding.25 
 
4.4.2 Truncation mutants of the 5-FDRPi based on a secondary structure prediction 
 
Many attempts have been made to crystallise native 5-FDRPi, involving the use of various 
screens, additives, incubation temperatures and seeding experiments, however any 
crystals obtained from these experiments were multi-layered and diffracted poorly. 25 
Therefore the protein sequence of 5-FDRPi was analysed through a secondary structure 
prediction software (PROF26) to identify any disordered loops at the terminus of the protein, 
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as deletion of such regions can often improve crystallisation.27,28 The PROF tool compares 
linear sequences of amino acids to a database of known secondary structures, and predicts 
the regions that are likely to fold either as α-helices, β-sheets or loop structures. Several 
disordered loop regions were identified in 5-FDRPi, out of which two regions were chosen 
from the N-terminus and two from the C-terminus. Truncated mutants were prepared and 
over-expressed in E. coli, however the 5-FDRPi over-expressed from all truncated mutants 
were found to be insoluble. Furthermore, systematic truncation mutants were also prepared 
of 5-FDRPi, where the peptide was sequentially shortened from both N terminus and C 
terminus, five residues at a time, and over-expressed in E. coli. The N-terminus shortened 
mutants were all found to produce insoluble protein whereas C-terminus mutants shortened 
by up to 25 residues were found to be partially soluble, demonstrating the importance of 
the N terminus in protein folding and solubility. A number of the C terminus truncated 
mutants of 5-FDRPi which produced soluble protein were over-expressed in E. coli in an 
attempt to produce crystallised protein, however these over-expressed proteins were found 
to be unstable and degraded over time.25  
 
4.4.3 A phosphonate analogue of the 5-FDRPi substrate 
 
In an attempt to crystallise a cyclic sugar to explore the key residues for binding and probe 
the catalytic mechanism of FDRPi, a non-hydrolysable analogue of 5-FDRP 24 was 
prepared by replacing the linking oxygen of the phosphate ester with a methylene group 
(Figure 3). The synthetic route to the 5′-fluororibosephosphonate 55 was designed by 
Nasomjai starting from D-ribose 39.29 It was postulated that this phosphonate would bind 
the active site despite the absence of the oxygen, but could not be hydrolysed by the 







Figure 3: The substrate 5-FDRP 24 and the non-hydrolysable 5′-fluororibosephosphonate 







4.5 Project aims 
 
In order to gain an insight into the mechanism of 5-FDRPi an attempt was made to 
co-crystallise the 5-FDRPi with the inert 5′-fluororibosephosphonate 55 substrate.25 5-
FDRPi has previously been cloned, over-expressed and purified successfully in E. coli, and 
as such the 5-FDRPi was again purified using the same protocol, and extensive 
crystallisation trials were performed. Furthermore, ITC and NMR binding assays were 
carried out to assess the binding affinity of 55 analogue with 5-FDRPi.  
 
4.6 Results and discussion 
 
4.6.1 Over-expression and purification of 5-FDRPi 
 
The cloning and over-expression of 5-FDRPi in E. coli has been reported previously.15 The 
genomic DNA of S. cattleya was obtained following the standard procedure described in 
Kieser et al (2000), 30 coupled with a phenol/chloroform DNA extraction.31 The SCATT 
20080 gene was amplified by PCR using genomic DNA as a template, and a set of primers 
designed to complement the gene. The PCR product was first cloned into the vector pGEM-
T (Promega), as direct cloning into pEHISTEV proved difficult. The recombinant vector 
pGEM-T-SCATT20080 was then transformed32 in to DH10β E. coli. The transformed E. coli 
were analysed by colony PCR and visualised by agarose gel electrophoresis for the 
presence of the pGEM-SCATT 20080. The colonies containing the recombinant plasmid 
were sequenced to confirm the accuracy of the inserted gene product. The correct 
recombinant plasmid was digested with the restriction endonucleases NcoI and XhoI, and 
the gene was subcloned into enzyme digested pEHISTEV. The recombinant plasmid, 
pEHISTEV-SCATT20080, was then transformed32 into BL21-Gold (DE3) E. coli cells. The 
pEHISTEV vector was designed to add a cleavable N-terminal poly-histidine tag (His6-tag) 
to the expressed protein. The His6-tag can be cleaved by treating the protein with TEV 
protease. This protease acts on a cleavage site inserted between the expressed protein 
and the His6-tag.33  
 
The over-expression and purification procedure for 5-FDRPi was adapted from that used 
to isolate S. coelicolor 5-FDRPi (SCO3014 gene product).15 The protocol used to purify S. 
cattleya 5-FDRPi was a modified version of the previously reported procedure.25 BL21-Gold 
(DE3) E. coli cells containing pEHISTEV-SCATT20080 were used to inoculate large 
cultures of LB supplemented with kanamycin. The 5-FDRPi expression was induced with 
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IPTG and the cultures were grown for 20 h at 25 ºC following which the cells were harvested 
and re-suspended in lysis buffer. The cells were lysed using one shot cell disrupter and the 
soluble fraction was loaded on to a Ni-NTA column pre equilibrated with wash buffer. The 
5-FDRPi was eluted using a buffer containing high imidazole concentration and the 
fractions obtained were analysed by SDS-PAGE. The 5-FDRPi was visualised as a ~42 
kDa protein in the elution fractions (Figure 4). Addition of 1 mM β-ME to all buffers was 
required to prevent the oxidation of the thiol groups of cysteine residues which would 











Figure 4: The SDS-PAGE gel electrophoresis of fractions obtained from Ni-NTA column. 
M: un-stained PageRuler protein ladder, S- soluble fraction, I- insoluble fraction, E- elutions.  
 
The pooled fractions containing 5-FDRPi was incubated with His6-tagged TEV protease in 
1:20 ratio (TEV: 5-FDRPi) whilst dialysing against 20 mM Tris-HCl pH 7.5, 150 mM NaCl 
and 1 mM β-M. The progress of the TEV protease mediated His6-tag cleavage of 5-FDRPi 
was monitored by SDS-PAGE gel. Subsequently, a second Ni-NTA column was run to 
separate the His6-tagged-TEV, uncleaved His6-tagged 5-FDRPi and cleaved His6-tags from 
the His6-tag cleaved 5-FDRPi. The dialysed TEV digested 5-FDRPi fraction was loaded 
onto a Ni column and all fractions obtained were monitored by SDS-PAGE gel. The flow-
through out of the Ni column was collected as the His6-tag removed 5-FDRPi would not 



















Figure 5: His6-tag of 5-FDRPi was cleaved by incubating with purified TEV protease. M: 
un-stained PageRuler protein ladder (Thermo scientific), 1= 5-FDRPi post incubation with 
TEV, 2= TEV protease and 5-FDRPi, 3= 5-FDRPi prior to incubation with TEV. 
 
The 5-FDRPi obtained was concentrated and loaded onto a Superdex 200 gel filtration 
column and eluted with buffer containing 20 mM Tris pH 7.5, 150 mM NaCl and 1 mM TCEP 
(Figure 6). TCEP is a considerably more stable reducing agent compared to more common 
reducing agents such as β-ME and dithiothreitol (DTT). In order to determine the molecular 
weight of the 5-FDRPi, gel filtration standard, which is a mixture of proteins of known 
molecular weight (Bio-Rad), was run using the same buffer as the 5-FDRPi in the same GF 
column. Based on the values obtained for the elution volume of each known protein, the 
logarithm of the molecular weights was plotted to a graph. Using the elution volume of 5-
FDRPi, the molecular weight (log) of 5-FDRPi could be obtained to a moderate accuracy, 
and was observed to be around 82,300 Da. This suggests the 5-FDRPi may exist as a 
dimer (~84,000 Da) analogous to the B. subtilis MTRPi.  
 
The SEC fractions containing 5-FDRPi were pooled and concentrated (10-20 mg/ml) for 
assays and crystallisation trials. The identity of the protein was confirmed as S. cattleya 5-






















Figure 6: Size exclusion column chromatography of S. cattleya 5-FDRPi showing the UV 
absorption in blue, concentration of buffer in brown, flow rate in green and fractions in red.  
4.6.2 NMR Assaying 5-FDRPi and small scale enzymatic preparation of 5-FDRP 24 
The activity of the purified 5-FDRPi was assayed by 19F-NMR.14,15 Previously, the 5-FDRP 
24 required for the 5-FDRPi assays was prepared enzymatically by treating synthetically 
prepared FDA 2334 with adenosine deaminase, to generate FDI 34, this was then treated 
with recombinant E. coli PNPase (Sigma) to form 24.13,25 The natural substrate for this 
PNPase is inosine, which is converted to hypoxanthine 56 and ribose-1-phosphate 54 with 
the use of free phosphate (Scheme 5). Incubation of this enzyme with the unnatural 
substrate FDI 34, mediated a slow, low yielding, reaction to produce 24 and xanthine which 
was then coupled to 5-FDRPi to generate 25. The production of 25 was confirmed by GC-
MS, however, the production of 24 from E. coli PNP was low yielding and inefficient, 











Scheme 5: E. coli PNP catalyses inosine/FDI 34 to ribose-1-phosphate 54 and 
hypoxanthine 56 in the presence of phosphate buffer at pH 7.5.  
Over expression and purification of S. cattleya PNP proved to be difficult as the 
overexpressed PNP was found to be insoluble, however some partially purified protein 
could be obtained as an MBP-tagged fusion protein (to increase its solubility). Partially 
purified S. cattleya PNP was successfully coupled with the 5-FDRPi enzymatic assays 
consistent with the proposed biosynthetic pathway for S. cattleya.15 However sufficient 
quantities of S. cattleya PNP could not be obtained to assay 5-FDRPi due to low quantities 
of soluble S. cattleya PNP obtained. Additionally an immobilised bacterial PNP enzyme, 
(kindly provided by GSK) was used to perform the PNP reaction starting from synthetic FDA 
23. This PNP proved to be much more efficient than E. coli PNP and was subsequently 
used to produce 5-FDRP 24 from 23. A solution of 23 (1 mg) was incubated with 
immobilised PNP in 20 mM phosphate pH 7.5 with shaking at 40 rpm for 2 h. The reaction 
was filtered and the supernatant was incubated with purified 5-FDRPi (120 mM) at 37 ºC 
for 3 h and analysed by 19F-NMR. This demonstrated the conversion of 24 to 5-FDRulP 25 
in addition to some unreacted 23. Therefore the immobilised PNP was found to be more 
efficient than PNP used in previous experiments.  
5-FDRP 24 has been produced as an intermediate in small quantities during these PNP 
mediated enzyme reactions (which are then coupled to 5-FDRPi). As such, 24 has not been 
isolated and characterised previously due to its low production. Using the immobilised PNP, 
small scale production of 5-FDRP 24 was achieved. FDA 23 (6mg) was incubated with 
immobilised PNP (GSK) in 20 mM phosphate buffer pH 7.8 in a total reaction volume of 5 
ml. The reaction was incubated at 37º C shaking at 180 rpm over 5 days. The progress of 
the reaction was monitored by 19F-NMR. The reaction was observed to be slow; however, 
after 5 days of incubation, almost 96% of 23 has been converted to 24 (Figure 7). 
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Figure 7: 19F {1H} NMR assays showing the conversion of 5′-FDA 23 to 5-FDRP 24 with 
immobilised PNP.  
In order to separate the unreacted 23 from 24 several solid phase extraction (SPE) 
cartridges were trialled. Initially Discovery® DSC-SCX (strong cation exchange) was 
utilised in an effort to retain 23 and allow 24 to elute, along with the phosphate buffer. 
However no separation was observed using this SCX cartridge. Following this the 
Discovery® DSC-NH2 (aminopropyl; weak anion exchanger) (Sigma) cartridge was used, 
however only ~20% of the 5-FDRP 24 was eluted with the remainder eluting with 23. The 
next SPE cartridge trialled was the SOLA™WAX (weak anion exchanger) (Thermo 
Scientific). The pH of the PNP reaction product was lowered to pH 3.5 prior to loading on 
to the SOLA™WAX cartridge (Thermo scientific), which was then equilibrated with water- 
formic acid pH 3.5 (Figure 8; wash 1). The cartridge was then flushed with 100% methanol-
formic acid pH 3.5 (Figure 8; wash 2 and 3) followed by 50% methanol- ammonium 
hydroxide pH 9 (Figure 8; elution) as described in Experimental 4.8.3. The fractions 
collected were freeze-dried and re-suspended in D2O and analysed by 19F {1H} NMR. Wash 
1 was observed to contain almost all of the unreacted 5′-FDA 23 and wash 2 was found to 
contain most of the 24 with a little 24 in elution 1. Wash 3 contained small quantities of both 
23 and 24. Wash 2 and elution 1 fractions were pooled and freeze-dried. This purification 
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procedure was found to be sufficient and 24 (~5mg) was obtained in phosphate buffer, and 
was characterised by 1H and 13C NMR (Figure 9). Furthermore 2D NMR analysis for 5-












Figure 8: PNP reaction mixture was loaded to SOLA™WAX SPE cartridges and fractions 
collected were analysed by 19F {1H} NMR. 
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5-FDRP 24 produced via PNP was used in an isomerase assay (according to a previously 
reported procedure25). Thus 24 (1 mg) was incubated with purified 5-FDRPi (3 mg) at 37 ºC 
for 5 h. The production of 25 was observed as determined by 19F {1H} NMR (Figure 10).  
Figure 10: A) 5-FDRP 24 (~1 mg) produced via PNP was incubated with 5-FDRPi (3 mg) 
at 37 ºC for 5 h. B) The production of 5-FDRulP 24 was observed by 19F {1H} NMR. (These 
5-FDRPi assays were carried out based on previous work25). 
  
4.6.3 Crystallisation of 5-FDRPi 
 
Attempts to crystallise native 5-FDRPi had previously proved unsuccessful, resulting in 
protein crystals with overlapping layers, which diffracted poorly.25 Despite this lack of 
success, attempts were made to crystallise the native 5-FDRPi using a wide range of 
commercial screens and performing successive grid search optimisations to narrow the 
crystal forming conditions. Purified 5-FDRPi in 20 mM Tris pH 7.5, 150 mM NaCl and 1 mM 
TCEP was crystallised using the sitting drop vapor diffusion method in 96 well crystallisation 
plates. Routine screening crystal trials for 5-FDRPi were performed at 20 ºC and 4 ºC using 
four commercial screens; JSCG+, Wizard 1+2 (Molecular dimensions), PEGs I and II suite 
(Qiagen). All crystal trials were set up with an Arts Robbins Gryphon at protein to precipitant 
ratios of 2:1 and 1:1. Two 5-FDRPi concentrations at 14 mg/ml and 7.5 mg/ml were used 




Table 1: Crystallisation conditions for 5-FDRPi used for initial screening and their 
outcomes.  
 
Small rice-shaped, trapezohedron crystals (Figure 11A & B) were observed in three wells 
(Table 2) one in each screen, Wizard 1+2 (E12), PEGs I (D10) and PEGs II (G1) incubated 
at 20 ºC with 14 mg/ml 5-FDRPi. No crystals were observed in plates incubated at 4 ºC and 
plates set up with 7.5mg/ml 5-FDRPi. The three conditions were optimised, increasing the 
5-FDRPi concentrations (16 mg/ml) and varying PEG concentrations, additive and buffer 










4 ºC 4 ºC 
No crystals were observed 
20 ºC 20 ºC 
Wizard 1+2 
4 ºC 4 ºC No crystals were observed 
20 ºC 20 ºC 
Small crystals in few conditions 
(Table 2) in plate containing 14 
mg/ml 5-FDRPi (E2) 
PEGs I 
4 ºC 4 ºC No crystals were observed 
20 ºC 20 ºC 
Small crystals in few conditions 
(Table 2) in plate containing 14 
mg/ml 5-FDRPi (D10) 
PEGs II 
4 ºC 4 ºC No crystals were observed 
20 ºC 20 ºC 
Small crystals in few conditions 
(Table 2) in plate containing 14 
mg/ml 5-FDRPi (G1) 
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mentioned in Table 3. Few wells in D10 and G1 optimisations produced rice shaped, 
trapezohedron crystals as seen in Figure 11A and B. One condition in G1 optimisation (E1 
well) produced thin sheet like crystals (Figure 11C) which had not been observed 
previously. Therefore, further optimisation screening of E1 well was set up using 16mg/ml 
5-FDRPi (Experimental 4.8.5; Table 4).  
The best crystals (Figure 11D) were obtained in 25% PEG 5K MME, 0.1 M Tris-HCl pH 7.6. 
These crystals were allowed to grow for 9 days before harvesting. The crystals grew as 
clustered bristles fanning outwards at one end. A small number of these bristles were 
broken off, picked and flash-frozen in a cryoprotectant containing precipitant, supplemented 
with 35% glycerol. The crystals were shot in-house at 100 K on a Rigaku 007 HFM rotating 
anode X-ray generator with a Saturn 944 CCD detector. A dataset of 236 frames of 0.5° 
oscillation with a crystal-to-detector distance of 60 mm and 240 sec exposure per frame 
was collected. The data were indexed and integrated using MOSFLM and scaled 
using SCALA to obtain a crystal structure up to 1.7 Å resolution with an R value of 0.25 (a 
measure of the quality of the atomic model obtained from the crystallographic data). The 
crystal structure was resolved by molecular replacement on MTRPi structure of B. subtilis 
by Dr Jesko Koehnke at University of St Andrews (X-ray diffraction data is presented in 
Appendix 2). The active site of the 5-FDRPi crystal structure was found to be empty. 
Subsequently, the same crystal forming conditions were used to set up co-crystallisation 




Table 2: Crystal forming conditions of the commercial screens, Wizard 1+2 (Molecular dimensions), PEGs and PEGs II suite (Qiagen) were 






FDRPi, 20 ºC) 
Well 
Contents of the well Optimisation 
Precipitant Buffer Salt Precipitant Buffer Salt  5-FDRPi 
concentration 
Wizard 1+2  
14 mg/ml 5-
FDRPi, 20 ºC 
E12 30 % w/v 





 None 30- 40% w/v 
PEG 400,  
0.1 M sodium 
cacodylate pH 
6.5 – 7.5 
 None 14 mg/ml or 
16 mg/ml 
PEGs I  
14 mg/ml 5-











15- 20% w/v 
PEG 8000 
0.1 M Tris-HCl 
pH 7.5-7.8  




 14 mg/ml or 
16 mg/ml 
PEGs II  
14 mg/ml 5-











 19-24% w/v 
PEG 5000 
MME  
0.1 M Tris-HCl 
pH 7.5-7.8  








Table 3: Summary of the 5-FDRPi crystallising trials obtained from initial optimisation 
conditions.  
 
The structure was solved with PHASER molecular replacement, using the B. subtilis 
MTRPi. The structure was refined iteratively through manual building in COOT, and an 










Figure 11: Crystals of 5-FDRPi A) Rice shaped crystals produced from initial optimisations 
B) Trapezohedron shaped crystals obtained during initial and secondary optimisation 
screens C) Thin sheet like crystals only obtained in E1 well of G1 optimisation screen D) 
Thick bristles of clustered crystals was obtained from E1 well optimisation screen.
Screen E12 ;20 ºC Screen D10 ;20 ºC Screen G1;20 ºC 
5-FDRPi concentration 5-FDRPi concentration 5-FDRPi concentration 
16 mg/ml 16 mg/ml 16 mg/ml 
Spherulites and precipitate. Few conditions with rice 
shaped, trapezohedron 
crystals 
Few conditions with rice 
shaped, trapezohedron 
crystals and one condition 




Co-incubation with the 5′-fluororibosephosphonate 55 failed to produce any co-crystals. It 
was possible that the 55 does not bind to 5-FDRPi, despite a close structural relationship 
to the natural substrate, therefore binding was explored by conducting Isothermal titration 
calorimetry (ITC) studies.  
4.6.4 Binding assays by Isothermal titration calorimetry (ITC) 
 
In order to assess the binding affinity of the 5′-fluororibosephosphonate 55, isothermal 
titration calorimetry was employed. This involved a series of independent experiments 
where 55 was titrated into a solution of 5-FDRPi in phosphate buffer. ITC analysis of 5-
FDRPi with ribose-1-phosphate 54 was considered as a prospective positive control. 
Ribose-1-phosphate 54 is not commercially available and would require to be produced 
enzymatically. Incubating E.coli PNP with either adenosine 47 inosine in phosphate buffer 
similar to the enzymatic synthesis of 5-FDRP 24 produced ribose-1-phosphate 54. However 
preparation of 54 in quantities required for ITC experiments proved difficult. In addition, the 
enzyme reaction required phosphate buffer which could not be completely removed from 
54. Any mismatch in buffer and salts between the ligand and enzyme would produce a high 
heat of dilution on ITC which potentially masks any heat produced upon binding. 
 
5′-Fluororibosephosphonate 55 (1 mM) was titrated into 5-FDRPi (60 µM or 100 µM) and 
analysed by ITC. No thermal signal was observed, only the heat of dilution and background 
enthalpy of mixing could be recorded, as shown in Figure 12A. As a positive control tri-N-
acetyl-glucosamine (tri-NAG) (1.5 mM) was titrated into chicken egg white lysozyme (150 
µM) in phosphate buffer (Figure 12B). Each exothermic heat pulse (Figure 12B; upper panel) 
corresponds to individual injections (10 µ) of tri-NAG. Integrated heat data (Figure 12B; 
lower panel) constitute a differential binding curve that fit to a standard single binding site 
model to calculate the binding affinity (Km).  
 
This suggests 5′-Fluororibosephosphonate 55 may not bind to 5-FDRPi and highlights the 
importance of the bridging oxygen of 55 which must form important interactions within the 
active site. Replacing the oxygen with a methylene group may abolish any such interaction 











Figure 12: A) Isothermal titration calorimetric (ITC) determination of the binding affinity of 
5′-fluororibosephosphonate 55 (1 mM) when titrated into FDRPi (60 µM). No binding was 
observed for 55. B) Positive control for ITC: binding affinity of tri-N-acetyl-glucosamine (tri-
NAG) (1.5 mM) titrated into chicken egg white lysozyme (150 µM).  
 
4.6.5 Structural comparison of B. subtilis MTRPi and S. cattleya 5-FDRPi  
 
X-ray structural analysis of apo-5-FDRPi indicated that it exists as a dimer. This was also 
supported by SEC chromatography (4.6.1). The crystal structure of apo-5-FDRPi was 
superimposed on to the crystal structure B. subtilis MTRPi and both were found to have a 
very similar monomeric arrangement (Figure 13A), despite only possessing a 35% aa 
sequence identity.20 The tertiary structure of B. subtilis MTRPi was found to exist as a dimer, 
matching that of the preferred arrangement of 5-FDRPi. The structural alignment of the 
dimers of 5-FDRPi and B. subtilis MTRPi confirmed them to be conformationally very similar 
(Figure 13B). The amino acid sequence similarity was assessed in both S. cattleya 5-FDRPi 
and B. subtilis MTRPi by pairwise sequence alignment as the crystal structures of both were 
very similar despite low sequence identity. The 5-FDRPi and MTRPi were found to share 
~48% amino acid sequence similarity which may contribute to the structural similarity 










Figure 13: Superimposition of the structures of S. cattleya 5-FDRPi and B. subtilis MTRPi. 
A) Superimposition of monomeric 5-FDRPi of S. cattleya (magenta) and MTRPi of B. 
subtilis (teal). B) Superimposition of dimeric 5-FDRPi of S. cattleya (magenta) and MTRPi 
of B. subtilis (teal). C) Sequence similarity of both S. cattleya 5-FDRPi and B. subtilis 
MTRPi. (Residues that are identical are marked in black background, and amino acids that 
are similar among the sequences are given a grey background. 
 
As the active site residues have been previously identified in the MTRulP 50 bound 
structure of B. subtilis, this MTRPi crystal structure was mapped on to the empty structure 
obtained from the S. cattleya 5-FDRPi, in order to observe any similarities of their active 
site formations (Figure 14A). All the amino acid residues which form hydrogen bonds with 
the phosphate group and backbone oxygens or hydroxyls of 50 were found to be conserved 
in 5-FDRPi (Figure 14A). Most of the residues providing the hydrophobic interactions with 
the methylthio group of 50 in B. subtilis MTRPi were also found to be conserved in the yeast 
MTRPi, except for Ala162, which is replaced with threonine in Ypr118w (PDB code: 
1W2W).20 Similarly Ala162 was now Thr179 in 5-FDRPi. In addition to this, Ala166 and 
Thr167 of B. subtilis MTRPi were found to be replaced by Val183 and S184 respectively in 
the 5-FDRPi structure. Close analysis of the active site of B. subtilis MTRPi revealed that 
the loop formed by the three amino acids Ala162, Ala166 and Thr167 is coiled twice, thus 
reducing the space available within the active site, conversely in 5-FDRPi the same loop 
now formed by Thr167, Val183 and S184 is more relaxed (Figure 14B). This reconfiguration 
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of the loop might be important in interacting with the terminal fluorine of the substrate, 5-
FDRP 24.  
 
The mapped arrangement of the active site of 5-FDRPi is very similar to the active site of 
B. subtilis MTRPi, consistent with the high level of residue similarity, and both enzymes 
may reasonably operate via a similar mechanism. 
 
 
Figure 14: A) Superimposition of predicted active site residues for S. cattleya 5-FDRPi 
using B. subtilis MTRPi–MTRulP 50 bound structure as reference. 5-FDRPi in cyan, MTRPi 
in grey, highly conserved active site residues interacting around the phosphate group and 
the backbone oxygens of MTRPi (light blue) and possibly around 5-FDRPi (dark blue). The 
residues interacting with methylthio group of MTRulP 50 (yellow). Same residues mapped 
on to 5-FDRPi (orange) B) Close up of the arrangement of residues interacting with the 
terminal methylthio group of B. subtilis MTRPi (yellow residues annotated in red). The same 
residues mapped on to S. cattleya 5-FDRPi which would bind 5-FDRulP 25 with a terminal 




The objective of this aspect of the research was to obtain an X-ray crystal structure of the 
S. cattleya 5-FDRPi with the phosphonate analogue of 5-FDRP 24 bound to the active site, 
in an effort to provide a structure of a ring closed substrate and perhaps some insight into 
the mechanism of this enzyme. A crystal was obtained which diffracted to provide a 
structure of 1.7 Å resolution. The structure obtained of 5-FDRPi had an empty active site. 
In order to assess if the 55 would bind to the 5-FDRPi, binding studies were performed by 
ITC and NMR. Both binding studies suggested 5-FDRPi does not bind 55 and therefore 
subsequent co-crystallisation attempts were terminated. Comparative crystal structure 
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analysis of the S. cattleya apo-5-FDRPi and B. subtilis MTRPi bound to MTRP 30 revealed 
a similar tertiary structure and similar arrangement within the active site, which suggests 
that the two enzymes function via a similar mechanism. However this remains to be 




4.8.1 Over-expression and purification of 5-FDRPi 
 
BL21-Gold (DE3) E. coli cells were transformed32 with pEHISTEV-SCATT20080, which has 
been cloned previously (peptide sequence of the 5-FDRPi is mentioned in Appendix 3).15 
The over-expression and purification procedure for 5-FDRPi was adapted from that used 
to isolate S. coelicolor 5-FDRPi (SCO3014 gene product).15 The protocol used to purify S. 
cattleya 5-FDRPi was a modified version of the previously reported procedure.25 A single 
colony of E. coli was picked and used to inoculate 10 ml of LB supplemented with 1 % 
glucose and 50 µg/ml kanamycin. This culture was incubated at 37 ºC, shaking at 180 rpm 
for 12 h and used to inoculate 2 L baffled flasks filled with 400 ml of auto-induction media 
prepared using a mixture of ZY media (372 ml), 1 mM MgSO4 (final concentration), 5052 
solution (10 ml of 50X), NPS (20 ml of 20X) and kanamycin (100 µg/ml) according to a 
method described by Studier.35 The cultures were grown at 20 ºC, shaking at 180 rpm, for 
36 h following which the cells were harvested by centrifugation at 3200 rpm for 30 min. The 
cell pellet was re-suspended in lysis buffer (20 mM Tris-HCl pH 7.5 and 150 mM NaCl; 250 
ml) supplemented with Deoxyribonuclease I from bovine pancreas (Sigma; 0.1 mg/ml) and 
protease inhibitor cocktail (1 x Complete Mini–EDTA free®, Roche). Then the cells were 
lysed using a one shot cell disrupter (Constant systems™, UK) at 30 kPsi, 4 ºC. The lysate 
was centrifuged (15000 rpm, 20 min) to remove the cell debris and the soluble fraction was 
filtered (0.45 µm syringe filter) prior to loading onto a prepacked Ni-Sepharose High 
Performance His-Trap (GE Healthcare; 5 ml) column pre equilibrated with wash buffer 
containing 20 mM Tris-HCl pH 7.5, 500 mM NaCl, 1 mM β-ME and 40 mM imidazole pH 
7.5. The column was washed with wash buffer several times and Ni-bound 5-FDRPi was 
eluted using elution buffer containing 20 mM Tris-HCl pH 7.5, 500 mM NaCl, 1 mM β-ME 
and 400 mM imidazole pH 7.5. An SDS-PAGE gel was run to analyse the fractions obtained 
from the Ni-NTA column. The eluted fractions containing FDRPi were pooled and diluted 
with lysis buffer and TEV protease (recombinant protein expressed in E. coli and kindly 
donated from Professor J. Naismith research group) at 1:20 ratio (TEV: protein) was added 
This protein cocktail was dialysed against 5 L of 20 mM Tris-HCl pH 7.5, 150 mM NaCl at 
4 ºC for 16 h. The progress of the TEV cleavage was monitored by SDS-PAGE gel and 
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compared against uncut 5-FDRPi. The dialysed 5-FDRPi and TEV cocktail was loaded onto 
a pre-packed Ni-Sepharose High Performance His-Trap (GE Healthcare; 5 ml) in order to 
separate the 5-FDRPi (His6-tag removed) from TEV and cleaved His6-tags. The flow-
through from this Ni column was collected and analysed by SDS-PAGE to reveal contain 
non His6-tagged 5-FDRPi. The flow-through was pooled and concentrated to ~7 ml using a 
centrifugal filter unit (30000 Da, GE Healthcare) and loaded to a Superdex S-200 (HR 
16/60;GE Healthcare) gel filtration column connected to a FPLC (ÅKTA express; 
Amersham Biosciences), equilibrated with 20 mM Tris pH 7.5, 150 mM NaCl and 1 mM 
TCEP. The fractions containing 5-FDRPi were pooled and concentrated using centrifugal 
filter unit (30000 Da, GE Healthcare) to approximately 18 mg/ml for assays and 
crystallisation. For ITC studies, 5-FDRPi was dialysed in to 20 mM phosphate pH 7.5, 150 
mM NaCl and concentrated using centrifugal filter unit (30000 Da, GE Healthcare). The 
protein concentration was measured by Nanodrop 1000 spectrophotometer (Thermo Fisher 
Scientific Inc.) and the identity of the protein was confirmed by MALDI-TOF. 
  
4.8.2 NMR assays to test for activity of 5-FDRPi 
A solution of synthetic FDA 23 (2 mg) in 20 mM phosphate buffer pH 7.5 (1 ml) was 
incubated with immobilised PNP beads at 37 ºC, shaking at 80 rpm for 12 h. The beads 
were filtered and the supernatant was freeze-dried and re-suspended in D2O and analysed 
by 19F {1H} NMR. The reaction was then incubated with 5-FDRPi (3 mg) for 6 h at 37 ºC. 
The reaction was heat treated at 95 ºC for 10 min to precipitate the protein and the solution 
was centrifuged at 13000 rpm for 10 min. The supernatant was removed and freeze-dried 
and re-suspended in D2O and analysed by 19F {1H} NMR.  
The 5-FDRP 24 produced by PNP biotransformation, was used in an isomerase reaction to 
assay the purified enzyme. 5-FDRP 24 (1 mg) was incubated with purified FDRPi (3 mg) in 
20 mM phosphate pH 7.5 at 37 ºC for 6 h. This reaction was heat treated at 95 ºC for 10 
min followed by centrifugation (13000 rpm for 10 min) and the supernatant was mixed with 
D2O and analysed by 19F {1H} NMR.  
 
The 19F {1H} NMR spectra was recorded on a Bruker AVIII-HD 500 MHz with a SmartProbe 





4.8.3 Small scale enzymatic preparation and purification of 5-FDRP 24 
A solution of synthetic 5′-FDA 23 (6 mg) was prepared in 20 mM phosphate buffer pH 7.5 
(4 ml) and incubated with immobilised PNP (GSK) at 37 ºC shaking at 80 rpm over 5-6 
days. The progress of the reaction was monitored by 19F-NMR. The sample was filtered 
and (the pH of which lowered to 3.5 using formic acid. A weak anion exchange cartridge 
(SOLA WAX, Thermo Scientific) was conditioned with methanol and equilibrated with water 
(the pH of which lowered to 3.5 with formic acid). The sample was loaded and the column 
was washed with water (pH 3.5). Another wash was performed with methanol pH lowered 
to 3.5 using formic acid. The column was then eluted with 50% methanol (the pH of which 
was increased to 9 using ammonium hydroxide). All fractions were analysed by 19F {1H} 
NMR and the two fractions containing 5-FDRP 24 (wash 2 and elution 1) were pooled, pH 
neutralised and freeze-dried. The freeze-dried sample was analysed by 1H and 13C NMR to 
confirm the purity of 24. 
4.8.4 Isothermal titration calorimetry (ITC) mediated binding assays 
ITC was performed using MicroCal VP-ITC calorimeter (Malvern). The 5-FDRPi was 
dialysed against 20 mM phosphate buffer pH 7.5 and concentrated to around 10 mg/ml. 
The same dialysis buffer was used to equilibrate the instrument. Dialysis buffer was used 
to prepare a stock solution of 5′-fluororibosephosphonate 55 (5 mM) and this stock solution 
was used to prepare 1 ml of 1 mM solutions. The 5-FDRPi was diluted in dialysis buffer to 
prepare a 2 ml solution at a concentration of 60 µM or 100 µM. All solutions were pH 
corrected to ± 0.05 and degassed at 25 ºC. The ligand was titrated into the 5-FDRPi solution 
at 25 ºC/ 15 ºC. The first injection volume was 2 µl, and was followed by multiple injections 
of 5 µl. Data were analysed by MicroCal Origin software. 
4.8.5 Crystallisation of 5-FDRPi 
 
All crystal trials were set up with an Arts Robbins Gryphon at protein to precipitant ratios of 
2:1 and 1:1. Initial screenings were carried out using commercial screens in a 96-well format 
(JSCG+ and Wizard 1+2; Molecular dimensions and PEGs I and II suite; Qiagen) prepared 
with 14 mg/ml and 7.5 mg/ml of purified 5-FDRPi using a sitting drop vapour diffusion 
technique at 20 ºC and 4 ºC (Table 1). Conditions that produced crystals were further 
optimised by varying the PEG concentrations, additive, buffer concentrations and the pH 
as mentioned in Table 2. Selected conditions which produced crystals were set up again 
with high FDRPi concentration (16 mg/ml) from which E1 well condition of G1 optimisation 
was chosen and further optimised (Table 4).  
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Part of the crystals formed were retrieved and flash-frozen in cryoprotectant containing 
precipitant supplemented with 35% glycerol. The crystals were shot in-house at 100 K on a 
Rigaku 007 HFM rotating anode X-ray generator with a Saturn 944 CCD detector. A dataset 
of 236 frames of 0.5° oscillation with a crystal-to-detector distance of 60 mm and 240 sec 
exposure per frame was collected.  
























Optimisation Screen ; Well in 
which crystals were observed 
Contents of the well 
Concentration range for 
optimisation 
G1 screen; E1 
24% w/v PEG 5000 MME 
and 0.1 M Tris-HCl pH 7.6 
24-27% w/v PEG 5000 MME, 
0- 0.2 M MgSO4 and 0.1 M 
Tris-HCl pH 7.5-7.7. 
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5. Thesis conclusion 
 
5.1 Thesis conclusion and future work 
 
This thesis is focused on enzymes involved in the fluorometabolite biosynthetic pathway in 
S.cattleya (Figure 1). The fluorinase enzyme catalyses the first step of this pathway 
between SAM 22 and inorganic fluoride to produce 5′-FDA 23 and L-methionine 27. 
Fluorinase has found applications in PET due to its ability to catalyse C–18F bond formation 
in the presence of [18F]F- which can be used to incorporate 18F into substrates for the 
synthesis of novel radiotracers. Chapter 2 of this thesis describes the preparation of a user-
friendly, shelf-stable, freeze-dried enzyme kit for PET, which couples fluorinase to a TvNH 
enzyme allowing efficient production of [18F]-FDR ([18F]-37). The enzymatically synthesised 
[18F]-37 was then studied for its potential as a PET radiotracer in tumour induced mice 
relative to [18F]FDG ([18F]-32). [18F] 5-FDR ([18F]-37) was observed to have high early influx 
rates into the tumour and was stable for around 20 min, after which the efflux rate dominated 
the influx rate, thus reducing the image resolution. In comparison [18F]-32 uptake increased 
over the duration of the scan, consistent with the metabolic trapping of [18F]-32 due to 
intracellular phosphorylation. Overall, [18F] 5-FDR ([18F]-37) was found to provide good 
image contrast up to 20 min post injection. The stability of the freeze dried enzymes was 
also assessed over a period of 8 weeks. Shelf stability during storage is an important 
requirement for producing an enzyme kit. The freeze-dried enzymes were found to exhibit 
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147 
 
As future work it would be beneficial to evaluate and optimise the protein purification 
methods used in the isolation of fluorinase and TvNH by monitoring the specific activity and 
yield of each protein at every step of the purification.1 The assessment of the specific activity 
of each enzyme from the cell pellet to the lysate, post affinity and size exclusion 
chromatography would allow for quantification of the efficiency of the purification method, 
which will aid in optimising the cost effectiveness of producing the enzyme kit. In addition, 
it would be valuable to record the activity loss over time for aqueous fluorinase and TvNH 
stored at either -20 ºC or 4 ºC in relation to the freeze dried enzymes stored at the same 
temperatures, to investigate the significance of the freeze drying step on enzyme stability. 
 
Following publication of the work above2, Keng and co-workers reported the application of 
fluorinase immobilised on a functional polymer monolith to catalyse C-F bond formation in 
an aqueous environment. This methodology was used to produce [18F]-FDA ([18F]-23) from 
SAM with a 68% yield in 2.5 h. The yield obtained via polymer immobilised fluorinase was 
much lower than the yields reported (over 98%) by using freeze-dried fluorinase produce 
[18F]-23. In addition, the reaction time reported to generate [18F]-23 using freeze-dried 
fluorinase was 20-30 min, significantly shorter than the 2.5 h reaction time reported for 
polymer immobilised fluorinase. Sergeev et.al demonstrated that the immobilised fluorinase 
could be recycled up to four times with an increase in yield up to 80%, however this also 
increased the reaction time considerably3 demonstrating that using freeze-dried fluorinase 
still remains to be the most efficient method in generating [18F]-23 with high yields. 
 
Most recent work on the applications of fluorinase explored the substrate tolerance of 
fluorinase to incorporate 18F into peptides for PET.4–6 Transhalogenation reactions were 
used to generate 18F labelled 5ʹ-fluoro-5ʹ-deoxy-2-ethynyladenosine linked to a monomeric 
arginyl-glycyl-aspartic acid (RGD) peptide through a PEG linker at C-2 of the adenine 
base.4,6 RGD peptides are known to bind upregulated α3ߚߥ integrin motifs on the surface of 
cancer cells7. The 18F labelled RGD peptide motifs were demonstrated to have high affinity 
to these integrins.8–10 Furthermore, fluorinase was successful in 18F labelling larger, more 
complex dendritic scaffolds carrying two to four cyclic RGD peptide motifs for clinical 
imaging.5 [18F]-FDR ([18F]-37) has been explored as an efficient bioconjugation ligand for 
radiolabelling RGD peptides. FDR 37 was demonstrated to be a superior bioconjugation 
agent in comparison to FDG 32 as the fluorine positioning on the ribose ring promotes ring 
opening to form the reactive aldehyde from the sugar, allowing for oxime ligations to 











Figure 2: The aminooxy ether functionalised RGD peptide bioconjugated to [18F] FDR 37 
to produce radiolabelled RGD peptides for PET.11 
 
The S. cattleya fluorinase was the only known fluorinase until recently, however four more 
fluorinases were identified by gene mining in the last four years. Chapter 3 discusses the 
cloning, over-expression and purification of Streptomyces sp. MA37 fluorinase, along with 
a subsequent investigation of the kinetic parameters of all four fluorinases relative to the 
S.cattleya fluorinase. The structure of the Streptomyces sp. MA37 fluorinase was solved by 
X-ray crystallography and was observed to be almost identical to that of the S.cattleya 
fluorinase. Two other flA genes were identified from N. brasiliensis and Actinoplanes sp. 
N902-109 which were found to be fluorinases possessing higher catalytic efficiency relative 
to both S. cattleya and Streptomyces sp. MA37. Following the identification of these three 
fluorinases, an additional fluorinase gene was identified from a marine Streptomyces 
xinghaiensis. This organism was observed to be a fluoroacetate producer in sea salt 
dependent media.12 The flA4 emerged as the most efficient fluorinase with an almost 8 fold 
higher efficiency than the N. brasiliensis and Actinoplanes sp. N902-109 fluorinases and an 
almost 12 fold higher efficiency than S.cattleya fluorinase.13  
 
Following the discovery of Streptomyces sp. MA37 fluorinase, Ang and co-workers have 
used this enzyme in directed evolution for improving the fluorination efficiency in the 
transhalogenation reaction to convert ClDA 28 to 5′-FDA 23 via SAM 22 intermediate for 
application in PET. Evolved FlA1 mutants A279Y and F213Y was capable of catalysing 
successful radiosynthesis of [18F]FDA ([18F]-23) with an overall radiochemical conversion 
over 3 fold higher than the wild type FlA1.14 This mutant fluorinase has prospects for 
catalysing more efficient transhalogenation reactions to produce a variety of 18F labelled 




Chapter 4 describes the successful crystallisation of 5-deoxy-5-fluoro-D-ribose 1-
phosphate isomerase (FDRPi), an aldose-ketose isomerase involved in the biosynthetic 
pathway of fluorometabolite biosynthesis in S.cattleya. The FDRPi was over-expressed, 
purified and assayed for activity. In an attempt to crystallise FDRPi with a cyclic sugar in 
order to explore the key residues for binding and to investigate the catalytic mechanism of 
FDRPi, a non-hydrolysable analogue of substrate, 5′-fluororibosephosphonate 55 was 
synthesised (by P. Nasomjai).15 Binding studies performed via ITC showed 5′-
fluororibosephosphonate 55 did not bind FDRPi. Therefore attempts to crystallise 55 bound 
FDRPi were discontinued, however apo- FDRPi crystals were obtained and the structure 
of FDRPi was resolved. The FDRPi protein structures was observed to be similar to that of 
B.subtilis MTRPi, the closest representative of 5-FDRPi of which the crystal structure has 
been previously resolved.16 The active sites of both B.subtilis MTRPi and S.cattleya FDRPi 
possessed similar arrangements despite a loop rearrangement in S.cattleya FDRPi, which 
may be important in an interaction with the terminal fluorine of 5-FDRP 24. Probing the 
catalytic mechanism of FDRPi is yet to be accomplished and may require the design of new 
inhibitors capable of binding FDRPi for crystallographic analysis.  
 
Overall this thesis has evaluated the prospects of using the fluorinase to generate [18F]-
FDR ([18F]-37) for PET imaging of tumours; characterised a more efficient fluorinase from 
Streptomyces sp. MA37 (through crystallography and kinetic evaluation) which may have 
applications in future PET studies; and explored the crystallisation of S. cattleya FDRPi 
revealing the arrangement of residues in the active site of FDRPi, which could be further 
explored for insight into its catalytic mechanism. The information obtained from the work 
carried out in this thesis has broadened the knowledge on the enzymes related to 
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Crystallographic Data for Streptomyces sp. MA37 fluorinase (PDB: 5LMZ) 
 
Crystallization experiments: 
Method: 7% w/v PEG 6000, 0.5 M NaCl; Vapor diffusion sitting drop  
Temperature = 293.0 K  







Space Group: P 21 3 
Diffraction:  
Detector = CCD, Rigaku Saturn 944 
Temperature = 100 K  
Protocol: single wavelength 
Data collection: 
Resolution (high) =2.55 Å  
Resolution (low) =18.17 Å 
No. of reflections observed= 21982 
Refinement: 
R-Value work = 0.166 






Length (Å) Angle (º) 
A = 125.92 α = 90 
B = 125.92 β = 90 








Method: 25% w/v PEG 5K MME, 0.1 M Tris-HCl pH 7.6; Vapor diffusion sitting drop  
Temperature = 293.0 K  






Space Group: P 21  
Diffraction:  
Detector = CCD, Rigaku Saturn 944  
Temperature = 100 K  
Protocol: single wavelength 
Data collection: 
Resolution (high) =1.67 Å  
Resolution (low) =57.61 Å 
No. of reflections observed= 75438 
Refinement: 
R-Value work = 0.185 






Length (Å) Angle (º) 
A = 60.73 α = 90 
B = 59.95 β = 108 




flA1 nucleotide sequence  



















FlA1 protein sequence 
Streptomyces sp. MA37 peptide sequence for fluorinase  
GenBank: CDH39444.1 







5-deoxy-5-fluoro-D-ribose 1-phosphate isomerase (FDRPi) peptide sequence  
Streptomyces cattleya peptide sequence for FDRPi 
GenBank: AEW94379.1 







































Figure 1: A) The 1H, 13C-HSQC 2D spectrum of 5-FDRP 24 in D2O. B) The 1H,1H–COSY 
2D spectrum of 5-FDRP 24 in D2O. 
